



Baltic Statistics on Medicines 2010–2012

Baltic Statistics on Medicines 2010–2012

Tartu 2013

Edited by:

Estonian State Agency of Medicines

Ly Rootslane, Ott Laius, Janne Sepp, Katrin Kurvits

Latvian State Agency of Medicines

Andis Seilis, Elma Gailīte, Dace Ķikute

Lithuanian State Medicines Control Agency

Dr Jolanta Gulbinovič, Renata Tomaševič, Vaida Stasevičiūtė

Published by:

Estonian State Agency of Medicines

1 Nooruse Street

50411 Tartu

Estonia

info@ravimiamet.ee

www.ravimiamet.ee

When using or quoting the data included in this issue, please indicate the source.

ISBN 978–9949–33–396–7 (print)

ISBN 978–9949–33–397–4 (pdf)



Printed by environmentally friendly printinghouse Ecoprint

Contents

1. Preface.....	3
2. Facts about the Baltic countries.....	3
3. Medicinal products regulation and pharmaceutical services 8	8
in the Baltic countries	
3.1. Procedures of marketing authorisation of medicinal..... 8	8
products in the Baltic states	
3.2. Marketing authorization licences..... 9	9
3.3. Non-authorised medicinal products 9	9
3.4. Medicinal products mark-up..... 10	10
3.5. Generics market..... 13	13
3.6. Retail and hospital pharmacies and wholesalers 14	14
4. Drug reimbursement systems in the Baltic countries17	17
4.1. Description of the reimbursement systems.....17	17
4.2. Changes in the reimbursement systems 20	20
(during the period of 2010–2012)	
4.3. Reference price systems.....22	22
5. Materials and methods used in the Baltic Statistics on Medicines ... 24	24
5.1. Data collection in the Baltic states 24	24
5.2. ATC/DDD methodology and interpretation of drug 25	25
sales statistics	
5.3. Factors affecting the interpretation of drug utilization data..... 26	26
6. Cost of drugs as a share of total health care expenditure 27	27
in the Baltic countries	
6.1. The medicinal products market27	27
6.2. Sale of drugs according to the ATC main groups..... 28	28
(DDD/1000 inhabitants/day)	
6.3. Sale of drugs according to the ATC main groups (turnover)..... 30	30
7. Sales statistics 2010–2012..... 33	33
8. TOP 15 of prescription only medicines 156	156
9. TOP 15 of ATC 3rd groups.....157	157
10. TOP 15 of over-the-counter medicines 158	158
11. Contacts..... 159	159
12. References 160	160

1. Preface



Kristin Raudsepp
Director General
State Agency
of Medicines
Estonia



Inguna Adoviča
Director
State Agency
of Medicines
Latvia



Gintautas Barcys
Director
State Medicines
Control Agency
Lithuania

This book is a statistical summary of the medicines consumption data of the Baltic countries (Estonia, Latvia and Lithuania) in 2010–2012.

The national consumption statistics are published annually in all the Baltic countries; this is the first joint publication which provides comparative data illustrating the trends of interest and the national differences.

Medicines are classified according to the Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) is used as a measurement – both of these are proposed by the World Health Organization (WHO) for the medicines consumption studies. These systems are coordinated by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo.

The history of the Baltic countries has been quite similar during last 70 years. At the beginning of the 1940's all Baltic countries were occupied by the Soviet Union – during the Soviet period all the medicinal products were supplied centrally and the selection and availability of the products was similarly limited in all countries. When countries regained their independence in the early 1990's the national health care systems and marketing authorization procedures were developed with some differences between the countries. Since May 1st, 2004 all the three countries are Member States of the EU and their frame for regulating the pharmaceutical market is based on the same basic directives and regulations. Still, national differences

may be met in some areas. Over the 20 years of development the drug regulatory agencies have become stable organisations with all the possibilities to meet the developments in science, pharmaceutical industry and legislation.

Current publication gives the reader an overview of how the differences and similarities of our countries have influenced the drug use.

You will find the description of the reimbursement systems, an overview of the medicinal products market and other related subjects followed by the data on the consumption of the main groups of medicines.

The specialists of the State Agencies of all three countries were involved in compiling this publication and we hope that it is the beginning of a new tradition.

2. Facts about the Baltic countries

	Estonia	Latvia	Lithuania
Population (01.01.2013)	1 286 540	2 023 825	2 979 310
Total health expenditure (2011, euro)	921 mln	1 242 mln	2 121 mln
Total health expenditure per capita (2011, euro)	687.4	634	614.5
GDP per capita (2011, euro)	11 904	9 873	10181
Total health expenditure as a % of GDP (2011)	5.8%	6.2%	6.6%
Medicinal products turnover (2012, wholesale, VAT excluded, euro)	222 mln	260 mln	404 mln
Number of general pharmacies per 100 000 inhabitants (01.01.2013)	37	43	47
Number of physicians per 100 000 inhabitants (01.01.2013)	468	343	420
Total number of reimbursed prescriptions (2012)	7.6 mln	5.7 mln	12 mln
Currency (01.01.2013)	euro	Latvian lat 1 euro is equal to 0.7028 lats	Lithuanian litas 1 euro is equal to 3.4528 litas

3. Medicinal products regulation and pharmaceutical services in the Baltic countries

3.1. Procedures of marketing authorisation of medicinal products in Baltic States

The procedure of the marketing authorisation of the medicinal products in the Baltic States is following the European Union (EU) law as well as the EU and international guidelines. The procedures are similar in all EU member states. An application for a marketing authorisation for a medicinal product may be filed under the mutual recognition, decentralised, centralised or national procedure.

The **National Procedure** may be used when an application for the marketing authorisation of a product is filed for the first time in the EU. This procedure may also be applied to the 'extensions of marketing authorisations', wherein an application is filed, for example, for a new strength or pharmaceutical form of a product already approved nationally. After the evaluation of the application the product may be granted a marketing authorisation nationally.

The **Mutual Recognition Procedure (MRP)** makes use of a marketing authorisation already granted for the medicinal product by an EU Member State (or by Norway or Iceland). The Member State whose evaluation statement is used as grounds for recognising the marketing authorisation is known as the Reference Member State (RMS), while the member state recognising the authorisation is known as the Concerned Member State (CMS).

The **Decentralised Procedure (DCP)** may be applied for products that do not have a marketing authorisation in any Member State. This procedure will allow concomitant application for authorisations in both the RMS and the CMS. The process is conducted by the RMS while the CMSs participate in the evaluation of the application prior to the granting of the marketing authorisation in any of the Member States taking part in the process.

In the event that a marketing authorisation is recognised, the product will be granted a national marketing authorisation as soon as the national translations of its summary of product characteristics (SPC), package information leaflet (PIL) and labelling confirming to the SPC mutually agreed in the Mutual Recognition or Decentralised Procedure are ready and approved.

The **Centralised Procedure** is used when a marketing authorisation is applied within the entire EU area for the new biotechnological and other innovative medicinal products. Such marketing authorisation applications are filed with the European Medicines Agency (EMA). Applications for the marketing authorisation concerning the medicinal products for human use are evaluated by the Committee for Medicinal Products for Human Use (CHMP) and those for veterinary use by the Committee for

Medicinal Products for Veterinary Use (CVMP). Each Member State has nominated one regular member and one alternate member to each of these committees. Furthermore, five auxiliary members have been elected to each committee based on their scientific competence.

For each application the Committees will elect a rapporteur and a co-rapporteur from among their members to carry out the evaluation of the application with the aid of the resources made available by the medicines agencies of the Member States. Based on the reviews obtained, the committees will issue a scientific statement to be submitted to the EU Commission for the actual decision-making process. The marketing authorisation granted by the Commission is valid in every Member State.

3.2. Marketing authorisation licences

Table 1. Marketing authorisations in January 2013

	Estonia	Latvia	Lithuania	Centrally Authorised Products (CAP) in EU
Number of trade names	2848	2734	2850	780
Number of INN	829	1340	921	365
Number of products	3905	4542	5004	1821

3.3. Non-authorised medicinal products

As a general rule, the medicines used in all three Baltic states must have a marketing authorisation. Considering the relatively small size of the pharmaceutical market in all three countries, non-authorised medicines may be used exceptionally if there is no suitable authorised medicine in the register or if the authorised medicine is not available.

■ ESTONIA

The use of the non-authorised medicines is permitted on the basis of applications from doctors (for ambulatory use per patient or for in-hospital use per medical institution for a maximum of 1 year) or from professional organisations (for a cohort of patients). The Agency assesses whether there are grounds for using a particular medicine and in justified cases may issue a permission for the use of a non-authorised medicine.

■ LATVIA

In exceptional cases the State Agency of Medicines issues a permit to wholesalers for the distribution of the medicines authorised in other countries. The medicines wholesaler basis its request for the distribution of the non-authorised medicines on a request from a pharmacy or from a healthcare institution.

■ LITHUANIA

To ensure the availability of all the necessary medicines for the patients the use of the non-authorised medicines is permitted under exceptional circumstances. The non-authorised medicines may be used in the ambulatory care and at the hospital on the basis of a special application from a doctor with signed informed consent of the patient. The treating physician is responsible for prescribing, information and safe use of the non-authorised medicines.

3.4. Medicinal products mark-up

All Baltic states regulate the maximum value that wholesalers and pharmacies are allowed to add to their purchasing price (PP).

■ ESTONIA

The level of maximum limits is required by law to allow the weighted average mark-up of 7–10% in wholesale and 21–25% in retail sale of pharmaceuticals and should be adjusted accordingly based on an annual market analysis by the Ministry of Social Affairs. In practice the applied mark-up may be lower than this maximum, which is frequent for the over-the-counter (OTC) pharmaceuticals. This is one of the commercial possibilities for the wholesalers and pharmacies to attract clients.

Table 2. Wholesale mark-up scheme in Estonia

Ex-factory price in €	Maximum mark-up (% of ex-factory price)
up to 1.60	20
1.61–2.88	15
2.89–6.39	10
6.40–12.78	5
over 12.78	3

Table 3. Pharmacy mark-up scheme in Estonia

Pharmacy purchasing price in €	Pharmacy mark-up coefficient (%)	Fixed pharmacy mark up in €
up to 0.64	-	0.38
0.65–1.28	40	0.38
1.29–1.92	35	-
1.93–2.56	30	-
2.57–3.20	25	-
3.21–6.39	20	-
6.40–44.74	15	-
over 44.74	-	5.11

A value-added tax (VAT) of 9% is applied for all pharmaceuticals and nutritional mixtures used for medicinal purposes. A standard value-added tax (VAT) of 20% is applied for other goods in Estonia. The value-added tax (VAT) was increased to 9% in the beginning of 2009, before that it was 5%.

■ LATVIA

The principles for the determination of the price of the medicinal products are described in the legislation.

The maximum wholesale mark-up is determined by the following formula:

Maximum wholesaler's price = manufacturer's price x correction factor + correction sum in currency + VAT. The correction factor and correction sum shall be determined on the basis of the manufacturer's price (see Table 4).

Table 4. Wholesale mark-up scheme in Latvia

Manufacturer's price in €	Correction factor	Correction sum in €
up to 4.26	1.18	-
4.27–14.22	1.15	0.13
14.23 and more	1.10	0.84

The maximum retail mark-up is determined by the following formula:

Maximum pharmacy price = procurement price x correction factor + correction sum in currency + VAT. The correction factor and correction sum shall be determined on the basis of the procurement price (see Table 5).

Table 5. Pharmacy mark-up scheme in Latvia

Procurement price €	Correction factor	Correction sum €
up to 1.41	1.4	-
1.42–2.84	1.35	0.07
2.85–4.26	1.3	0.21
4.27–7.10	1.25	0.43
7.11–14.22	1.2	0.78
14.23–28.45	1.15	1.49
28.46 and more	1.1	2.92

The manufacturer's prices are declared to the State Agency of Medicines by the manufacturers twice a year and every time the prices are changed or a new product is placed on the market. The maximum retail prices are then calculated and published on the Agency's website for consumers and other interested parties.

The standard rate of value added tax (VAT) in Latvia is 21%. The reduced rate of 12% is applied to the medicinal products. The VAT for medicines in Latvia was increased twofold from 5% to 10% in 2010 and then to 12% in 2011.

■ LITHUANIA

Wholesalers and pharmacy maximum mark-ups of reimbursable pharmaceuticals is regulated by law and a combination of linear and regressive schemes is used.

In Lithuania VAT for reimbursed pharmaceuticals is 5 % and 21% for not reimbursed pharmaceuticals.

Table 6. Wholesale mark-up scheme in Lithuania

Ex-Factory Price in €	Maximum wholesale mark-up in %	Maximum wholesale mark-up in €
up to 1.86	14	-
1.87–2.89	-	0.26
2.90–5.63	9	-
5.64–7.24	-	0.51
7.25–15.51	7	-
15.52–19.74	-	1.09
19.75–263.28	5.5	
263.29 and more	-	14.48

Table 7. Pharmacy mark-up scheme in Lithuania

Pharmacy purchase price (PPP) in €	Maximum pharmacy mark-up in %	Maximum pharmacy mark-up in €
up to 2.37	22	-
2.38–2.89	-	0.52
2.90–4.42	18	-
4.43–7.24	-	0.80
7.25–7.90	11	-
7.91–21.72	-	0.87
21.73–144.81	4	-
144.81 and more	-	5.79

3.5. Generics market

■ ESTONIA

Although there is no explicit regulation on the (mandatory) use of generics in Estonia (i.e. generic substitution), there are some regulative measures in place, directing doctors and patients towards the wider use of generics where these are available.

Doctors have to prescribe pharmaceuticals by their International Non-proprietary Name (INN) as the default option; if prescribing by the trade name, they have to document this in the medical record of the patient providing the justification and to mark “not to substitute” on the prescription.

If the pharmaceutical has been prescribed by the INN, the pharmacist has to offer different preparations to the patient, including the cheapest alternative for the patient. In discussion with the patient the most appropriate preparation is to be chosen.

The prevailing reference price system, establishing the reference price of a pharmaceutical as the basis for the reimbursed amount, is a strong incentive to accept substitution, as patients would have to pay the price difference between the reference price and the reimbursed amount on top of their statutory out-of-pocket payments.

■ LATVIA

According to the Latvian legislation a physician may prescribe the medicinal product by the trade name and the pharmacist is allowed to substitute it with an analogue if the doctor has not forbidden this possibility on the prescription.

However in case of the first prescription of a reimbursed medicinal product the INN name of the medicinal product should be indicated on the prescription and the pharmacist has to offer different preparations to the patient, including the cheapest alternative for the patient.

■ LITHUANIA

Several measures have been introduced in order to stimulate the use of generic medicines.

According to the Lithuanian legislation the medicines should be prescribed by the INN. The prescribing by the trade name is only allowed for the biological pharmaceuticals. Some medicines with narrow therapeutic window may be prescribed by the trade name after the decision of the specialists' commission. All pharmacies are obliged to provide data on prices to the patients via computer screens and are obliged to have the cheapest product in the store.

3.6. Retail and hospital pharmacies and wholesalers

Tabel 8. Pharmacies and wholesalers in the Baltic states (as of January 1st, 2013)

	Estonia	Latvia	Lithuania
Retail pharmacies	475 (including 166 structural units)	873 (including 96 structural units)	1404 (including 1130 structural units)
Hospital pharmacies	25 (including 2 structural units)	36 (no structural units)	50 (including 3 structural units)
Wholesalers (incl. human and veterinary medicines distribution)	58	58	143
Wholesalers (only veterinary medicines)	5	25	38

Structural unit is a separate pharmacy acting under the same activity licence as the main pharmacy.

■ ESTONIA

In January 2013 there were 58 drug wholesalers in Estonia and 5 of them were specialised only in veterinary drugs. 18 wholesalers had both, human and veterinary products wholesale licences.

The total number of wholesalers in Estonia has been growing rapidly during the last five years, while the proportion of the veterinary wholesalers has been decreasing.

In 2012, 29 wholesale companies sold drugs to the general or hospital pharmacies or to other institutions. Over 90% of the medicinal products market was covered by the seven major wholesalers: Magnum Medical (29.5%), Tamro Estonia (27.7%), Apteekide Koostöö Hulgimüük (21.3%), Estonian Health Board (4.8%), Roche Estonia (3.4%), Oriola (3.3%) and Chirurgicus (2.3%).

Table 9. Wholesalers of the medicinal products in Estonia

	2009	2010	2011	2012	2013
Wholesalers (human and veterinary medicines)	40	44	46	50	53
Wholesalers (only veterinary medicines)	8	7	7	5	5
Total	48	51	53	55	58

At the beginning of 2013 there were 475 general pharmacies (including 166 structural units), 25 hospital pharmacies (including 2 structural unit) and 4 veterinary pharmacies in Estonia. 35% of the general pharmacies were situated in the bigger cities – Tallinn and Tartu.

Table 10. Pharmacies in Estonia

	2009	2010	2011	2012	2013
Retail pharmacies	496	486	477	469	475
Hospital pharmacies	28	26	26	24	25
Veterinary pharmacies	7	7	7	5	4

■ LATVIA

In January 2013 there were 58 drug wholesalers in Latvia. 6 of them had both, human and veterinary products wholesale licences, only one of those 6 was actually selling veterinary medicines.

Since January 1st, 2011 the licences for the distribution of veterinary medicines are being issued by the Food and Veterinary Service.

In 2012, 46 wholesalers of human medicines distributed medicines to the pharmacies, health care institutions, medical practitioners and other recipients. The remaining 11 wholesalers have either sold medicines to other wholesalers or exported them. Over 90% of medicinal products market was covered by the nine major wholesalers: Recipe Plus (35.0%), Tamro (21.4%), Magnum Medical (14.1%), Euroaptieka (7.1%), Oriola Rīga (4.6%), GlaxoSmithKline Latvia (2.8%), Medelens (2.5%), Vita-Farm (Baltfarma) (2.2%) and Jelgavfarm (2.2%). The market share of the other wholesalers covered 8% of the total market.

Table 11. Wholesalers of the medicinal products in Latvia

	2009	2010	2011	2012	2013
Wholesalers (incl. human and veterinary medicines)	40	50 (7)	57 (7)	57(6)	58 (6)
Wholesalers (only veterinary medicines)	23	23	24	24	25
Total	63	73	74	81	83

At the beginning of 2013 there were 896 retail pharmacies (including 94 structural units) and 41 hospital pharmacies in Latvia. 55% of all retail pharmacies are located in the 9 largest cities of Latvia – 34% in Riga, 5% in Daugavpils, 4% in Liepaja, 3% in Jelgava and Jurmala, 2% in Rezekne and Ventspils, 1% in Jekabpils and Valmiera.

Table 12. Pharmacies in Latvia

	2009	2010	2011	2012	2013
Retail pharmacies (including structural units)	896	882	880	873	873
Hospital pharmacies	41	38	38	36	36

■ LITHUANIA

In 2012, 40 out of 96 wholesalers sold medicines to the general or hospital pharmacies or to other institutions. The following 5 wholesalers cover 90% of the medicinal product market: UAB "EVD" (34%), UAB „Limedika“ (25%), UAB „Nemuno vaistinė“ (20%), UAB „Armila“ (6%) and UAB „Medikona“ (6%). The market share of the other wholesalers made up 9% of the total market.

Table 13. Wholesalers of the medicinal products in Lithuania

	2009	2010	2011	2012	2013
Wholesalers (human medicines, including suspended licences)	82	83	89	96 (7)	105 (9)

Hospital pharmacies are funded by the hospitals and do not dispense medicines to outpatients. Not every hospital has a hospital pharmacy for inpatients; however the majority of health care providers have ordinary community pharmacies on the premises.

Table 14. Pharmacies in Lithuania

	2009	2010	2011	2012	2013
Retail pharmacies	1515	1504	1483	1442	1404
Hospital pharmacies	58	56	55	54	50
Veterinary pharmacies	119	127	133	135	137

4. Drug reimbursement systems in the Baltic countries.

4.1 Description of the reimbursement systems

The structure of the reimbursement systems has similarities in Baltic states:

- Medicinal products are compensated for on the basis of the diagnosis.
- Reimbursement rates are divided according to the severity of the disease. There are Positive Lists of the products.
- For certain patient groups additional discounts are provided, for example children and the elderly.
- Medicinal products are compensated for according to the reference prices in case it exists.

Details of the systems are described below.

■ ESTONIA

The Estonian health insurance relies on the principle of solidarity. The Estonian Health Insurance Fund (EHIF) covers the costs of health services required by a person in case of an illness regardless of the amount of the social tax paid for the person concerned. The Fund uses the social tax paid for the working population also for covering the cost of the health services provided to the persons who have no income with regard to work activities. The employers are required by law to pay social tax for all persons employed, the rate of this tax is 33% of the taxable amount, 20% of which is allocated for the pension insurance and 13% for the health insurance.

The purpose of the health insurance in Estonia is to cover the costs of the health services provided to the insured persons to prevent and cure diseases, finance the purchase of the medicinal products and medical devices, and provide the benefits for the temporary incapacity for work and other benefits.

Only the medicinal products included in the EHIF's list of medicinal products and authorised in Estonia are compensated for. Special reimbursement mechanism is available for the products not having a marketing authorisation in Estonia. Medicinal products are compensated for according to the reference prices and price agreements in case these exist; in other cases the refund is based on the product's retail price. At the manufacturing level there is statutory pricing (after the negotiations) for reimbursable pharmaceuticals. The process of pricing is incorporated into the procedure of reimbursement decision making. Medicinal products are compensated for on the basis of the diagnosis. Medicinal products intended for hospital use are compensated to health care providers if their cost is included in service fee.

Reimbursement rates for medicinal products for out-patient use:

100% reimbursement – pharmaceuticals for the treatment of choice of serious, life-threatening or epidemic diseases.

Patient shall make an own contribution of 1.27 EUR and in case there is a reference price or a price agreement, pay the sum that exceeds that price. Health Insurance Fund will cover 100% of the sum that exceeds 1.27 EUR and is within the reference price or price agreement.

75% reimbursement – pharmaceuticals for the treatment of choice of chronic diseases, threatening the quality of life.

The patient makes an own contribution of 1.27 EUR per prescription, pays 25% of the sum remaining between 1.27 EUR and the reference price/price agreement and everything exceeding the reference price/price agreement. The Health Insurance Fund shall pay 75% of the amount between 1.27 EUR and the reference price/price agreement.

50% reimbursement – all other pharmaceuticals in the Positive List.

The patient shall make an own contribution of 3.19 EUR, pay 50% of the sum between 3.19 EUR and the reference price/price agreement and everything exceeding the reference price/price agreement. The Health Insurance Fund shall pay 50% of the amount exceeding 3.19 EUR.

A compensation rate of 90% applies to medicinal products with a discount rate of 75% in case of the following patient groups:

- children aged 4 to 16 years;
- insured persons over 63 years of age, in addition, all persons who have been granted pension under the State Pension Insurance Act.

For children under 4 years old, compensation rate of 100% is applied on all medicinal products included in the EHIF list of medicinal products.

The out-of-pocket payment (OPP) system is rather intricate and combines fixed co-payments, percentage co-payments and deductibles. The fixed co-payments are, e.g., prescription fees of € 1.28 at the 100% and 75/90% reimbursement levels and € 3.20 at the 50% reimbursement level. These prescription fees have not been changed since the mid-1990s and there have been minor changes in the overall unavoidable percentage of OPP (90% reimbursement level divided into 75/90% in 2002).

■ LATVIA

The general principles of the reimbursement system of pharmaceuticals are set in the legislation. The reimbursement of pharmaceuticals shall be provided according to the character and severity of the disease. The following categories are applied:

100% reimbursement – for chronic, life threatening diseases or diseases causing irreversible disability, where the use of pharmaceuticals ensures and maintains the patient's life functions,

75% reimbursement – for chronic diseases, for which the maintenance of the patient's life functions are aggravated without the use of pharmaceuticals,

50% reimbursement – for diseases where pharmaceuticals maintain or improve the patient's health and for vaccines.

All drugs for the same indication are reimbursed at the same rate. For the pharmaceuticals for which the reference price is calculated the reimbursement rate is applied to the reference price.

The pharmaceuticals eligible for the reimbursement are listed in the Positive List elaborated by the National Health Service (NHS) of Latvia.

The Positive List consists of three parts – List A, List B and List C according to the following basic principles:

- List A includes pharmaceuticals, which have several preparations of the same therapeutic effectiveness within the scope of the INN or the pharmaco-therapeutic group and medical devices of the same type.
- List B includes pharmaceuticals and medical devices, without an authorised alternative.
- List C includes pharmaceuticals, costs of which exceed 4270 € per patient per year and special medical restrictions cannot be applied to reduce the expenditure.

Reimbursable pharmaceuticals are prescribed by family doctors and certain specialists who have an agreement with the NHS of Latvia.

Reimbursement is provided through pharmacies on the basis of a special reimbursable prescription, patients have to pay the co-payment in the case of the 75% or 50% reimbursement levels or € 0.71 at the 100% reimbursement level.

A pharmaceutical to be included in the Positive List is to:

- be authorised by the national medicines agency or by the European Commission, or parallel imported according to the regulations;
- be classified as a “prescription only” (over-the-counter (OTC) products are not reimbursable);
- have an approved indication relevant to the diseases listed in Appendix of the Regulation of Cabinet of Ministers.

In Latvia, there is statutory pricing (after the negotiations) for reimbursable pharmaceuticals and free pricing for non-reimbursable pharmaceuticals at the manufacturer level. The process of pricing is incorporated into the procedure of

the reimbursement decision making. During the price negotiations both external and internal price referencing mechanisms are used. Prescription-only medicines that are not included in the Positive List, are reimbursed for children up to 24 months of age (reimbursement rate 50%) and for pregnant women and women within 42 days of postnatal period (reimbursement rate 25%).

■ LITHUANIA

The state health care system is intended to serve the entire population, and the Health Insurance Law requires all permanent residents to participate in the compulsory health insurance scheme without an option to opt-out. Compulsory health insurance covers almost all inhabitants. Compulsory health insurance provides a standard benefits package for all beneficiaries. There is no positive list of health services provided in the state-financed health care facilities. Emergency care is rendered free of charge to all permanent residents irrespective of their insurance status. Drugs prescribed by a physician are reimbursed according to the reimbursement lists. Expensive hospital medicines are centrally purchased by the National Health Insurance Fund.

There are two reimbursement lists, A and B.

List A covers pharmaceuticals for specific diseases in four reimbursement categories:

100% reimbursement: Covers the most serious and expensive diseases, including oncology, diabetes, haemophilia, schizophrenia, asthma etc.

80% reimbursement: Provides coverage for less serious diseases such conditions as cardiovascular diseases.

At **90% and 50% reimbursement** level are reimbursed only a few diseases.

Reimbursement from the disease-based list A accounts to approximately 95% of the country's total pharmaceutical reimbursement.

List B is a list of 75 active substances or combinations reimbursed for certain social groups, including children under 18 years old, the disabled and pensioners with two reimbursement rates:

- 100% is granted to children and the severely disabled,
- 50% is given for other disabled patients and pensioners.

4.2 Changes in the reimbursement systems (during the period of 2010–2012)

■ ESTONIA

There were no major changes in the reimbursement system during this period in Estonia. New active substances have been added to the list of reimbursed medicines on a regular basis according to the decisions of the Minister of Social Affairs.

Midwives obtained a right to prescribe a limited list of prescription medicines (including contraceptives) in 2010.

Since the same year wholesalers of medicinal products have to stock medicines which are priced cheaper than (or equal to) the reference price and pharmacists have an obligation to stock and offer to patient medicines with the smallest co-payment.

In 2012 the digital prescription IT tool was changed so that written justification is mandatory on digital prescription if the prescription is issued by the trade name.

The previously existing reimbursement ceiling of €12.79 per prescription in the 50% reimbursement category was removed in 2012.

■ LATVIA

In 2009 the reimbursement rates were reduced, the rate of 90% was abandoned.

From 2012 the doctor is obliged to prescribe by the INN for the newly diagnosed patients, but one can prescribe INN also for other patients. The pharmacist is obliged to dispense the cheapest drug in case the doctor has prescribed by the INN.

Managed entry agreements have been allowed by legislation.

From September 2012 reimbursement of prescription-only medicines that are not included in the Positive List, for children up to 24 months of age, pregnant women and women within 42 days of postnatal period has been introduced.

■ LITHUANIA

The onset of the financial crisis in 2008 has forced Lithuanian policy-makers to seek more efficiency in the pharmaceutical sector and to reduce the public expenditure on pharmaceuticals. Special plan was introduced in 2009 and as a result, while the number of prescriptions between 2008 and 2010 increased by 9%, the expenditure on pharmaceuticals and medical devices covered by the NHIF has decreased over the same period from 198 to 189 million Euros. This reduction has been achieved through the following measures (Garuoliene et al., 2011):

- Introduction of new requirements for generic pricing such that the first generic has to be priced 30% below the originator, while the second and third generics must be priced at least 10% below the first generic to be reimbursed;
- Trade-name based prescribing is only allowed for biological products, and all pharmacies are obliged to provide data on prices to the patients via computer screens and are obliged to have the cheapest product in store;
- Price-volume agreement schemes agreed and valid for a minimum of three years regarding all new pharmaceuticals that will increase the NHIF pharmaceutical budget compared with the current treatment approaches for the target population groups.

4.3 Reference price systems

■ ESTONIA

Estonia established a reference price system in January 2003. The reference price is based on the internal price referencing, where the pharmaceuticals are grouped on the basis of active ingredients (Anatomic Therapeutic Chemical classification ATC-5 level), route of administration and pharmaceutical forms. Parallel traded pharmaceuticals have been incorporated into the reference price system as well.

The procedures for setting manufacturer prices differ depending on whether the pharmaceutical in questions is an innovative or a generic product. There are specific criteria for reimbursement of the parallelly traded pharmaceuticals: the price for these has to be 10% lower than the price of the primary authorised product on the market.

Statutory pricing – in combination with price negotiations – is applied to the innovative and in-patent reimbursable pharmaceuticals in Estonia. The statutory price levels are set according to the prices of the product in the reference countries (Latvia, Lithuania, Hungary, Portugal, France and the country of origin). If applicable, and similarity is proven, the prices of pharmaceuticals of similar effect are also compared.

The Ministry of Social Affairs is the main authority involved in the pricing decisions, receiving advice from the Pharmaceutical Committee.

If the price of the pharmaceutical is according to the opinion of the Pharmaceutical Committee set too high, price negotiations with the manufacturer are started. Negotiations are possible for the same pharmaceuticals and on the basis of the same legal framework/procedure as statutory pricing. This has been applied since 2003.

■ LATVIA

The reference price system is used in Latvia. The products are grouped into clusters:

- within the INN or
- within the pharmacotherapeutic group if there are no clinically relevant differences in the effectiveness and side-effects for the same indication and drugs are intended for the same patient group.

Products are clustered according to the pharmaceutical form, dosage and pack size. Then the reference product for each cluster is identified (the cheapest pharmaceutical) and on the basis of the price of the reference product the reimbursement price for each pharmaceutical in the cluster is calculated.

■ LITHUANIA

There have been a number of changes to the reference price system in Lithuania in the recent years. The system is based on both external and internal reference

pricing measures. Previously, maximum reimbursement prices, or reference prices, were set taking into account the lowest price on the Lithuanian market and ex-manufacturers' prices were negotiated taking into account prices in the neighbouring markets, including Latvia and Estonia. With effect from 2002, phased changes were introduced, to take into account the pricing of products relative to that in other EU states. In 2004, a temporary external reference pricing mechanism was based on a review of pricing in the then 15 EU member states (prior to the EU accession of Lithuania and other countries included in this report). This identified the lowest price in these states, to which 5% was added for Lithuanian pricing.

From 2005, six countries deemed to have similar per capita income to Lithuania: Latvia, Estonia, Poland, Czech Republic, Slovakia and Hungary are used to detect reference price level. Under the revised approach, the declared manufacturer price is compared with a level which is 95% of the average of that found in the reference countries. In cases where the product is not on the market in some of these countries, the average is taken from the markets in which it is present. In cases where the product is not on the market in any of the reference countries, the price of the product in the country of manufacture is used. From 2009 onwards, Romania and Bulgaria were added to the list of reference countries.

Both patent-protected and off-patent medicines are covered by the reference price system:

- **Patent-protected drugs:** the maximum reimbursement price (reference price) for each active ingredient is determined with a reference to the reference country/EU prices
- **Off-patent drugs:** the reference price is calculated taking into account the reference country/EU prices for the active ingredient, as well as the cheapest version of the drug available in Lithuania. In cases where the price of the cheapest version of the drug in Lithuania is above the level of 95% of the average seen in the reference countries, the price may be reduced to this level.

For the purposes of determining the reference price, products are grouped by the active ingredient, with separate clusters drawn up for the same route of administration and pharmaceutical form. Separate clusters are formed for modified release drugs and products for paediatric use. There are 445 clusters, corresponding to 1876 reimbursed pharmaceuticals, covered by the reference price system.

Given the nature of the system, patented products are at the moment protected from the impact of internal price referencing, which in effect results in reimbursement pricing at the level of the cheapest product in the group.

5. Materials and methods used for the Baltic Statistics on Medicines

5.1. Data collection in the Baltic states.

■ ESTONIA

Estonian State Agency of Medicines (SAM) is collecting and analysing drug utilization data in Estonia.

According to the Medicinal Product Act and Decree of the Minister of Social Affairs all wholesalers of medicinal products have to report their sales data quarterly to SAM. The reports include the following data for each product: package ID, ATC code, active substance(s), trade name, pharmaceutical form, strength, package size and the manufacturer. The sales data are presented in monetary value and by unit of volume (number of packages).

From these reports only the sale to end-consumers (retail and hospital pharmacies, nursing homes etc) are used for calculating the medicines consumption.

Estonian SAM has been collecting and analysing the data since 1994. Statistics on medicines are annually published at the Agency's website (www.ravimiamet.ee).

■ LATVIA

Statistical data regarding consumption of medicines in Latvia is collected and processed by the State Agency of Medicines (SAM). In accordance with the Pharmaceutical Law and Regulations of the Cabinet of Ministers all wholesalers of medicines submit their sales data (including data regarding parallel imported and parallel distributed medicines) for each month by uploading it to the Agency's database. The reports include the following data for each product: medicinal product identification code in accordance with medicinal product register; trade name; price per package; number of packages sold for the particular price and consumer group to which the product was sold.

Only data regarding sales of medicines to the final recipient (pharmacies, healthcare institutions, private practices) are used for calculating medicines consumption statistics. Latvian SAM has been collecting and analysing the data since 2001. The report on statistics on medicines consumption is annually published on the Agency's website (www.zva.gov.lv).

■ LITHUANIA

Lithuanian State Medicines Control Agency (SMCA) is responsible for collection and analysis of drug utilization data in Lithuania.

According to the Pharmaceutical Law and Order of the Head of State Medicines Control Agency all wholesalers of medicinal products have to report their sales data monthly to SMCA. The reports include the following data: a number of wholesaler's licence, package ID of medicinal product, and the number of packages sold. The sales data are presented in volume (number of packages).

From these reports only the sale to end-consumers are used to calculate the medicines consumption.

The Lithuanian SMCA has been collecting and analysing the data since 2009. Since 2010 statistics on medicines are annually published at the Agency's website (www.vvkt.lt).

5.2. ATC/DDD methodology and interpretation of drug sales statistics (www.whocc.no)

The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit have become the gold standard for international drug utilization research.

The purpose of the ATC/DDD system is to serve as a tool for drug utilization research in order to improve quality of drug use. One component of this is the presentation and comparison of the drug consumption statistics at international and national levels.

In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. The complete classification of metformin illustrates the structure of the code:

A	Alimentary tract and metabolism (1st level, anatomical main group)
A10	Drugs used in diabetes (2nd level, therapeutic subgroup)
A10B	Blood glucose lowering drugs, excl. insulins (3rd level, pharmacological subgroup)
A10BA	Biguanides (4th level, chemical subgroup)
A10BA02	metformin (5th level, chemical substance)

Thus, in the ATC system all plain metformin preparations are given the code A10BA02.

Medicinal products are classified according to the main therapeutic use of their main active ingredient, on the basic principle of assigning only one ATC code for each pharmaceutical formulation (i.e. similar ingredients, strength and pharmaceutical form). A medicinal product can be given more than one ATC code if it is available in two or more strengths or formulations with clearly different therapeutic uses.

The Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults.

A DDD will only be assigned for drugs that already have an ATC code. DDDs are not established for topical products (e.g. dermatologicals), sera, vaccines, antineoplastic agents, allergen extracts, general and local anaesthetics and contrast media.

It should be emphasised that the defined daily dose is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose (PDD). Doses for individual patients and patient groups will often differ from the DDD and will necessarily have to be based on individual characteristics (e.g. age and weight) and pharmacokinetic considerations.

Drug consumption data presented in DDDs only give a rough estimate of consumption and not an exact picture of actual use. The DDD provide a fixed unit of measurement independent of price and dosage form (e.g. tablet strength) enabling the researcher to assess trends in drug consumption and to perform comparisons between population groups.

Drug consumption figures are usually presented as numbers of DDDs/1000 inhabitants/day. Sales data presented in DDD/1000 inhabitants/day provides a rough estimate of the proportion of the population within a defined area treated daily with certain drugs. For example, the figure 10 DDDs/1000 inhabitants/day indicates that 1% of the population on average gets a certain treatment daily.

The use of a drug expressed as DDD/1000 population/day is derived by calculating the overall amount of a drug being used over a specified period of time (e.g. a year) and dividing this by the DDD multiplied by the population and the number of days in the period.

$$\text{DDD/1000 population/day} = \frac{\text{Amount used in 1 year} \times 1000}{\text{DDD} \times \text{population} \times 365(\text{days})}$$

Collecting and publishing drug utilization statistics are critical elements in the process of improving the prescription and dispensing of medicines. For drug utilization statistics to have the best possible impact on drug use, the statistics need to be used in a focused and active manner.

All figures presented in this publication are based on the ATC/DDD version valid from January 2013.

More detailed information can be found at www.whocc.no.

5.3. Factors affecting the interpretation of drug utilization data

Classification of the medicinal products in the Baltic States

The classification of medicinal products may vary between countries. Consequently, data on drug use in different countries may not be directly comparable in all of the drug classes. For example some products may be classified as food supplements or natural remedies in one country and as a medicine in another country. For this reason the ATC groups A11 (vitamins) and A12 (mineral supplements) have been excluded from this publication.


6. Cost of drugs as a share of total health care expenditure in the Baltic countries

6.1. Medicinal products market

■ ESTONIA

As shown below, the Estonian human medicines market plateaued during 2008–2010. In 2011 the human medicinal products market showed slight increase and in 2012 the market increased 8.5%, reaching 222 mln euros (excl. VAT).


Estonian medicinal products market in 2008–2012



■ LATVIA


After a 6% decrease in 2009 the total turnover of medicines in Latvia has increased each year and in 2012 it reached 260 million euros (excl. VAT).

Latvian medicinal products market in 2008–2012



■ LITHUANIA


In 2009 the human medicinal products market decreased 6.5% and in 2010 reached the 2008 level. In 2012 market increased 6.3 %, reaching 473 mln euros (excl VAT).



6.2. Sale of drugs according to the ATC main groups (DDD/1000 inhabitants/day)

Comparing the consumption of the ATC main groups using ATC/DDD methodology the group of cardiovascular drugs stands out as the most widely used one in all Baltic countries. The second most used group is alimentary tract and metabolism drugs in Estonia and Latvia but nervous system drugs in Lithuania. On average the consumption of the main groups is quite similar in all the countries with differences around 10–15 % from median to minimum and maximum consumption. The biggest differences occur in the consumption of nervous system drugs, genitourinary system and sex hormones and systemic hormonal preparations with 40–60% differences in median consumption and maximum consumption.


**Consumption of medicinal products in the Baltic countries in 2012
(defined daily doses 1000/inhabitants/day)**



6.3. Sale of drugs according to the ATC main groups (turnover)


■ ESTONIA

In 2012, 2392 different medicinal preparations and 1197 active substances were used in Estonia. Based on ATC classification, the antineoplastic and immunomodulating drugs had the greatest market share (19%), the cardiovascular drugs followed with 15% and the alimentary tract and metabolism medicines with 12%. Also anti-infectives for systemic use (11%) and nervous system medicines (10%) had significant market share. The other ATC groups covered one third of medicinal products market. In 2012 the turnover increased in all ATC groups.




■ **LATVIA**

2964 different medicines containing 1146 different active substances were distributed in Latvia in 2012. By comparing the turnover of medicines (EUR) according to the main ATC groups, the medicines intended for treatment of cardiovascular system diseases make up the largest part (19%) of the market of medicines in Latvia, followed by the medicines for treatment of alimentary tract and metabolic diseases (13%), antineoplastic medicines and immunomodulating agents (12%), medicines for treatment of nervous system diseases (11%) and anti-infectives for systemic use (10%). The other ATC groups covered about one third of medicinal products market 35%.



LITHUANIA

Lithuanian expenditure data is based on the NHIF database and depicts expenditure for medicines reimbursement and not wholesale turnover as the Estonian and Latvian data. OTC medicines and non-reimbursed medicines are not included on the figure.



7. Sales statistics 2010-2012

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A	ALIMENTARY TRACT AND METABOLISM				
	Estonia	90.93	96.06	107.31	12
	Latvia	95.84	102.91	107.81	5
	Lithuania	98.91	103.43	113.93	10
A01	STOMATOLOGICAL PREPARATIONS				
	Estonia	0.51	0.39	0.07	-82
	Latvia	7.32	7.80	6.50	-17
	Lithuania	-	-	-	
A01A	STOMATOLOGICAL PREPARATIONS				
	Estonia	0.51	0.39	0.07	-82
	Latvia	7.32	7.80	6.50	-17
	Lithuania	0.41	0.44	0.38	-14
A01AA	Caries prophylactic agents				
	Estonia	-	-	-	
	Latvia	7.10	7.58	6.33	-16
	Lithuania	-	-	-	
A01AA01	sodium fluoride				
	Estonia	-	-	-	
	Latvia	7.10	7.58	6.33	-16
	Lithuania	-	-	-	
A01AB	Antifectives and antiseptics for local oral treatment				
	Estonia	0.51	0.39	0.07	-82
	Latvia	0.23	0.23	0.17	-25
	Lithuania	0.32	0.07	0.07	
A01AB03	chlorhexidine				
	Estonia	0.44	0.31	-	
	Latvia	0.23	0.23	0.17	-25
	Lithuania	0.27	<0.01	-	
A01AB09	miconazole				
	Estonia	0.07	0.07	0.07	
	Latvia	-	-	-	
	Lithuania	0.06	0.06	0.07	17
A02	DRUGS FOR ACID RELATED DISORDERS				
	Estonia	24.53	27.16	31.43	16
	Latvia	25.02	26.47	29.02	10
	Lithuania	25.46	26.62	32.60	22
A02A	ANTACIDS				
	Estonia	0.87	0.87	0.95	9
	Latvia	0.71	0.73	0.77	5
	Lithuania	0.20	0.27	0.73	170
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds				
	Estonia	0.87	0.87	0.95	9
	Latvia	0.71	0.73	0.77	5
	Lithuania	0.20	0.26	0.72	177

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A02AD01	ordinary salt combinations				
	Estonia	0.87	0.87	0.95	9
	Latvia	0.71	0.73	0.77	5
	Lithuania	0.20	0.26	0.72	177
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)				
	Estonia	23.66	26.29	30.48	16
	Latvia	24.30	25.74	28.26	10
	Lithuania	25.26	26.35	31.87	21
A02BA	H2-receptor antagonists				
	Estonia	5.33	4.40	3.99	-9
	Latvia	4.24	4.06	3.58	-12
	Lithuania	9.46	9.09	10.16	12
A02BA02	ranitidine				
	Estonia	5.17	4.38	3.99	-9
	Latvia	4.12	3.96	3.50	-11
	Lithuania	9.28	8.90	9.97	12
A02BA03	famotidine				
	Estonia	0.16	0.02	-	
	Latvia	0.12	0.10	0.07	-27
	Lithuania	0.18	0.18	0.19	6
A02BC	Proton pump inhibitors				
	Estonia	18.32	21.89	26.49	21
	Latvia	19.87	21.59	24.57	14
	Lithuania	15.68	17.22	21.65	26
A02BC01	omeprazole				
	Estonia	14.32	16.35	18.73	15
	Latvia	16.47	17.62	18.76	6
	Lithuania	12.30	12.71	15.15	19
A02BC02	pantoprazole				
	Estonia	2.07	2.96	4.51	52
	Latvia	2.71	3.33	5.12	54
	Lithuania	1.82	3.18	5.04	58
A02BC03	lansoprazole				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.37	0.27	0.23	-17
	Lithuania	0.99	0.70	0.73	4
A02BC04	rabeprazole				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.03	50
A02BC05	esomeprazole				
	Estonia	1.93	2.58	3.26	26
	Latvia	0.31	0.36	0.47	28
	Lithuania	0.54	0.62	0.71	15

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)				
	Estonia	-	-	-	
	Latvia	0.20	0.08	0.11	28
	Lithuania	0.12	0.04	0.06	50
A02BX01	carbenoxolone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.04	0.06	50
A02BX02	sucralfate				
	Estonia	-	-	-	
	Latvia	0.18	0.07	0.09	31
	Lithuania	-	-	-	
A02BX05	bismuth subcitrate				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.02	19
	Lithuania	-	-	-	
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS				
	Estonia	4.56	4.73	5.22	10
	Latvia	10.46	10.05	10.06	
	Lithuania	6.96	7.18	7.70	7
A03A	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS				
	Estonia	3.68	3.78	4.25	12
	Latvia	5.13	5.19	5.25	1
	Lithuania	5.35	5.46	5.88	8

Consumption of drugs for acid related disorders (A02)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A03AA	Synthetic anticholinergics, esters with tertiary amino group				
	Estonia	0.44	0.53	0.63	19
	Latvia	0.16	0.16	0.17	6
	Lithuania	0.24	0.26	0.29	12
A03AA04	mebeverine				
	Estonia	0.44	0.53	0.63	19
	Latvia	0.15	0.16	0.17	7
	Lithuania	0.24	0.26	0.29	12
A03AA07	dicycloverine				
	Estonia	-	-	-	
	Latvia	0.01	0.01	<0.01	
	Lithuania	-	-	-	
A03AD	Papaverine and derivatives				
	Estonia	3.23	3.25	3.61	11
	Latvia	4.34	4.33	4.41	2
	Lithuania	4.48	4.61	4.95	7
A03AD02	drotaverine				
	Estonia	3.23	3.25	3.61	11
	Latvia	4.34	4.33	4.41	2
	Lithuania	4.48	4.61	4.95	7
A03AX	Other drugs for functional gastrointestinal disorders				
	Estonia	-	-	-	
	Latvia	0.63	0.70	0.67	-4
	Lithuania	0.64	0.59	0.64	8
A03AX13	silicones				
	Estonia	-	-	-	
	Latvia	0.63	0.70	0.67	-4
	Lithuania	0.64	0.59	0.64	8
A03B	BELLADONNA AND DERIVATIVES, PLAIN				
	Estonia	0.12	0.12	0.11	-8
	Latvia	3.66	3.23	3.23	
	Lithuania	0.05	0.06	0.06	
A03BA	Belladonna alkaloids, tertiary amines				
	Estonia	0.10	0.10	0.09	-10
	Latvia	3.64	3.22	3.22	
	Lithuania	0.05	0.06	0.06	
A03BA01	atropine				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.05	0.06	0.05	-3
	Lithuania	0.05	0.06	0.06	
A03BA04	belladonna total alkaloids				
	Estonia	-	-	-	
	Latvia	3.59	3.16	3.16	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A03BB	Belladonna alkaloids, semisynthetic, quaternary ammonium compounds				
	Estonia	0.02	0.03	0.02	-33
	Latvia	0.01	0.02	0.02	
	Lithuania	-	-	-	
A03BB01	butylscopolamine				
	Estonia	0.02	0.03	0.02	-33
	Latvia	0.01	0.02	0.02	
	Lithuania	-	-	-	
A03F	PROPULSIVES				
	Estonia	0.76	0.83	0.87	5
	Latvia	1.67	1.62	1.57	-3
	Lithuania	1.57	1.67	1.77	6
A03FA	Propulsives				
	Estonia	0.76	0.83	0.87	5
	Latvia	1.67	1.62	1.57	-3
	Lithuania	1.57	1.67	1.77	6
A03FA01	metoclopramide				
	Estonia	0.75	0.81	0.84	4
	Latvia	1.41	1.33	1.22	-9
	Lithuania	1.29	1.26	1.33	6
A03FA03	domperidone				
	Estonia	0.01	0.01	0.02	100
	Latvia	0.26	0.29	0.36	23
	Lithuania	0.28	0.41	0.43	5
A04	ANTIEMETICS AND ANTINAUSEANTS				
	Estonia	0.12	0.10	0.11	10
	Latvia	0.03	0.04	0.05	16
	Lithuania	0.09	0.10	0.10	
A04A	ANTIEMETICS AND ANTINAUSEANTS				
	Estonia	0.12	0.10	0.11	10
	Latvia	0.03	0.04	0.05	16
	Lithuania	0.09	0.10	0.10	
A04AA	Serotonin (5HT3) antagonists				
	Estonia	0.11	0.09	0.10	11
	Latvia	0.03	0.04	0.05	17
	Lithuania	0.09	0.10	0.10	
A04AA01	ondansetron				
	Estonia	0.03	0.03	0.04	33
	Latvia	0.02	0.03	0.04	36
	Lithuania	0.09	0.10	0.10	
A04AA02	granisetron				
	Estonia	0.08	0.06	0.06	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A04AA05	palonosetron				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	-11
	Lithuania	-	-	<0.01	
A04AD	Other antiemetics				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A04AD12	aprepitant				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A05	BILE AND LIVER THERAPY				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.19	
A05A	BILE THERAPY				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.19	
A05AA	Bile acid preparations				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.24	26
A05AA02	ursodeoxycholic acid				
	Estonia	0.35	0.35	0.41	17
	Latvia	0.18	0.19	0.22	13
	Lithuania	0.15	0.19	0.24	26
A06	DRUGS FOR CONSTIPATION				
	Estonia	10.82	11.38	12.44	9
	Latvia	7.91	8.14	8.34	2
	Lithuania	7.14	7.85	8.44	8
A06A	DRUGS FOR CONSTIPATION				
	Estonia	10.82	11.38	12.44	9
	Latvia	7.91	8.14	8.34	2
	Lithuania	7.14	7.85	8.44	8
A06AB	Contact laxatives				
	Estonia	6.01	6.09	6.33	4
	Latvia	6.22	6.25	6.51	4
	Lithuania	4.49	4.79	5.02	5
A06AB02	bisacodyl				
	Estonia	3.60	3.55	3.52	-1
	Latvia	2.78	2.78	2.72	-2
	Lithuania	2.61	2.71	2.78	3
A06AB05	castor oil				
	Estonia	0.02	0.01	0.01	
	Latvia	0.07	0.06	0.06	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A06AB06	senna glycosides				
	Estonia	0.06	0.05	0.05	
	Latvia	1.56	1.47	1.74	19
	Lithuania	-	-	-	
A06AB08	sodium picosulfate				
	Estonia	2.33	2.48	2.75	11
	Latvia	1.81	1.93	1.99	3
	Lithuania	1.88	2.08	2.24	8
A06AC	Bulk-forming laxatives				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.05	66
	Lithuania	0.06	0.07	0.07	
A06AC01	ispaghula (psylla seeds)				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.05	66
	Lithuania	0.06	0.07	0.07	
A06AD	Osmotically acting laxatives				
	Estonia	4.45	4.86	5.55	14
	Latvia	1.67	1.86	1.78	-5
	Lithuania	2.35	2.71	3.01	11
A06AD11	lactulose				
	Estonia	4.37	4.77	5.44	14
	Latvia	1.58	1.75	1.64	-6
	Lithuania	1.91	2.15	2.42	13
A06AD15	macrogol				
	Estonia	0.08	0.08	0.11	38
	Latvia	0.09	0.12	0.14	19
	Lithuania	0.44	0.56	0.59	5
A06AG	Enemas				
	Estonia	0.35	0.43	0.56	30
	Latvia	-	-	-	
	Lithuania	0.24	0.28	0.35	25
A06AG11	laurilsulfate, incl. combinations				
	Estonia	0.35	0.43	0.56	30
	Latvia	-	-	-	
	Lithuania	0.24	0.28	0.35	25
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS				
	Estonia	2.91	2.98	3.26	9
	Latvia	2.17	2.43	3.03	24
	Lithuania	2.63	2.94	3.08	5
A07A	INTESTINAL ANTIINFECTIVES				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.12	0.12	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A07AA	Antibiotics				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.12	0.12	
A07AA02	nystatin				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.12	0.12	
A07B	INTESTINAL ADSORBENTS				
	Estonia	0.38	0.38	0.41	8
	Latvia	0.61	0.58	0.69	18
	Lithuania	0.97	1.08	1.05	-3
A07BA	Charcoal preparations				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.06	0.01	0.01	
A07BA01	medicinal charcoal				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.06	0.01	0.01	
A07BC	Other intestinal adsorbents				
	Estonia	0.38	0.38	0.41	8
	Latvia	0.60	0.58	0.69	18
	Lithuania	0.91	1.07	1.03	-4
A07BC05	diosmectite				
	Estonia	0.38	0.38	0.41	8
	Latvia	0.60	0.58	0.69	18
	Lithuania	0.91	1.07	1.03	-4
A07D	ANTIPROPULSIVES				
	Estonia	0.70	0.74	0.81	9
	Latvia	0.88	0.88	0.91	4
	Lithuania	0.85	0.96	0.98	2
A07DA	Antipropulsives				
	Estonia	0.70	0.74	0.81	9
	Latvia	0.88	0.88	0.91	4
	Lithuania	0.85	0.96	0.98	2
A07DA03	loperamide				
	Estonia	0.70	0.74	0.81	9
	Latvia	0.88	0.88	0.91	4
	Lithuania	0.85	0.96	0.98	2
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS				
	Estonia	1.52	1.54	1.66	8
	Latvia	0.50	0.73	0.93	27
	Lithuania	0.61	0.67	0.79	18


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A07EA	Corticosteroids acting locally				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
A07EA06	budesonide				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
A07EC	Aminosalicylic acid and similar agents				
	Estonia	1.52	1.54	1.66	8
	Latvia	0.50	0.73	0.93	27
	Lithuania	0.60	0.67	0.78	16
A07EC01	sulfasalazine				
	Estonia	0.95	0.91	0.92	1
	Latvia	0.33	0.51	0.70	37
	Lithuania	0.25	0.26	0.28	8
A07EC02	mesalazine				
	Estonia	0.57	0.63	0.74	17
	Latvia	0.17	0.22	0.23	5
	Lithuania	0.36	0.41	0.50	22
A07F	ANTIDIARRHEAL MICROORGANISMS				
	Estonia	0.31	0.32	0.38	19
	Latvia	0.17	0.24	0.49	105
	Lithuania	0.09	0.11	0.15	36
A07FA	Antidiarrheal microorganisms				
	Estonia	0.31	0.32	0.38	19
	Latvia	0.17	0.24	0.49	105
	Lithuania	0.09	0.11	0.15	36
A07FA02	saccharomyces boulardii				
	Estonia	0.31	0.32	0.38	19
	Latvia	0.17	0.19	0.22	18
	Lithuania	0.09	0.11	0.15	36
A07FA07	lactic acid producing organisms				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.08	0.04	0.04	10
	Lithuania	0.08	0.02	0.01	-50
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.08	0.04	0.04	10
	Lithuania	0.08	0.02	0.01	-50

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A08AA	Centrally acting antiobesity products				
	Estonia	<0.01	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
A08AA10	sibutramine				
	Estonia	<0.01	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
A08AB	Peripherally acting antiobesity products				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.06	0.04	0.04	10
	Lithuania	0.05	0.02	0.01	-50
A08AB01	orlistat				
	Estonia	0.22	0.11	0.04	-64
	Latvia	0.06	0.04	0.04	10
	Lithuania	0.05	0.02	0.01	-50
A09	DIGESTIVES, INCL. ENZYMES				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
A09A	DIGESTIVES, INCL. ENZYMES				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
A09AA	Enzyme preparations				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
A09AA02	multienzymes (lipase, protease etc.)				
	Estonia	1.27	1.27	1.31	3
	Latvia	3.80	4.45	4.44	
	Lithuania	-	-	-	
A10	DRUGS USED IN DIABETES				
	Estonia	45.23	47.15	52.57	11
	Latvia	36.21	40.37	42.91	6
	Lithuania	30.11	32.37	36.96	14
A10A	INSULINS AND ANALOGUES				
	Estonia	13.81	13.89	15.12	9
	Latvia	10.34	10.49	11.05	5
	Lithuania	9.75	10.05	11.38	13
A10AB	Insulins and analogues for injection, fast-acting				
	Estonia	4.93	5.13	5.67	11
	Latvia	4.07	4.14	4.33	4
	Lithuania	2.67	2.33	2.84	22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A10AB01	insulin (human)				
	Estonia	0.08	0.07	0.06	-14
	Latvia	0.15	0.13	0.12	-7
	Lithuania	0.08	0.07	0.07	
A10AB04	insulin lispro				
	Estonia	1.19	1.22	1.26	3
	Latvia	0.85	0.83	0.90	8
	Lithuania	1.09	0.68	0.72	6
A10AB05	insulin aspart				
	Estonia	3.16	3.28	3.73	14
	Latvia	2.05	2.13	2.26	6
	Lithuania	1.04	1.03	1.37	33
A10AB06	insulin glulisine				
	Estonia	0.50	0.56	0.62	11
	Latvia	1.02	1.05	1.05	
	Lithuania	0.46	0.55	0.68	24
A10AC	Insulins and analogues for injection, intermediate-acting				
	Estonia	0.62	0.27	0.24	-11
	Latvia	1.52	1.55	1.77	14
	Lithuania	0.56	0.45	0.52	16
A10AC01	insulin (human)				
	Estonia	0.62	0.27	0.24	-11
	Latvia	1.52	1.55	1.77	14
	Lithuania	0.28	0.13	0.10	-23
A10AC04	insulin lispro				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.28	0.32	0.42	31
A10AD	Insulins and analogues for injection, intermediate-acting combined with fast-acting				
	Estonia	2.27	2.07	2.04	-1
	Latvia	2.44	2.39	2.51	5
	Lithuania	4.95	5.42	5.76	6
A10AD04	insulin lispro				
	Estonia	0.78	0.72	0.72	
	Latvia	0.91	0.93	1.07	15
	Lithuania	1.68	2.03	2.23	10
A10AD05	insulin aspart				
	Estonia	1.49	1.35	1.32	-2
	Latvia	1.52	1.46	1.44	-1
	Lithuania	3.28	3.39	3.53	4
A10AE	Insulins and analogues for injection, long-acting				
	Estonia	5.99	6.43	7.17	12
	Latvia	2.32	2.41	2.45	2
	Lithuania	1.57	1.85	2.25	22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A10AE04	insulin glargine				
	Estonia	3.35	3.37	3.79	12
	Latvia	1.31	1.39	1.40	1
	Lithuania	0.91	1.12	1.38	23
A10AE05	insulin detemir				
	Estonia	2.63	3.05	3.38	11
	Latvia	1.00	1.02	1.05	3
	Lithuania	0.65	0.73	0.87	19
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS				
	Estonia	31.43	33.25	37.44	13
	Latvia	25.87	29.87	31.86	7
	Lithuania	20.36	22.32	25.58	15
A10BA	Biguanides				
	Estonia	15.06	15.75	17.57	12
	Latvia	11.49	12.43	13.22	6
	Lithuania	9.16	10.50	12.51	19
A10BA02	metformin				
	Estonia	15.06	15.75	17.57	12
	Latvia	11.49	12.43	13.22	6
	Lithuania	9.16	10.50	12.51	19
A10BB	Sulfonamides, urea derivatives				
	Estonia	14.79	15.46	16.90	9
	Latvia	11.82	13.94	14.39	3
	Lithuania	10.50	11.09	12.35	11
A10BB07	glipizide				
	Estonia	0.69	0.59	0.51	-14
	Latvia	0.77	0.71	0.65	-8
	Lithuania	0.74	0.80	0.87	9


Consumption of insulins (A10A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A10BB08	gliquidone				
	Estonia	-	-	-	
	Latvia	0.21	0.24	0.26	10
	Lithuania	0.09	0.08	0.09	13
A10BB09	gliclazide				
	Estonia	8.59	8.37	9.33	11
	Latvia	4.97	7.17	7.72	8
	Lithuania	5.99	6.72	7.91	18
A10BB12	glimepiride				
	Estonia	5.51	6.50	7.07	9
	Latvia	5.87	5.82	5.76	-1
	Lithuania	3.68	3.49	3.49	
A10BD	Combinations of oral blood glucose lowering drugs				
	Estonia	0.20	0.55	1.02	85
	Latvia	1.79	2.31	2.79	21
	Lithuania	-	-	0.21	
A10BD03	metformin and rosiglitazone				
	Estonia	0.12	-	-	
	Latvia	0.88	<0.01	<0.01	
	Lithuania	-	-	-	
A10BD04	glimepiride and rosiglitazone				
	Estonia	-	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	-	-	-	
A10BD05	metformin and pioglitazone				
	Estonia	-	-	-	
	Latvia	0.89	1.56	1.32	-16
	Lithuania	-	-	0.17	
A10BD07	metformin and sitagliptin				
	Estonia	0.07	0.55	1.02	85
	Latvia	<0.01	0.75	1.33	77
	Lithuania	-	-	0.04	
A10BD08	metformin and vildagliptin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.15	
	Lithuania	-	-	-	
A10BG	Thiazolidinediones				
	Estonia	0.34	0.28	0.24	-14
	Latvia	0.57	0.60	0.51	-14
	Lithuania	0.61	0.48	0.38	-21
A10BG02	rosiglitazone				
	Estonia	0.05	-	-	
	Latvia	0.04	<0.01	<0.01	
	Lithuania	0.09	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A10BG03	pioglitazone				
	Estonia	0.29	0.28	0.24	-14
	Latvia	0.53	0.60	0.51	-14
	Lithuania	0.52	0.48	0.38	-21
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors				
	Estonia	1.04	1.21	1.54	27
	Latvia	0.01	0.39	0.75	94
	Lithuania	-	-	0.72	
A10BH01	sitagliptin				
	Estonia	1.04	1.21	1.48	22
	Latvia	0.01	0.30	0.49	61
	Lithuania	-	-	0.72	
A10BH03	saxagliptin				
	Estonia	-	-	-	
	Latvia	<0.01	0.08	0.15	81
	Lithuania	-	-	-	
A10BH05	linagliptin				
	Estonia	-	-	0.06	
	Latvia	<0.01	<0.01	0.11	
	Lithuania	-	-	-	
A10BX	Other blood glucose lowering drugs, excl. insulins				
	Estonia	0.01	<0.01	0.18	
	Latvia	0.20	0.21	0.19	-8
	Lithuania	0.09	0.26	0.34	31
A10BX02	repaglinide				
	Estonia	0.01	<0.01	-	
	Latvia	0.20	0.21	0.19	-9
	Lithuania	0.08	0.06	0.05	-17
A10BX04	exenatide				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.20	0.29	45
A10BX07	liraglutide				
	Estonia	-	-	0.18	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A14	ANABOLIC AGENTS FOR SYSTEMIC USE				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	
A14A	ANABOLIC STEROIDS				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	

Consumption of blood glucose lowering drugs excl. insulins (A10B)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A14AB	Estren derivatives				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	
A14AB01	nandrolone				
	Estonia	0.02	0.01	0.01	
	Latvia	0.13	0.13	0.12	-12
	Lithuania	0.09	0.09	0.09	
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS				
	Estonia	0.39	0.43	0.45	5
	Latvia	2.53	2.80	3.09	10
	Lithuania	0.30	0.33	0.38	15
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS				
	Estonia	0.39	0.43	0.45	5
	Latvia	2.53	2.80	3.09	10
	Lithuania	0.30	0.33	0.38	15
A16AA	Amino acids and derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AA01	levocarnitine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AA06	betaine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
A16AB	Enzymes				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.03	
	Lithuania	-	-	-	
A16AB05	laronidase				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.03	
	Lithuania	-	-	-	
A16AX	Various alimentary tract and metabolism products				
	Estonia	0.38	0.42	0.45	7
	Latvia	2.53	2.80	3.06	9
	Lithuania	0.30	0.33	0.37	12
A16AX01	thioctic acid				
	Estonia	0.38	0.42	0.44	5
	Latvia	2.53	2.80	3.06	9
	Lithuania	0.30	0.33	0.37	12
A16AX05	zinc acetate				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
B	BLOOD AND BLOOD FORMING ORGANS				
	Estonia	67.53	74.52	90.43	21
	Latvia	66.34	78.47	82.91	6
	Lithuania	53.81	59.06	69.13	17
B01	ANTITHROMBOTIC AGENTS				
	Estonia	59.09	64.88	78.83	22
	Latvia	59.40	70.52	74.04	5
	Lithuania	48.96	53.57	63.49	19
B01A	ANTITHROMBOTIC AGENTS				
	Estonia	59.09	64.88	78.83	22
	Latvia	59.40	70.52	74.04	5
	Lithuania	48.96	53.57	63.49	19
B01AA	Vitamin K antagonists				
	Estonia	5.36	5.94	7.15	20
	Latvia	3.12	3.49	4.00	15
	Lithuania	6.23	6.91	8.11	17
B01AA03	warfarin				
	Estonia	5.36	5.94	7.15	20
	Latvia	3.12	3.49	4.00	15
	Lithuania	6.20	6.87	8.09	18
B01AA07	acenocoumarol				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.04	0.02	-50
B01AB	Heparin group				
	Estonia	2.04	1.78	2.03	14
	Latvia	1.41	1.29	1.56	21
	Lithuania	3.73	2.05	1.69	-18
B01AB01	heparin				
	Estonia	0.12	0.10	0.09	-10
	Latvia	0.39	0.23	0.23	
	Lithuania	2.63	0.38	0.34	-11
B01AB04	dalteparin				
	Estonia	0.04	0.05	0.07	40
	Latvia	0.19	0.24	0.46	94
	Lithuania	0.48	0.76	0.38	-50
B01AB05	enoxaparin				
	Estonia	1.63	1.38	1.58	14
	Latvia	0.50	0.46	0.45	-2
	Lithuania	0.18	0.35	0.28	-20
B01AB06	nadroparin				
	Estonia	0.11	0.06	0.07	17
	Latvia	0.29	0.33	0.39	21
	Lithuania	0.32	0.36	0.47	31

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
B01AB12	bemiparin				
	Estonia	0.14	0.19	0.23	21
	Latvia	0.04	0.04	0.04	-2
	Lithuania	0.12	0.19	0.22	16
B01AC	Platelet aggregation inhibitors excl. heparin				
	Estonia	51.61	56.96	69.16	21
	Latvia	54.82	65.69	68.36	4
	Lithuania	38.96	44.51	53.59	20
B01AC04	clopidogrel				
	Estonia	2.04	3.01	3.95	31
	Latvia	2.24	2.91	2.96	2
	Lithuania	3.72	4.52	6.04	34
B01AC06	acetylsalicylic acid				
	Estonia	9.91	11.53	13.87	20
	Latvia	52.57	62.52	64.61	3
	Lithuania	35.24	39.98	47.53	19
B01AC22	prasugrel				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AC24	ticagrelor				
	Estonia	-	0.01	0.26	
	Latvia	<0.01	<0.01	0.02	
	Lithuania	-	0.01	0.03	200
B01AC30	combinations				
	Estonia	39.66	42.41	53.39	
	Latvia	<0.01	0.25	0.77	201
	Lithuania	-	-	-	
B01AE	Direct thrombin inhibitors				
	Estonia	0.06	0.13	0.27	108
	Latvia	0.03	0.04	0.10	142
	Lithuania	0.01	0.01	0.04	300
B01AE07	dabigatran etexilate				
	Estonia	0.06	0.13	0.27	108
	Latvia	0.03	0.04	0.10	142
	Lithuania	0.01	0.01	0.04	300
B01AF	Direct factor Xa inhibitors				
	Estonia	<0.01	0.04	0.18	350
	Latvia	-	-	-	
	Lithuania	-	-	0.05	
B01AF01	rivaroxaban				
	Estonia	<0.01	0.04	0.18	350
	Latvia	-	-	-	
	Lithuania	-	-	0.05	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
B01AX	Other antithrombotic agents				
	Estonia	0.03	0.03	0.03	
	Latvia	0.02	0.02	0.01	-13
	Lithuania	<0.01	<0.01	<0.01	
B01AX05	fondaparinux				
	Estonia	0.03	0.03	0.03	
	Latvia	0.02	0.02	0.01	-13
	Lithuania	<0.01	<0.01	<0.01	
B02	ANTIHEMORRHAGICS				
	Estonia	0.17	0.17	0.19	12
	Latvia	0.03	0.04	0.03	-29
	Lithuania	0.04	0.05	0.07	40
B02A	ANTIFIBRINOLYTICS				
	Estonia	0.07	0.08	0.09	13
	Latvia	0.01	0.01	0.01	24
	Lithuania	-	-	-	
B02AA	Amino acids				
	Estonia	0.07	0.08	0.09	13
	Latvia	0.01	0.01	0.01	24
	Lithuania	-	-	-	
B02AA01	aminocaproic acid				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
B02AA02	tranexamic acid				
	Estonia	0.07	0.08	0.09	13
	Latvia	0.01	0.01	0.01	24
	Lithuania	-	-	-	

Consumption of antithrombotic agents (B01A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
B02B	VITAMIN K AND OTHER HEMOSTATICS				
	Estonia	0.10	0.08	0.10	25
	Latvia	0.02	0.03	0.02	-48
	Lithuania	0.04	0.05	0.07	40
B02BA	Vitamin K				
	Estonia	0.10	0.07	0.07	
	Latvia	0.01	0.01	0.01	
	Lithuania	0.03	0.03	0.03	
B02BA01	phytomenadione				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.01	
	Lithuania	0.03	0.03	0.03	
B02BA02	menadione				
	Estonia	0.09	0.07	0.07	
	Latvia	-	-	-	
	Lithuania	-	-	-	
B02BD	Blood coagulation factors				
	Estonia	0.01	0.01	0.02	100
	Latvia	0.02	0.02	0.01	-67
	Lithuania	0.01	0.01	0.03	200
B02BD02	coagulation factor VIII				
	Estonia	0.01	0.01	0.02	100
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	0.01	0.03	200
B02BD03	factor VIII inhibitor bypassing activity				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.02	<0.01	
	Lithuania	-	-	-	
B02BD04	coagulation factor IX				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
B03	ANTIANEMIC PREPARATIONS				
	Estonia	8.26	9.47	11.42	21
	Latvia	6.90	7.91	8.84	12
	Lithuania	4.81	5.44	5.53	2
B03A	IRON PREPARATIONS				
	Estonia	1.97	2.11	2.40	14
	Latvia	4.06	4.67	5.57	19
	Lithuania	2.64	2.84	3.23	14
B03AA	Iron bivalent, oral preparations				
	Estonia	1.97	2.03	2.23	10
	Latvia	0.32	0.04	<0.01	
	Lithuania	1.28	1.44	1.63	13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
B03AA05	ferrous chloride				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.03	0.03	
B03AA07	ferrous sulfate				
	Estonia	1.97	2.03	2.23	10
	Latvia	0.32	0.04	<0.01	
	Lithuania	1.25	1.42	1.61	13
B03AB	Iron trivalent, oral preparations				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.67	2.01	2.38	18
	Lithuania	0.36	0.34	0.36	6
B03AB05	ferric oxide polymaltose complexes				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.67	2.01	2.38	18
	Lithuania	0.36	0.34	0.36	6
B03AC	Iron trivalent, parenteral preparations				
	Estonia	-	-	-	
	Latvia	0.06	0.07	0.08	10
	Lithuania	-	-	-	
B03AC02	saccharated iron oxide				
	Estonia	-	-	-	
	Latvia	0.02	0.01	0.02	132
	Lithuania	-	-	-	
B03AC06	ferric oxide dextran complexes				
	Estonia	-	-	-	
	Latvia	0.04	0.06	0.05	-11
	Lithuania	-	-	-	
B03AD	Iron in combination with folic acid				
	Estonia	-	0.07	0.18	157
	Latvia	2.01	2.55	3.11	22
	Lithuania	0.15	0.18	0.18	
B03AD02	ferrous fumarate				
	Estonia	-	0.07	0.18	157
	Latvia	2.01	2.55	3.11	22
	Lithuania	0.15	0.18	0.18	
B03B	VITAMIN B12 AND FOLIC ACID				
	Estonia	5.79	6.84	8.51	24
	Latvia	2.09	2.40	2.37	-1
	Lithuania	1.65	1.91	1.50	-21
B03BA	Vitamin B12 (cyanocobalamin and analogues)				
	Estonia	4.07	3.95	4.82	22
	Latvia	2.09	2.40	2.37	-1
	Lithuania	1.65	1.91	1.50	-21


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
B03BA01	cyanocobalamin				
	Estonia	4.07	3.94	4.81	22
	Latvia	2.09	2.40	2.37	-1
	Lithuania	1.65	1.91	1.50	-21
B03BA03	hydroxocobalamin				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
B03BB	Folic acid and derivatives				
	Estonia	1.72	2.89	3.69	28
	Latvia	-	-	-	
	Lithuania	-	-	-	
B03BB01	folic acid				
	Estonia	1.72	2.89	3.69	28
	Latvia	-	-	-	
	Lithuania	-	-	-	
B03X	OTHER ANTIANEMIC PREPARATIONS				
	Estonia	0.50	0.52	0.50	-4
	Latvia	0.75	0.83	0.90	8
	Lithuania	0.52	0.70	0.80	14
B03XA	Other antianemic preparations				
	Estonia	0.50	0.52	0.50	-4
	Latvia	0.75	0.83	0.90	8
	Lithuania	0.52	0.70	0.80	14
B03XA01	erythropoietin				
	Estonia	0.14	0.10	0.09	-10
	Latvia	0.08	0.09	0.10	8
	Lithuania	0.16	0.16	0.20	25
B03XA02	darbepoetin alfa				
	Estonia	0.21	0.26	0.31	19
	Latvia	0.36	0.45	0.59	32
	Lithuania	0.36	0.54	0.60	11
B03XA03	methoxy polyethylene glycol-epoetin beta				
	Estonia	0.15	0.16	0.09	-44
	Latvia	0.31	0.30	0.22	-27
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C	CARDIOVASCULAR SYSTEM				
	Estonia	349.60	355.75	394.88	11
	Latvia	285.27	313.37	349.10	11
	Lithuania	357.62	373.14	425.45	14
C01	CARDIAC THERAPY				
	Estonia	33.73	33.01	34.27	4
	Latvia	24.63	25.44	27.06	6
	Lithuania	40.10	40.30	49.82	24
C01A	CARDIAC GLYCOSIDES				
	Estonia	6.04	5.35	5.20	-3
	Latvia	4.91	4.68	4.61	-2
	Lithuania	4.15	3.90	4.20	8
C01AA	Digitalis glycosides				
	Estonia	6.04	5.35	5.20	-3
	Latvia	4.91	4.68	4.61	-2
	Lithuania	4.15	3.90	4.20	8
C01AA05	digoxin				
	Estonia	6.04	5.35	5.20	-3
	Latvia	4.91	4.68	4.61	-2
	Lithuania	4.15	3.90	4.20	8
C01B	ANTIARRHYTHMICS, CLASS I AND III				
	Estonia	4.56	4.92	5.61	14
	Latvia	2.33	2.35	2.38	1
	Lithuania	5.55	2.80	6.29	125
C01BC	Antiarrhythmics, class Ic				
	Estonia	1.95	2.28	2.80	23
	Latvia	0.29	0.38	0.43	12
	Lithuania	1.41	1.63	1.95	20
C01BC03	propafenone				
	Estonia	1.93	2.26	2.77	23
	Latvia	0.29	0.38	0.43	12
	Lithuania	1.41	1.63	1.95	20
C01BC04	flecainide				
	Estonia	0.03	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
C01BD	Antiarrhythmics, class III				
	Estonia	2.60	2.64	2.81	6
	Latvia	2.04	1.97	1.95	-1
	Lithuania	4.15	1.20	4.36	263
C01BD01	amiodarone				
	Estonia	2.59	2.62	2.78	6
	Latvia	2.04	1.97	1.95	-1
	Lithuania	4.14	1.18	4.34	268

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C01BD07	dronedarone				
	Estonia	0.01	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.02	0.02	
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES				
	Estonia	0.86	0.85	0.82	-4
	Latvia	0.34	0.35	0.32	-10
	Lithuania	0.74	0.80	0.86	8
C01CA	Adrenergic and dopaminergic agents				
	Estonia	0.86	0.85	0.82	-4
	Latvia	0.34	0.35	0.32	-10
	Lithuania	0.74	0.8	0.85	6
C01CA03	norepinephrine				
	Estonia	0.10	0.12	0.11	-8
	Latvia	-	-	-	
	Lithuania	-	-	-	
C01CA04	dopamine				
	Estonia	0.02	0.02	0.02	
	Latvia	0.01	0.01	<0.01	
	Lithuania	0.02	0.02	0.03	50
C01CA06	phenylephrine				
	Estonia	0.14	0.13	0.13	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C01CA07	dobutamine				
	Estonia	0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01CA24	epinephrine				
	Estonia	0.57	0.55	0.53	-4
	Latvia	0.32	0.34	0.32	-8
	Lithuania	0.72	0.78	0.83	6
C01CA26	ephedrine				
	Estonia	0.03	0.03	0.03	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C01D	VASODILATORS USED IN CARDIAC DISEASES				
	Estonia	12.58	11.30	11.23	-1
	Latvia	10.51	10.07	9.33	-7
	Lithuania	12.69	12.79	13.26	4
C01DA	Organic nitrates				
	Estonia	12.58	11.30	11.23	-1
	Latvia	10.51	10.07	9.33	-7
	Lithuania	12.69	12.79	13.26	4

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C01DA02	glyceryl trinitrate				
	Estonia	0.63	0.61	0.61	
	Latvia	0.82	0.95	0.87	-8
	Lithuania	3.95	3.97	3.73	-6
C01DA08	isosorbide dinitrate				
	Estonia	0.82	0.68	0.67	-1
	Latvia	1.15	0.81	0.51	-37
	Lithuania	1.49	1.42	1.47	4
C01DA14	isosorbide mononitrate				
	Estonia	11.12	10.01	9.95	-1
	Latvia	8.54	8.31	7.95	-4
	Lithuania	7.24	7.40	8.05	9
C01E	OTHER CARDIAC PREPARATIONS				
	Estonia	9.69	10.58	11.41	8
	Latvia	6.54	7.98	10.43	31
	Lithuania	16.97	20.01	25.23	26
C01EA	Prostaglandins				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01EA01	alprostadil				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01EB	Other cardiac preparations				
	Estonia	9.69	10.58	11.41	8
	Latvia	6.54	7.98	10.43	31
	Lithuania	16.97	20.01	25.23	26
C01EB10	adenosine				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
C01EB15	trimetazidine				
	Estonia	9.64	10.53	11.33	8
	Latvia	6.22	7.38	9.49	29
	Lithuania	16.44	19.23	22.92	19
C01EB17	ivabradine				
	Estonia	0.05	0.04	0.05	25
	Latvia	0.32	0.60	0.94	57
	Lithuania	0.54	0.79	2.30	191
C01EB18	ranolazine				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	<0.01	0.01	

Consumption of drugs for cardiac therapy (C01)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C02	ANTIHYPERTENSIVES				
	Estonia	3.42	3.43	3.77	10
	Latvia	6.12	6.91	7.73	12
	Lithuania	20.17	21.92	25.65	17
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING				
	Estonia	1.83	1.88	2.16	15
	Latvia	3.76	4.61	5.49	19
	Lithuania	12.97	14.21	17.25	21
C02AB	Methyldopa				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.07	23
	Lithuania	0.06	0.06	0.07	17
C02AB01	methyldopa (levorotatory)				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.07	23
	Lithuania	0.06	0.06	0.07	17
C02AC	Imidazoline receptor agonists				
	Estonia	1.83	1.88	2.16	15
	Latvia	3.71	4.55	5.42	19
	Lithuania	12.91	14.15	17.18	21
C02AC01	clonidine				
	Estonia	0.09	0.08	0.07	-13
	Latvia	1.11	1.16	1.23	6
	Lithuania	-	-	-	
C02AC05	moxonidine				
	Estonia	1.74	1.80	2.09	16
	Latvia	2.59	3.38	4.19	24
	Lithuania	12.91	14.15	17.18	21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING				
	Estonia	1.58	1.55	1.60	3
	Latvia	2.36	2.30	2.24	-3
	Lithuania	7.20	7.70	8.40	9
C02CA	Alpha-adrenoreceptor antagonists				
	Estonia	1.58	1.55	1.60	3
	Latvia	2.36	2.30	2.24	-3
	Lithuania	7.20	7.70	8.40	9
C02CA04	doxazosin				
	Estonia	1.58	1.55	1.60	3
	Latvia	2.36	2.30	2.24	-3
	Lithuania	7.20	7.70	8.40	9
C02D	ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C02DD	Nitroferricyanide derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C02DD01	nitroprusside				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C02K	OTHER ANTIHYPERTENSIVES				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
C02KX	Other antihypertensives				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
C02KX01	bosentan				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
C03	DIURETICS				
	Estonia	21.68	21.15	22.67	7
	Latvia	18.22	17.91	18.63	4
	Lithuania	18.26	17.68	19.83	12
C03A	LOW-CEILING DIURETICS, THIAZIDES				
	Estonia	5.50	4.41	4.17	-5
	Latvia	0.84	0.78	0.72	-8
	Lithuania	0.12	0.13	0.13	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C03AA	Thiazides, plain				
	Estonia	5.50	4.41	4.17	-5
	Latvia	0.84	0.78	0.72	-8
	Lithuania	0.12	0.13	0.13	
C03AA03	hydrochlorothiazide				
	Estonia	5.50	4.41	4.17	-5
	Latvia	0.84	0.78	0.72	-8
	Lithuania	0.12	0.13	0.13	
C03B	LOW-CEILING DIURETICS, EXCL. THIAZIDES				
	Estonia	1.67	1.91	2.25	18
	Latvia	5.44	5.23	5.07	-3
	Lithuania	6.58	5.52	5.48	-1
C03BA	Sulfonamides, plain				
	Estonia	1.67	1.91	2.25	18
	Latvia	5.44	5.23	5.07	-3
	Lithuania	6.58	5.52	5.48	-1
C03BA11	indapamide				
	Estonia	1.67	1.91	2.25	18
	Latvia	5.44	5.23	5.07	-3
	Lithuania	6.58	5.52	5.48	-1
C03C	HIGH-CEILING DIURETICS				
	Estonia	11.33	11.83	13.21	12
	Latvia	7.03	7.11	7.82	10
	Lithuania	8.39	8.78	10.28	17
C03CA	Sulfonamides, plain				
	Estonia	11.33	11.83	13.21	12
	Latvia	7.03	7.11	7.82	10
	Lithuania	8.39	8.78	10.28	17
C03CA01	furosemide				
	Estonia	5.77	5.38	5.30	-1
	Latvia	3.42	3.12	3.23	4
	Lithuania	2.80	2.74	2.90	6
C03CA04	torasemide				
	Estonia	5.57	6.45	7.90	22
	Latvia	3.60	3.99	4.58	15
	Lithuania	5.59	6.05	7.38	22
C03D	POTASSIUM-SPARING AGENTS				
	Estonia	3.05	2.96	3.02	2
	Latvia	4.92	4.79	5.03	5
	Lithuania	3.17	3.24	3.94	22
C03DA	Aldosterone antagonists				
	Estonia	3.05	2.96	3.02	2
	Latvia	4.92	4.79	5.03	5
	Lithuania	3.17	3.24	3.94	22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C03DA01	spironolactone				
	Estonia	3.05	2.96	3.02	2
	Latvia	4.92	4.79	5.02	5
	Lithuania	3.16	3.23	3.93	22
C03DA04	eplerenone				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
C03E	DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION				
	Estonia	0.12	0.04	0.02	-50
	Latvia	-	-	-	
	Lithuania	-	-	-	
C03EA	Low-ceiling diuretics and potassium-sparing agents				
	Estonia	0.12	0.04	0.02	-50
	Latvia	-	-	-	
	Lithuania	-	-	-	
C03EA01	hydrochlorothiazide and potassium-sparing agents				
	Estonia	0.12	0.04	0.02	-50
	Latvia	-	-	-	
	Lithuania	-	-	-	
C04	PERIPHERAL VASODILATORS				
	Estonia	2.52	2.57	2.72	6
	Latvia	2.96	3.00	3.22	7
	Lithuania	4.42	4.53	4.89	8
C04A	PERIPHERAL VASODILATORS				
	Estonia	2.52	2.57	2.72	6
	Latvia	2.96	3.00	3.22	7
	Lithuania	4.42	4.53	4.89	8
C04AD	Purine derivatives				
	Estonia	2.31	2.33	2.45	5
	Latvia	1.46	1.40	1.44	2
	Lithuania	4.42	4.53	4.89	8
C04AD02	xantinol nicotinate				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	0.04	0.04	0.04	
C04AD03	pentoxifylline				
	Estonia	2.31	2.32	2.44	5
	Latvia	1.46	1.40	1.44	2
	Lithuania	4.38	4.49	4.85	8
C04AX	Other peripheral vasodilators				
	Estonia	0.21	0.24	0.27	13
	Latvia	1.50	1.60	1.79	12
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C04AX21	naftidrofuryl				
	Estonia	0.21	0.24	0.27	13
	Latvia	1.50	1.60	1.79	12
	Lithuania	-	-	-	
C07	BETA BLOCKING AGENTS				
	Estonia	33.53	35.52	40.38	14
	Latvia	32.62	36.64	40.12	10
	Lithuania	46.12	51.35	60.19	17
C07A	BETA BLOCKING AGENTS				
	Estonia	33.53	35.52	40.38	14
	Latvia	32.62	36.64	40.12	10
	Lithuania	46.12	50.56	57.95	15
C07AA	Beta blocking agents, non-selective				
	Estonia	2.20	2.16	2.28	6
	Latvia	0.48	0.50	0.54	9
	Lithuania	0.06	0.09	0.13	44
C07AA05	propranolol				
	Estonia	0.39	0.40	0.44	10
	Latvia	0.37	0.36	0.37	4
	Lithuania	0.06	0.09	0.13	44
C07AA07	sotalol				
	Estonia	1.81	1.76	1.84	5
	Latvia	0.12	0.14	0.17	22
	Lithuania	-	-	-	
C07AB	Beta blocking agents, selective				
	Estonia	30.61	32.67	37.33	14
	Latvia	31.49	35.54	39.02	10
	Lithuania	43.82	47.95	55.00	15
C07AB02	metoprolol				
	Estonia	21.97	21.05	22.31	6
	Latvia	12.57	13.10	13.52	3
	Lithuania	15.20	16.30	18.34	13
C07AB03	atenolol				
	Estonia	1.56	1.32	1.23	-7
	Latvia	0.84	0.77	0.72	-7
	Lithuania	0.88	0.85	0.90	6
C07AB05	betaxolol				
	Estonia	-	-	-	
	Latvia	1.62	1.89	2.15	14
	Lithuania	4.75	4.86	5.44	12
C07AB07	bisoprolol				
	Estonia	0.36	0.40	0.51	28
	Latvia	14.09	15.56	17.12	10
	Lithuania	0.03	0.05	0.06	20

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C07AB12	nebivolol				
	Estonia	6.71	9.89	13.28	34
	Latvia	2.38	4.21	5.52	31
	Lithuania	22.95	25.89	30.26	17
C07AG	Alpha and beta blocking agents				
	Estonia	0.71	0.70	0.77	10
	Latvia	0.65	0.60	0.56	-7
	Lithuania	2.24	2.52	2.82	12
C07AG01	labetalol				
	Estonia	0.05	0.06	0.06	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C07AG02	carvedilol				
	Estonia	0.66	0.64	0.71	11
	Latvia	0.65	0.60	0.56	-7
	Lithuania	2.24	2.52	2.82	12
C07B	BETA BLOCKING AGENTS AND THIAZIDES				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	0.79	2.24	184
C07BB	Beta blocking agents, selective, and thiazides				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	0.79	2.24	184
C07BB12	nebivolol and thiazides				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	0.79	2.24	184
C08	CALCIUM CHANNEL BLOCKERS				
	Estonia	66.03	64.18	68.13	6
	Latvia	34.05	36.46	37.50	3
	Lithuania	36.23	36.37	37.88	4
C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS				
	Estonia	63.58	61.85	65.60	6
	Latvia	33.17	35.66	36.73	3
	Lithuania	32.26	32.38	33.70	4
C08CA	Dihydropyridine derivatives				
	Estonia	63.58	61.85	65.60	6
	Latvia	33.17	35.66	36.73	3
	Lithuania	32.26	32.38	33.70	4
C08CA01	amlodipine				
	Estonia	37.68	35.87	37.05	3
	Latvia	19.93	20.36	20.28	
	Lithuania	11.92	10.84	10.83	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C08CA02	felodipine				
	Estonia	7.59	6.72	6.62	-1
	Latvia	1.80	1.58	1.50	-5
	Lithuania	0.71	0.60	0.53	-12
C08CA05	nifedipine				
	Estonia	3.38	2.80	2.64	-6
	Latvia	1.69	1.50	1.52	1
	Lithuania	0.19	0.19	0.19	
C08CA06	nimodipine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.01	2
	Lithuania	-	-	-	
C08CA08	nitrendipine				
	Estonia	6.50	6.22	6.64	7
	Latvia	3.19	3.12	3.26	5
	Lithuania	0.60	0.50	0.47	-6
C08CA09	lacidipine				
	Estonia	7.77	7.00	6.96	-1
	Latvia	4.34	4.22	4.20	-1
	Lithuania	7.01	6.52	6.26	-4
C08CA13	lercanidipine				
	Estonia	0.66	3.23	5.69	76
	Latvia	2.21	4.87	5.97	23
	Lithuania	11.84	13.74	15.42	12
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS				
	Estonia	2.45	2.33	2.53	9
	Latvia	0.89	0.80	0.77	-4
	Lithuania	3.97	4.00	4.18	5
C08DA	Phenylalkylamine derivatives				
	Estonia	2.33	2.22	2.43	9
	Latvia	0.44	0.41	0.41	-2
	Lithuania	1.53	1.62	1.83	13
C08DA01	verapamil				
	Estonia	2.33	2.22	2.43	9
	Latvia	0.44	0.41	0.41	-2
	Lithuania	1.53	1.62	1.83	13
C08DB	Benzothiazepine derivatives				
	Estonia	0.12	0.11	0.09	-18
	Latvia	0.45	0.39	0.36	-7
	Lithuania	2.45	2.38	2.36	-1
C08DB01	diltiazem				
	Estonia	0.12	0.11	0.09	-18
	Latvia	0.45	0.39	0.36	-7
	Lithuania	2.45	2.38	2.36	-1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM				
	Estonia	162.35	164.13	183.36	12
	Latvia	140.47	154.55	173.02	12
	Lithuania	184.33	191.10	214.04	12
C09A	ACE INHIBITORS, PLAIN				
	Estonia	93.98	90.23	95.73	6
	Latvia	65.30	66.05	69.13	5
	Lithuania	113.68	105.66	111.79	6
C09AA	ACE inhibitors, plain				
	Estonia	93.98	90.23	95.73	6
	Latvia	65.30	66.05	69.13	5
	Lithuania	113.68	105.66	111.79	6
C09AA01	captopril				
	Estonia	0.22	0.17	0.15	-12
	Latvia	1.02	1.01	0.99	-3
	Lithuania	8.72	8.90	10.57	19
C09AA02	enalapril				
	Estonia	19.83	17.76	18.91	6
	Latvia	25.43	23.89	22.92	-4
	Lithuania	14.83	12.81	11.75	-8
C09AA03	lisinopril				
	Estonia	0.17	0.14	<0.01	
	Latvia	1.09	0.97	0.96	-1
	Lithuania	3.95	3.35	3.29	-2
C09AA04	perindopril				
	Estonia	0.91	0.82	0.87	6
	Latvia	19.76	20.36	21.00	3
	Lithuania	19.65	19.25	21.32	11
C09AA05	ramipril				
	Estonia	58.18	58.21	62.86	8
	Latvia	13.51	15.78	19.47	23
	Lithuania	38.96	36.57	38.90	6
C09AA06	quinapril				
	Estonia	0.09	0.06	0.06	
	Latvia	1.79	1.64	1.54	-6
	Lithuania	11.03	9.31	9.18	-1
C09AA09	fosinopril				
	Estonia	14.51	13.01	12.81	-2
	Latvia	2.59	2.32	2.16	-7
	Lithuania	7.24	6.11	6.00	-2
C09AA10	trandolapril				
	Estonia	0.04	0.06	0.08	33
	Latvia	0.06	0.05	0.07	46
	Lithuania	1.54	1.89	2.05	8


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C09AA11	spirapril				
	Estonia	<0.01	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.56	0.46	0.30	-35
C09AA15	zofenopril				
	Estonia	0.02	<0.01	<0.01	
	Latvia	0.03	0.02	0.02	
	Lithuania	7.20	7.02	8.43	20
C09B	ACE INHIBITORS, COMBINATIONS				
	Estonia	27.21	26.26	29.35	12
	Latvia	62.11	72.51	84.88	17
	Lithuania	32.39	37.36	44.18	18
C09BA	ACE inhibitors and diuretics				
	Estonia	26.21	23.95	25.54	7
	Latvia	50.98	56.12	62.84	12
	Lithuania	25.74	26.30	28.19	7
C09BA02	enalapril and diuretics				
	Estonia	17.06	15.07	14.82	-2
	Latvia	14.61	13.80	13.27	-4
	Lithuania	1.11	0.82	0.68	-17
C09BA03	lisinopril and diuretics				
	Estonia	-	-	-	
	Latvia	0.03	<0.01	<0.01	
	Lithuania	-	-	-	
C09BA04	perindopril and diuretics				
	Estonia	2.19	2.47	4.14	68
	Latvia	20.96	26.13	33.16	27
	Lithuania	15.40	17.05	19.64	15
C09BA05	ramipril and diuretics				
	Estonia	4.09	3.75	3.86	3
	Latvia	0.92	1.72	2.38	39
	Lithuania	1.07	1.54	1.46	-5
C09BA06	quinapril and diuretics				
	Estonia	0.24	0.18	0.17	-6
	Latvia	11.37	11.57	11.30	-2
	Lithuania	6.05	5.19	4.79	-8
C09BA09	fosinopril and diuretics				
	Estonia	2.63	2.47	2.56	4
	Latvia	3.09	2.90	2.73	-6
	Lithuania	2.11	1.70	1.62	-5
C09BB	ACE inhibitors and calcium channel blockers				
	Estonia	1.00	2.32	3.81	64
	Latvia	11.13	16.40	22.04	34
	Lithuania	6.65	11.06	15.99	45

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C09BB03	lisinopril and amlodipine				
	Estonia	0.45	1.48	2.12	43
	Latvia	0.86	1.84	2.45	33
	Lithuania	0.17	1.08	1.66	54
C09BB04	perindopril and amlodipine				
	Estonia	-	-	0.53	
	Latvia	10.26	14.55	19.59	35
	Lithuania	4.47	7.62	11.41	50
C09BB07	ramipril and amlodipine				
	Estonia	-	-	0.10	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C09BB10	trandolapril and verapamil				
	Estonia	0.56	0.83	1.06	28
	Latvia	-	-	-	
	Lithuania	2.01	2.36	2.92	24
C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN				
	Estonia	29.53	32.97	38.46	17
	Latvia	8.19	9.64	10.17	6
	Lithuania	31.95	38.59	44.24	15
C09CA	Angiotensin II antagonists, plain				
	Estonia	29.53	32.97	38.46	17
	Latvia	8.19	9.64	10.17	6
	Lithuania	31.95	38.59	44.24	15
C09CA01	losartan				
	Estonia	8.64	7.74	7.32	-5
	Latvia	0.73	1.50	1.84	23
	Lithuania	16.79	13.10	10.95	-16
C09CA02	eprosartan				
	Estonia	0.06	0.04	0.03	-25
	Latvia	0.02	0.01	0.01	-32
	Lithuania	0.10	0.07	0.05	-29
C09CA03	valsartan				
	Estonia	4.56	5.12	6.04	18
	Latvia	0.22	0.09	0.16	65
	Lithuania	12.49	15.02	19.45	29
C09CA04	irbesartan				
	Estonia	0.06	0.03	<0.01	
	Latvia	0.43	0.34	0.29	-13
	Lithuania	0.41	0.33	0.29	-12
C09CA06	candesartan				
	Estonia	6.61	5.84	6.18	6
	Latvia	3.43	2.14	1.92	-11
	Lithuania	0.20	0.16	0.14	-13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C09CA07	telmisartan				
	Estonia	8.39	12.47	16.72	34
	Latvia	2.37	4.01	4.43	11
	Lithuania	1.12	9.11	12.50	37
C09CA08	olmesartan medoxomil				
	Estonia	1.22	1.73	2.16	25
	Latvia	0.98	1.54	1.53	-1
	Lithuania	0.85	0.80	0.85	6
C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS				
	Estonia	11.62	14.66	19.83	35
	Latvia	4.87	6.35	8.85	39
	Lithuania	6.31	9.48	13.83	46
C09DA	Angiotensin II antagonists and diuretics				
	Estonia	11.62	13.36	16.10	21
	Latvia	4.66	5.55	7.14	29
	Lithuania	6.30	9.07	12.24	35
C09DA01	losartan and diuretics				
	Estonia	4.57	3.86	3.96	3
	Latvia	0.19	1.15	1.50	30
	Lithuania	3.68	3.53	2.87	-19
C09DA03	valsartan and diuretics				
	Estonia	0.51	1.19	1.81	52
	Latvia	0.14	0.10	0.44	346
	Lithuania	2.29	4.91	7.79	59
C09DA04	irbesartan and diuretics				
	Estonia	-	-	-	
	Latvia	0.16	0.14	0.12	-19
	Lithuania	-	-	-	
C09DA06	candesartan and diuretics				
	Estonia	1.63	1.44	1.48	3
	Latvia	-	0.01	0.21	
	Lithuania	-	-	-	
C09DA07	telmisartan and diuretics				
	Estonia	4.52	6.57	8.66	32
	Latvia	3.29	3.49	4.12	18
	Lithuania	0.07	0.29	1.12	286
C09DA08	olmesartan medoxomil and diuretics				
	Estonia	0.39	0.30	0.19	-37
	Latvia	0.87	0.66	0.75	13
	Lithuania	0.26	0.34	0.45	32
C09DB	Angiotensin II antagonists and calcium channel blockers				
	Estonia	<0.01	1.30	3.72	186
	Latvia	0.21	0.76	1.50	97
	Lithuania	0.01	0.41	1.60	290


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C09DB01	valsartan and amlodipine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.14	0.27	0.27	
	Lithuania	0.01	0.22	0.85	286
C09DB02	olmesartan medoxomil and amlodipine				
	Estonia	-	-	-	
	Latvia	0.07	0.34	0.73	117
	Lithuania	-	0.19	0.75	295
C09DB04	telmisartan and amlodipine				
	Estonia	-	1.30	3.72	186
	Latvia	-	0.15	0.49	234
	Lithuania	-	-	-	
C09DX	Angiotensin II antagonists, other combinations				
	Estonia	-	-	-	
	Latvia	-	0.03	0.20	481
	Lithuania	-	-	-	
C09DX01	valsartan, amlodipine and hydrochlorothiazide				
	Estonia	-	-	-	
	Latvia	-	0.03	0.20	481
	Lithuania	-	-	-	
C10	LIPID MODIFYING AGENTS				
	Estonia	26.34	31.76	39.57	25
	Latvia	26.20	32.47	41.82	29
	Lithuania	7.99	9.89	13.15	33
C10A	LIPID MODIFYING AGENTS, PLAIN				
	Estonia	26.34	31.74	39.18	23
	Latvia	26.11	32.40	41.68	29
	Lithuania	7.96	9.80	13.08	33

Consumption of antihypertensive drugs (C02–C09)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C10AA	HMG CoA reductase inhibitors				
	Estonia	26.13	31.48	38.85	23
	Latvia	25.59	31.84	40.97	29
	Lithuania	7.85	9.68	12.86	33
C10AA01	simvastatin				
	Estonia	7.05	6.92	7.48	8
	Latvia	0.78	0.79	0.70	-11
	Lithuania	0.27	0.19	0.24	26
C10AA02	lovastatin				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C10AA03	pravastatin				
	Estonia	0.72	0.59	0.58	-2
	Latvia	-	-	-	
	Lithuania	-	-	-	
C10AA04	fluvastatin				
	Estonia	1.05	1.05	1.03	-2
	Latvia	0.06	0.07	0.07	8
	Lithuania	0.24	0.17	0.12	-29
C10AA05	atorvastatin				
	Estonia	6.68	8.27	10.33	25
	Latvia	22.31	24.91	30.31	22
	Lithuania	6.42	8.29	10.83	31
C10AA07	rosuvastatin				
	Estonia	10.64	14.64	19.42	33
	Latvia	2.43	6.07	9.89	63
	Lithuania	0.92	1.04	1.68	62
C10AB	Fibrates				
	Estonia	0.10	0.12	0.17	42
	Latvia	0.32	0.35	0.50	42
	Lithuania	0.10	0.12	0.21	75
C10AB05	fenofibrate				
	Estonia	0.06	0.08	0.12	50
	Latvia	0.32	0.35	0.50	42
	Lithuania	0.10	0.12	0.21	75
C10AB08	ciprofibrate				
	Estonia	0.04	0.04	0.05	25
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	-	
C10AX	Other lipid modifying agents				
	Estonia	0.10	0.14	0.17	21
	Latvia	0.20	0.21	0.21	-4
	Lithuania	<0.01	<0.01	<0.01	

Consumption of statins (C10AA)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
C10AX09	ezetimibe				
	Estonia	0.10	0.14	0.17	21
	Latvia	0.20	0.21	0.21	-4
	Lithuania	<0.01	<0.01	<0.01	
C10B	LIPID MODIFYING AGENTS, COMBINATIONS				
	Estonia	-	0.01	0.39	
	Latvia	0.09	0.06	0.14	113
	Lithuania	0.03	0.09	0.07	-22
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents				
	Estonia	-	-	-	
	Latvia	0.09	0.06	0.14	113
	Lithuania	-	-	-	
C10BA02	simvastatin and ezetimibe				
	Estonia	-	-	-	
	Latvia	0.09	0.06	0.14	113
	Lithuania	-	-	-	
C10BX	HMG CoA reductase inhibitors, other combinations				
	Estonia	-	0.01	0.39	
	Latvia	-	-	-	
	Lithuania	0.03	0.09	0.07	-22
C10BX03	atorvastatin and amlodipine				
	Estonia	-	0.01	0.39	
	Latvia	-	-	-	
	Lithuania	0.03	0.09	0.07	-22

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
D	DERMATOLOGICALS				
	Estonia	1.37	1.51	1.62	7
	Latvia	0.28	0.33	0.37	13
	Lithuania	0.39	0.48	0.54	13
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE				
	Estonia	0.93	1.02	1.07	5
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
D01B	ANTIFUNGALS FOR SYSTEMIC USE				
	Estonia	0.93	1.02	1.07	5
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
D01BA	Antifungals for systemic use				
	Estonia	0.93	1.01	1.07	6
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
D01BA02	terbinafine				
	Estonia	0.93	1.01	1.07	6
	Latvia	0.23	0.28	0.32	14
	Lithuania	0.33	0.41	0.43	5
D05	ANTIPSORIATICS				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
D05B	ANTIPSORIATICS FOR SYSTEMIC USE				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
D05BB	Retinoids for treatment of psoriasis				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
D05BB02	acitretin				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
D10	ANTI-ACNE PREPARATIONS				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43
D10B	ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
D10BA	Retinoids for treatment of acne				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43
D10BA01	isotretinoin				
	Estonia	0.37	0.42	0.47	12
	Latvia	0.04	0.05	0.05	12
	Lithuania	0.06	0.07	0.10	43
D11	OTHER DERMATOLOGICAL PREPARATIONS				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	
D11A	OTHER DERMATOLOGICAL PREPARATIONS				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	
D11AX	Other dermatologicals				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	
D11AX10	finasteride				
	Estonia	0.06	0.05	0.05	
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G	GENITO URINARY SYSTEM AND SEX HORMONES				
	Estonia	50.16	51.85	54.42	5
	Latvia	31.84	33.29	32.82	-1
	Lithuania	28.79	27.37	30.07	10
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS				
	Estonia	1.09	0.83	0.77	-7
	Latvia	0.67	0.71	0.68	-3
	Lithuania	2.26	2.32	2.61	13
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS				
	Estonia	1.09	0.83	0.77	-7
	Latvia	0.67	0.71	0.68	-3
	Lithuania	1.64	1.69	1.89	12
G01AA	Antibiotics				
	Estonia	0.11	0.11	0.10	-9
	Latvia	0.03	0.04	0.04	4
	Lithuania	0.89	0.94	1.06	13
G01AA10	clindamycin				
	Estonia	0.11	0.11	0.10	-9
	Latvia	0.03	0.04	0.04	4
	Lithuania	0.28	0.32	0.36	13
G01AA51	nystatin, combinations				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.61	0.62	0.70	13
G01AD	Organic acids				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	<0.01	<0.01	
G01AD01	lactic acid				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	<0.01	<0.01	
G01AF	Imidazole derivatives				
	Estonia	0.98	0.72	0.66	-8
	Latvia	0.56	0.58	0.57	-1
	Lithuania	0.51	0.57	0.60	5
G01AF01	metronidazole				
	Estonia	0.17	0.13	0.10	-23
	Latvia	0.04	0.04	0.04	-4
	Lithuania	0.02	0.03	0.03	
G01AF02	clotrimazole				
	Estonia	0.68	0.45	0.42	-7
	Latvia	0.33	0.36	0.37	1
	Lithuania	0.15	0.16	0.17	6


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G01AF05	econazole				
	Estonia	0.13	0.15	0.15	
	Latvia	0.09	0.09	0.08	-5
	Lithuania	0.03	0.03	0.03	
G01AF12	fenticonazole				
	Estonia	-	-	-	
	Latvia	0.09	0.07	0.07	-7
	Lithuania	0.31	0.35	0.37	6
G01AF15	butoconazole				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	7
	Lithuania	-	-	-	
G01AX	Other antiinfectives and antiseptics				
	Estonia	-	<0.01	0.01	
	Latvia	0.08	0.08	0.07	-20
	Lithuania	0.11	0.07	0.12	71
G01AX03	policresulen				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G01AX05	nifuratel				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.07	0.03	0.09	200
G01AX11	povidone-iodine				
	Estonia	-	-	-	
	Latvia	0.08	0.08	0.07	-20
	Lithuania	0.04	0.04	0.04	
G02	OTHER GYNECOLOGICALS				
	Estonia	4.32	4.58	4.74	3
	Latvia	1.03	1.20	1.24	3
	Lithuania	1.17	1.13	1.13	
G02A	OXYTOCICS				
	Estonia	0.02	0.02	0.01	-50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G02AB	Ergot alkaloids				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
G02AB01	methylergometrine				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G02AD	Prostaglandins				
	Estonia	0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G02AD02	dinoprostone				
	Estonia	0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G02B	CONTRACEPTIVES FOR TOPICAL USE				
	Estonia	3.24	3.44	3.49	1
	Latvia	1.03	1.19	1.23	3
	Lithuania	1.01	0.97	0.98	1
G02BA	Intrauterine contraceptives				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
G02BA03	plastic IUD with progestogen				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
G02BB	Intravaginal contraceptives				
	Estonia	3.24	3.43	3.48	1
	Latvia	1.03	1.19	1.23	3
	Lithuania	1.01	0.97	0.98	1
G02BB01	vaginal ring with progestogen and estrogen				
	Estonia	3.24	3.43	3.48	1
	Latvia	1.03	1.19	1.23	3
	Lithuania	1.01	0.97	0.98	1
G02C	OTHER GYNECOLOGICALS				
	Estonia	1.06	1.13	1.24	10
	Latvia	0.01	0.01	0.01	45
	Lithuania	0.16	0.16	0.16	
G02CB	Prolactine inhibitors				
	Estonia	0.15	0.15	0.17	13
	Latvia	0.01	0.01	0.01	45
	Lithuania	0.16	0.16	0.16	
G02CB01	bromocriptine				
	Estonia	0.15	0.14	0.16	14
	Latvia	-	-	-	
	Lithuania	0.16	0.16	0.16	
G02CB03	cabergoline				
	Estonia	0.01	0.01	0.01	
	Latvia	0.01	0.01	0.01	45
	Lithuania	-	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G02CX	Other gynecologicals				
	Estonia	0.91	0.98	1.07	9
	Latvia	-	-	-	
	Lithuania	-	-	-	
G02CX03	Agni casti fructus				
	Estonia	0.42	0.44	0.53	20
	Latvia	-	-	-	
	Lithuania	-	-	-	
G02CX04	Cimicifugae rhizoma				
	Estonia	0.48	0.54	0.54	
	Latvia	-	-	-	
	Lithuania	-	-	-	
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM				
	Estonia	36.18	36.73	37.75	3
	Latvia	22.10	23.08	22.17	-4
	Lithuania	17.88	16.06	16.33	2
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE				
	Estonia	25.71	26.48	27.40	3
	Latvia	11.99	12.35	12.54	2
	Lithuania	13.25	12.71	13.04	3
G03AA	Progestogens and estrogens, fixed combinations				
	Estonia	22.62	23.48	24.46	4
	Latvia	10.59	10.85	10.82	
	Lithuania	11.45	11.33	11.39	1
G03AA07	levonorgestrel and ethinylestradiol				
	Estonia	-	-	-	
	Latvia	0.66	0.59	0.58	-3
	Lithuania	0.67	0.39	0.34	-13
G03AA09	desogestrel and ethinylestradiol				
	Estonia	2.96	2.96	2.84	-4
	Latvia	1.97	1.96	1.72	-12
	Lithuania	2.93	2.64	2.37	-10
G03AA10	gestodene and ethinylestradiol				
	Estonia	7.14	7.30	8.01	10
	Latvia	3.67	3.75	3.62	-4
	Lithuania	4.12	4.27	4.06	-5
G03AA11	norgestimate and ethinylestradiol				
	Estonia	0.23	0.19	0.17	-11
	Latvia	0.35	0.29	0.26	-11
	Lithuania	0.52	0.43	0.34	-21
G03AA12	drospirenone and ethinylestradiol				
	Estonia	9.29	10.20	10.59	4
	Latvia	3.48	3.92	4.07	4
	Lithuania	2.67	3.12	3.79	21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03AA13	norelgestromin and ethinylestradiol				
	Estonia	2.37	2.28	2.26	-1
	Latvia	0.34	0.31	0.25	-20
	Lithuania	0.55	0.50	0.49	-2
G03AA14	nomegestrol and estradiol				
	Estonia	-	-	0.06	
	Latvia	-	-	0.13	
	Lithuania	-	-	-	
G03AA15	chlormadinone and ethinylestradiol				
	Estonia	0.64	0.56	0.54	-4
	Latvia	0.13	0.03	0.20	571
	Lithuania	-	-	-	
G03AB	Progestogens and estrogens, sequential preparations				
	Estonia	0.97	0.85	0.79	-7
	Latvia	0.84	0.85	1.04	23
	Lithuania	1.44	1.09	1.28	17
G03AB03	levonorgestrel and ethinylestradiol				
	Estonia	0.80	0.67	0.62	-7
	Latvia	0.49	0.42	0.37	-12
	Lithuania	0.66	0.62	0.60	-3
G03AB05	desogestrel and ethinylestradiol				
	Estonia	0.08	0.08	0.07	-13
	Latvia	0.12	0.12	0.10	-11
	Lithuania	0.19	0.16	0.15	-6
G03AB07	chlormadinone and ethinylestradiol				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.29	0.01	0.12	
G03AB08	dienogest and estradiol				
	Estonia	0.09	0.10	0.11	10
	Latvia	0.23	0.31	0.56	83
	Lithuania	0.29	0.30	0.42	40
G03AC	Progestogens				
	Estonia	2.05	2.08	2.08	
	Latvia	0.33	0.43	0.45	5
	Lithuania	0.22	0.29	0.32	10
G03AC09	desogestrel				
	Estonia	2.05	2.08	2.08	
	Latvia	0.33	0.43	0.45	5
	Lithuania	0.22	0.29	0.32	10
G03AD	Emergency contraceptives				
	Estonia	0.06	0.07	0.07	
	Latvia	0.23	0.23	0.23	2
	Lithuania	0.14	0.01	0.05	400

Consumption of hormonal contraceptives (G02BB and G03A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03AD01	levonorgestrel				
	Estonia	0.06	0.07	0.07	
	Latvia	0.23	0.23	0.23	2
	Lithuania	0.14	<0.01	0.05	
G03B	ANDROGENS				
	Estonia	0.14	0.19	0.21	11
	Latvia	0.16	0.22	0.26	20
	Lithuania	0.06	0.08	0.07	-13
G03BA	3-oxoandrosten (4) derivatives				
	Estonia	0.14	0.19	0.21	11
	Latvia	0.16	0.22	0.26	20
	Lithuania	0.06	0.08	0.07	-13
G03BA03	testosterone				
	Estonia	0.14	0.19	0.21	11
	Latvia	0.16	0.22	0.26	20
	Lithuania	0.06	0.08	0.07	-13
G03C	ESTROGENS				
	Estonia	1.64	1.74	1.75	1
	Latvia	3.06	3.38	3.36	
	Lithuania	0.74	0.73	0.73	
G03CA	Natural and semisynthetic estrogens, plain				
	Estonia	1.51	1.59	1.59	
	Latvia	3.01	3.32	3.30	
	Lithuania	0.68	0.67	0.66	-1
G03CA03	estradiol				
	Estonia	1.12	1.08	1.13	5
	Latvia	2.85	3.12	3.10	-1
	Lithuania	0.45	0.45	0.42	-7

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03CA04	estriol				
	Estonia	0.38	0.51	0.46	-10
	Latvia	0.16	0.20	0.21	1
	Lithuania	0.23	0.23	0.24	4
G03CX	Other estrogens				
	Estonia	0.14	0.15	0.16	7
	Latvia	0.05	0.06	0.06	-3
	Lithuania	0.06	0.06	0.07	17
G03CX01	tibolone				
	Estonia	0.14	0.15	0.16	7
	Latvia	0.05	0.06	0.06	-3
	Lithuania	0.06	0.06	0.07	17
G03D	PROGESTOGENS				
	Estonia	1.93	1.86	1.98	6
	Latvia	1.06	1.02	0.96	-6
	Lithuania	0.92	0.90	0.94	4
G03DA	Pregnen (4) derivatives				
	Estonia	0.99	0.97	1.04	7
	Latvia	0.26	0.23	0.20	-10
	Lithuania	0.21	0.22	0.23	5
G03DA02	medroxyprogesterone				
	Estonia	0.59	0.53	0.53	
	Latvia	0.26	0.23	0.20	-10
	Lithuania	0.21	0.22	0.23	5
G03DA04	progesterone				
	Estonia	0.40	0.44	0.52	18
	Latvia	-	-	-	
	Lithuania	-	-	-	
G03DB	Pregnadien derivatives				
	Estonia	0.94	0.89	0.94	6
	Latvia	0.80	0.79	0.76	-5
	Lithuania	0.72	0.68	0.71	4
G03DB01	dydrogesterone				
	Estonia	0.94	0.88	0.90	2
	Latvia	0.80	0.79	0.76	-5
	Lithuania	0.72	0.67	0.70	4
G03DB08	dienogest				
	Estonia	-	0.01	0.03	200
	Latvia	-	-	-	
	Lithuania	-	<0.01	0.01	
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION				
	Estonia	4.88	4.65	4.66	
	Latvia	1.45	1.50	1.51	
	Lithuania	1.30	1.32	1.33	1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03FA	Progestogens and estrogens, fixed combinations				
	Estonia	4.25	4.07	4.06	
	Latvia	1.37	1.40	1.38	-2
	Lithuania	1.03	1.03	1.05	2
G03FA01	norethisterone and estrogen				
	Estonia	1.40	1.30	1.31	1
	Latvia	0.62	0.64	0.62	-3
	Lithuania	0.28	0.29	0.29	
G03FA14	dydrogesterone and estrogen				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.02	0.06	200
G03FA15	dienogest and estrogen				
	Estonia	2.62	2.52	2.50	-1
	Latvia	0.57	0.55	0.52	-6
	Lithuania	0.69	0.67	0.65	-3
G03FA17	drospirenone and estrogen				
	Estonia	0.23	0.24	0.25	4
	Latvia	0.19	0.21	0.24	14
	Lithuania	0.05	0.06	0.06	
G03FB	Progestogens and estrogens, sequential preparations				
	Estonia	0.63	0.58	0.60	3
	Latvia	0.08	0.10	0.13	29
	Lithuania	0.27	0.29	0.28	-3
G03FB05	norethisterone and estrogen				
	Estonia	0.54	0.48	0.46	-4
	Latvia	-	-	-	
	Lithuania	0.18	0.19	0.19	
G03FB06	medroxyprogesterone and estrogen				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03FB08	dydrogesterone and estrogen				
	Estonia	0.09	0.10	0.13	30
	Latvia	0.08	0.10	0.13	29
	Lithuania	0.01	0.02	-	
G03FB09	levonorgestrel and estrogen				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.08	0.09	0.09	
G03G	GONADOTROPINS AND OTHER OVULATION STIMULANTS				
	Estonia	0.42	0.46	0.41	-11
	Latvia	3.32	3.53	2.50	-29
	Lithuania	0.19	0.18	0.17	-6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03GA	Gonadotropins				
	Estonia	0.11	0.15	0.12	-20
	Latvia	3.21	3.41	2.37	-31
	Lithuania	0.07	0.06	0.06	
G03GA01	chorionic gonadotrophin				
	Estonia	0.03	0.03	0.02	-33
	Latvia	0.12	0.06	0.01	-84
	Lithuania	0.06	0.05	0.06	20
G03GA02	human menopausal gonadotrophin				
	Estonia	-	0.03	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
G03GA05	follitropin alfa				
	Estonia	0.06	0.07	0.07	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	<0.01	
G03GA06	follitropin beta				
	Estonia	0.01	0.02	0.02	
	Latvia	<0.01	0.01	0.01	-15
	Lithuania	<0.01	<0.01	<0.01	
G03GA08	choriogonadotropin alfa				
	Estonia	0.01	0.01	0.01	
	Latvia	3.08	3.34	2.35	-30
	Lithuania	<0.01	<0.01	-	
G03GB	Ovulation stimulants, synthetic				
	Estonia	0.31	0.31	0.29	-6
	Latvia	0.11	0.12	0.14	12
	Lithuania	0.13	0.12	0.11	-8
G03GB02	clomifene				
	Estonia	0.31	0.31	0.29	-6
	Latvia	0.11	0.12	0.14	12
	Lithuania	0.13	0.12	0.11	-8
G03H	ANTIANDROGENS				
	Estonia	1.47	1.36	1.33	-2
	Latvia	1.04	1.08	1.04	-3
	Lithuania	1.42	0.14	0.06	-57
G03HA	Antiandrogens, plain				
	Estonia	0.50	0.43	0.36	-16
	Latvia	0.21	0.16	0.12	-22
	Lithuania	0.19	0.14	0.06	-57
G03HA01	cyproterone				
	Estonia	0.50	0.43	0.36	-16
	Latvia	0.21	0.16	0.12	-22
	Lithuania	0.19	0.14	0.06	-57

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G03HB	Antiandrogens and estrogens				
	Estonia	0.97	0.93	0.97	4
	Latvia	0.84	0.92	0.92	
	Lithuania	1.23	1.16	1.20	3
G03HB01	cyproterone and estrogen				
	Estonia	0.97	0.93	0.97	4
	Latvia	0.84	0.92	0.92	
	Lithuania	1.23	1.16	1.20	3
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03XB	Antiprogestogens				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03XB01	mifepristone				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G04	UROLOGICALS				
	Estonia	8.56	9.69	11.16	15
	Latvia	8.04	8.31	8.72	5
	Lithuania	7.48	7.86	9.99	27
G04B	UROLOGICALS				
	Estonia	1.18	1.34	1.58	18
	Latvia	0.62	0.74	0.79	6
	Lithuania	1.22	1.65	2.06	25
G04BD	Drugs for urinary frequency and incontinence				
	Estonia	0.73	0.78	0.89	14
	Latvia	0.32	0.40	0.43	8
	Lithuania	0.86	1.14	1.41	24
G04BD02	flavoxate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	0.04	0.05	25
G04BD04	oxybutynin				
	Estonia	0.55	0.58	0.65	12
	Latvia	0.26	0.28	0.31	9
	Lithuania	0.34	0.34	0.36	6
G04BD07	tolterodine				
	Estonia	0.07	0.08	0.10	25
	Latvia	0.05	0.09	0.08	-6
	Lithuania	0.51	0.76	1.00	32

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G04BD08	solifenacin				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.04	265
	Lithuania	<0.01	<0.01	0.01	
G04BD09	trospium				
	Estonia	0.10	0.11	0.15	36
	Latvia	<0.01	0.02	<0.01	
	Lithuania	<0.01	<0.01	-	
G04BE	Drugs used in erectile dysfunction				
	Estonia	0.45	0.56	0.69	23
	Latvia	0.30	0.34	0.36	5
	Lithuania	0.36	0.51	0.65	27
G04BE01	alprostadil				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
G04BE03	sildenafil				
	Estonia	0.30	0.42	0.56	33
	Latvia	0.20	0.24	0.25	6
	Lithuania	0.26	0.42	0.55	31
G04BE08	tadalafil				
	Estonia	0.10	0.09	0.09	
	Latvia	0.04	0.04	0.04	8
	Lithuania	0.08	0.07	0.07	
G04BE09	varденаfil				
	Estonia	0.04	0.04	0.04	
	Latvia	0.06	0.06	0.06	-5
	Lithuania	0.02	0.02	0.03	50
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY				
	Estonia	7.38	8.35	9.58	15
	Latvia	7.42	7.57	7.93	5
	Lithuania	6.26	6.21	7.93	28
G04CA	Alpha-adrenoreceptor antagonists				
	Estonia	4.24	5.54	6.84	23
	Latvia	3.22	4.11	4.75	16
	Lithuania	3.53	4.09	5.06	24
G04CA01	alfuzosin				
	Estonia	1.28	1.33	1.58	19
	Latvia	0.19	0.16	0.15	-4
	Lithuania	0.10	0.11	0.11	
G04CA02	tamsulosin				
	Estonia	2.94	3.41	3.98	17
	Latvia	2.82	2.77	2.84	2
	Lithuania	3.43	3.59	3.99	11

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
G04CA52	tamsulosin and dutasteride				
	Estonia	0.02	0.79	1.28	62
	Latvia	0.21	1.18	1.76	50
	Lithuania	0.01	0.39	0.96	146
G04CB	Testosterone-5-alpha reductase inhibitors				
	Estonia	0.78	0.53	0.45	-15
	Latvia	1.84	1.53	1.48	-3
	Lithuania	2.73	2.12	2.88	36
G04CB01	finasteride				
	Estonia	0.23	0.19	0.16	-16
	Latvia	0.93	0.83	0.83	
	Lithuania	1.51	0.84	1.74	107
G04CB02	dutasteride				
	Estonia	0.55	0.34	0.29	-15
	Latvia	0.91	0.70	0.65	-7
	Lithuania	1.21	1.28	1.14	-11
G04CX	Other drugs used in benign prostatic hypertrophy				
	Estonia	2.36	2.29	2.29	
	Latvia	2.37	1.93	1.70	-12
	Lithuania	-	-	-	
G04CX01	Prunus africana cortex				
	Estonia	-	-	-	
	Latvia	0.02	<0.01	<0.01	
	Lithuania	-	-	-	
G04CX02	Sabalıs serrulatae fructus				
	Estonia	2.36	2.29	2.29	
	Latvia	2.35	1.91	1.70	-11
	Lithuania	-	-	-	
G04CX03	mepartricin				
	Estonia	-	-	-	
	Latvia	<0.01	0.02	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
H	SYSTEMIC HORMONAL PREPARATIONS, EXCL.				
	Estonia	19.24	19.66	21.88	11
	Latvia	18.11	19.32	20.76	7
	Lithuania	27.70	30.45	34.60	14
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES				
	Estonia	0.34	0.34	0.35	3
	Latvia	0.38	0.43	0.46	8
	Lithuania	0.25	0.27	0.29	7
H01A	ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES				
	Estonia	0.08	0.08	0.08	
	Latvia	0.15	0.19	0.22	12
	Lithuania	0.10	0.11	0.13	18
H01AC	Somatropin and somatropin agonists				
	Estonia	0.08	0.08	0.08	
	Latvia	0.15	0.19	0.22	12
	Lithuania	0.10	0.11	0.13	18
H01AC01	somatropin				
	Estonia	0.08	0.08	0.08	
	Latvia	0.15	0.19	0.22	12
	Lithuania	0.10	0.11	0.13	18
H01B	POSTERIOR PITUITARY LOBE HORMONES				
	Estonia	0.22	0.21	0.21	
	Latvia	0.20	0.19	0.19	2
	Lithuania	0.14	0.14	0.15	7
H01BA	Vasopressin and analogues				
	Estonia	0.08	0.09	0.10	11
	Latvia	0.06	0.06	0.06	-3
	Lithuania	0.10	0.10	0.10	
H01BA02	desmopressin				
	Estonia	0.08	0.09	0.10	11
	Latvia	0.06	0.06	0.06	-3
	Lithuania	0.10	0.10	0.10	
H01BB	Oxytocin and analogues				
	Estonia	0.14	0.12	0.11	-8
	Latvia	0.14	0.12	0.13	5
	Lithuania	0.04	0.04	0.04	
H01BB01	demoxycocin				
	Estonia	0.11	0.10	0.09	-10
	Latvia	0.09	0.08	0.09	3
	Lithuania	-	-	-	
H01BB02	oxytocin				
	Estonia	0.03	0.03	0.03	
	Latvia	0.05	0.04	0.04	8
	Lithuania	0.04	0.04	0.04	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
H01C	HYPOTHALAMIC HORMONES				
	Estonia	0.04	0.05	0.05	
	Latvia	0.04	0.05	0.05	11
	Lithuania	0.01	0.02	0.01	-50
H01CB	Somatostatin and analogues				
	Estonia	0.03	0.04	0.04	
	Latvia	0.03	0.04	0.05	10
	Lithuania	0.01	0.02	0.01	-50
H01CB02	octreotide				
	Estonia	0.03	0.03	0.03	
	Latvia	0.01	0.02	0.02	28
	Lithuania	0.01	0.02	0.01	-50
H01CB03	lanreotide				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.02	0.02	0.02	-5
	Lithuania	0.01	<0.01	-	
H01CC	Anti-gonadotropin-releasing hormones				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
H01CC01	ganirelix				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01CC02	cetrorelix				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
H02	CORTICOSTEROIDS FOR SYSTEMIC USE				
	Estonia	6.28	6.52	6.97	7
	Latvia	7.46	7.69	7.91	3
	Lithuania	17.08	18.75	21.24	13
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN				
	Estonia	6.28	6.52	6.97	7
	Latvia	7.46	7.69	7.91	3
	Lithuania	6.74	7.39	8.22	11
H02AA	Mineralocorticoids				
	Estonia	0.09	0.10	0.12	20
	Latvia	0.05	0.04	0.05	24
	Lithuania	0.05	0.06	0.06	
H02AA02	fludrocortisone				
	Estonia	0.09	0.10	0.12	20
	Latvia	0.05	0.04	0.05	24
	Lithuania	0.05	0.06	0.06	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
H02AB	Glucocorticoids				
	Estonia	6.19	6.42	6.85	7
	Latvia	7.41	7.65	7.86	3
	Lithuania	6.69	7.34	8.16	11
H02AB01	betamethasone				
	Estonia	0.03	0.02	0.02	
	Latvia	-	-	-	
	Lithuania	-	-	-	
H02AB02	dexamethasone				
	Estonia	0.95	1.03	1.11	8
	Latvia	3.10	3.34	3.22	-4
	Lithuania	2.97	3.36	3.95	18
H02AB04	methylprednisolone				
	Estonia	1.90	2.00	2.22	11
	Latvia	1.98	2.07	2.28	10
	Lithuania	1.92	2.14	2.24	5
H02AB06	prednisolone				
	Estonia	2.75	2.87	2.92	2
	Latvia	1.70	1.69	1.77	4
	Lithuania	1.56	1.60	1.69	6
H02AB07	prednisone				
	Estonia	0.03	0.02	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
H02AB08	triamcinolone				
	Estonia	0.38	0.29	0.36	24
	Latvia	0.40	0.29	0.34	16
	Lithuania	0.18	0.17	0.21	24
H02AB09	hydrocortisone				
	Estonia	0.16	0.19	0.22	16
	Latvia	0.21	0.26	0.27	3
	Lithuania	0.06	0.06	0.07	17
H03	THYROID THERAPY				
	Estonia	12.62	12.77	14.53	14
	Latvia	10.24	11.16	12.35	11
	Lithuania	10.34	11.35	13.03	15
H03A	THYROID PREPARATIONS				
	Estonia	11.47	11.60	13.32	15
	Latvia	8.75	9.56	10.59	11
	Lithuania	8.98	9.95	11.58	16
H03AA	Thyroid hormones				
	Estonia	11.47	11.60	13.32	15
	Latvia	8.75	9.56	10.59	11
	Lithuania	8.98	9.95	11.58	16

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
H03AA01	levothyroxine sodium				
	Estonia	11.47	11.60	13.32	15
	Latvia	8.75	9.56	10.59	11
	Lithuania	8.98	9.95	11.58	16
H03B	ANTITHYROID PREPARATIONS				
	Estonia	1.14	1.16	1.21	4
	Latvia	1.49	1.61	1.76	9
	Lithuania	1.36	1.41	1.45	3
H03BA	Thiouracils				
	Estonia	0.78	0.71	0.64	-10
	Latvia	-	-	-	
	Lithuania	-	-	-	
H03BA02	propylthiouracil				
	Estonia	0.78	0.71	0.64	-10
	Latvia	-	-	-	
	Lithuania	-	-	-	
H03BB	Sulfur-containing imidazole derivatives				
	Estonia	0.36	0.45	0.57	27
	Latvia	1.49	1.61	1.76	9
	Lithuania	1.36	1.41	1.45	3
H03BB02	thiamazole				
	Estonia	0.36	0.45	0.57	27
	Latvia	1.49	1.61	1.76	9
	Lithuania	1.36	1.41	1.45	3
H04	PANCREATIC HORMONES				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H04A	GLYCOGENOLYTIC HORMONES				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H04AA	Glycogenolytic hormones				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H04AA01	glucagon				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
H05	CALCIUM HOMEOSTASIS				
	Estonia	0.01	0.03	0.02	-33
	Latvia	0.02	0.03	0.03	7
	Lithuania	0.03	0.08	0.04	-50
H05A	PARATHYROID HORMONES AND ANALOGUES				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.07	0.02	-71
H05AA	Parathyroid hormones and analogues				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.07	0.02	-71
H05AA02	teriparatide				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.07	0.01	-86
H05AA03	parathyroid hormone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	-	<0.01	
H05B	ANTI-PARATHYROID AGENTS				
	Estonia	0.01	0.02	0.02	
	Latvia	0.02	0.03	0.03	11
	Lithuania	<0.01	0.01	0.03	200
H05BX	Other anti-parathyroid agents				
	Estonia	0.01	0.02	0.02	
	Latvia	0.02	0.03	0.03	11
	Lithuania	<0.01	0.01	0.03	200
H05BX01	cinacalcet				
	Estonia	0.01	0.02	0.02	
	Latvia	0.02	0.02	0.02	-15
	Lithuania	<0.01	0.01	0.03	200
H05BX02	paricalcitol				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	0.01	0.02	61
	Lithuania	-	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J	ANTIINFECTIVES FOR SYSTEMIC USE				
	Estonia	16.34	18.08	17.99	
	Latvia	15.24	17.06	17.39	2
	Lithuania	19.83	21.04	20.26	-4
J01	ANTIBACTERIALS FOR SYSTEMIC USE				
	Estonia	13.07	14.12	13.84	-2
	Latvia	13.74	15.42	16.03	4
	Lithuania	18.57	19.52	19.01	-3
J01A	TETRACYCLINES				
	Estonia	1.99	2.18	1.88	-14
	Latvia	2.48	2.67	2.70	1
	Lithuania	1.72	1.67	1.61	-4
J01AA	Tetracyclines				
	Estonia	1.99	2.18	1.88	-14
	Latvia	2.48	2.67	2.70	1
	Lithuania	1.72	1.67	1.61	-4
J01AA02	doxycycline				
	Estonia	1.91	2.10	1.80	-14
	Latvia	2.48	2.67	2.70	1
	Lithuania	1.72	1.67	1.61	-4
J01AA07	tetracycline				
	Estonia	0.08	0.08	0.08	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS				
	Estonia	4.86	5.22	5.11	-2
	Latvia	6.14	6.76	6.84	1
	Lithuania	10.09	10.76	10.32	-4
J01CA	Penicillins with extended spectrum				
	Estonia	2.86	2.97	2.77	-7
	Latvia	4.37	4.89	4.83	-1
	Lithuania	7.71	8.37	7.89	-6
J01CA01	ampicillin				
	Estonia	0.08	0.07	0.05	-29
	Latvia	0.39	0.24	0.21	-13
	Lithuania	1.08	0.89	0.37	-58
J01CA04	amoxicillin				
	Estonia	2.78	2.90	2.73	-6
	Latvia	3.98	4.65	4.62	-1
	Lithuania	6.63	7.48	7.52	1
J01CE	Beta-lactamase sensitive penicillins				
	Estonia	0.29	0.27	0.25	-7
	Latvia	0.08	0.02	0.02	-16
	Lithuania	0.54	0.45	0.43	-4

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01CE01	benzylpenicillin				
	Estonia	0.03	0.03	0.03	
	Latvia	0.03	0.02	0.02	-16
	Lithuania	0.36	0.28	0.25	-11
J01CE02	phenoxymethylpenicillin				
	Estonia	0.25	0.24	0.22	-8
	Latvia	0.05	<0.01	<0.01	
	Lithuania	0.18	0.16	0.18	13
J01CF	Beta-lactamase resistant penicillins				
	Estonia	0.14	0.13	0.15	15
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
J01CF04	oxacillin				
	Estonia	0.14	0.13	0.15	15
	Latvia	0.02	<0.01	<0.01	
	Lithuania	0.03	-	-	
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors				
	Estonia	1.57	1.85	1.94	5
	Latvia	1.67	1.85	2.00	8
	Lithuania	1.82	1.95	2.00	3
J01CR01	ampicillin and enzyme inhibitor				
	Estonia	0.16	0.17	0.17	
	Latvia	0.05	0.07	0.05	-26
	Lithuania	0.01	-	-	
J01CR02	amoxicillin and enzyme inhibitor				
	Estonia	1.29	1.56	1.66	6
	Latvia	1.61	1.77	1.93	9
	Lithuania	1.69	1.80	1.87	4
J01CR04	sultamicillin				
	Estonia	0.10	0.10	0.10	
	Latvia	-	-	-	
	Lithuania	0.12	0.14	0.12	-14
J01CR05	piperacillin and enzyme inhibitor				
	Estonia	0.02	0.02	0.02	
	Latvia	0.01	0.01	0.01	14
	Lithuania	<0.01	0.01	0.01	
J01D	OTHER BETA-LACTAM ANTIBACTERIALS				
	Estonia	1.36	1.50	1.52	1
	Latvia	1.12	1.08	1.10	2
	Lithuania	1.12	1.34	1.48	10
J01DB	First-generation cephalosporins				
	Estonia	0.30	0.31	0.31	
	Latvia	0.52	0.43	0.38	-12
	Lithuania	0.40	0.44	0.44	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01DB01	cefalexin				
	Estonia	-	-	-	
	Latvia	0.10	0.08	<0.01	
	Lithuania	-	-	-	
J01DB04	cefazolin				
	Estonia	0.07	0.07	0.07	
	Latvia	0.27	0.17	0.20	16
	Lithuania	0.18	0.23	0.25	9
J01DB05	cefadroxil				
	Estonia	0.22	0.24	0.24	
	Latvia	0.15	0.18	0.18	
	Lithuania	0.22	0.21	0.19	-10
J01DC	Second-generation cephalosporins				
	Estonia	0.97	1.08	1.10	2
	Latvia	0.22	0.24	0.28	20
	Lithuania	0.62	0.77	0.88	14
J01DC02	cefuroxime				
	Estonia	0.86	0.96	1.00	4
	Latvia	0.21	0.23	0.28	20
	Lithuania	0.62	0.77	0.88	14
J01DC10	cefprozil				
	Estonia	0.11	0.11	0.09	-18
	Latvia	0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	-	
J01DD	Third-generation cephalosporins				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.34	0.39	0.43	10
	Lithuania	0.08	0.11	0.14	27
J01DD01	cefotaxime				
	Estonia	0.02	0.02	0.03	50
	Latvia	0.01	0.01	0.01	-54
	Lithuania	0.01	0.01	0.01	
J01DD02	ceftazidime				
	Estonia	0.02	0.02	0.02	
	Latvia	0.01	0.01	0.01	-33
	Lithuania	0.01	0.01	0.01	
J01DD04	ceftriaxone				
	Estonia	0.01	0.01	0.01	
	Latvia	0.32	0.36	0.41	13
	Lithuania	0.07	0.09	0.13	44
J01DE	Fourth-generation cephalosporins				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01DE01	cefepime				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J01DH	Carbapenems				
	Estonia	0.03	0.03	0.04	33
	Latvia	0.04	0.03	0.01	-61
	Lithuania	0.02	0.02	0.02	
J01DH02	meropenem				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.04	0.02	0.01	-59
	Lithuania	0.01	0.01	0.01	
J01DH03	ertapenem				
	Estonia	0.01	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J01DH51	imipenem and enzyme inhibitor				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
J01E	SULFONAMIDES AND TRIMETHOPRIM				
	Estonia	0.49	0.54	0.52	-4
	Latvia	0.98	1.09	1.04	-5
	Lithuania	0.40	0.39	0.38	-3
J01EA	Trimethoprim and derivatives				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
J01EA01	trimethoprim				
	Estonia	0.02	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives				
	Estonia	0.47	0.52	0.49	-6
	Latvia	0.98	1.09	1.03	-5
	Lithuania	0.39	0.39	0.37	-5
J01EE01	sulfamethoxazole and trimethoprim				
	Estonia	0.40	0.52	0.49	-6
	Latvia	0.91	0.99	0.98	-1
	Lithuania	0.39	0.39	0.37	-5
J01EE03	sulfametrole and trimethoprim				
	Estonia	0.07	<0.01	-	
	Latvia	0.07	0.10	0.05	-47
	Lithuania	-	-	-	


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS				
	Estonia	2.35	2.66	2.65	
	Latvia	1.20	1.47	1.65	12
	Lithuania	1.91	2.12	2.21	4
J01FA	Macrolides				
	Estonia	2.22	2.51	2.47	-2
	Latvia	1.09	1.35	1.51	12
	Lithuania	1.88	2.09	2.18	4
J01FA01	erythromycin				
	Estonia	<0.01	-	<0.01	
	Latvia	0.09	0.08	0.06	-17
	Lithuania	0.07	0.07	0.05	-29
J01FA02	spiramycin				
	Estonia	0.01	0.01	0.01	
	Latvia	0.05	0.04	0.04	-7
	Lithuania	0.04	0.03	0.03	
J01FA09	clarithromycin				
	Estonia	1.84	2.02	1.88	-7
	Latvia	0.70	0.89	1.02	14
	Lithuania	1.43	1.53	1.56	2
J01FA10	azithromycin				
	Estonia	0.36	0.48	0.58	21
	Latvia	0.26	0.34	0.39	15
	Lithuania	0.34	0.45	0.55	22
J01FF	Lincosamides				
	Estonia	0.13	0.15	0.18	20
	Latvia	0.11	0.12	0.14	8
	Lithuania	0.03	0.03	0.03	
J01FF01	clindamycin				
	Estonia	0.13	0.15	0.18	20
	Latvia	0.10	0.11	0.12	9
	Lithuania	-	-	<0.01	
J01FF02	lincomycin				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	3
	Lithuania	0.03	0.03	0.03	
J01G	AMINOGLYCOSIDE ANTIBACTERIALS				
	Estonia	0.14	0.06	0.07	17
	Latvia	0.16	0.63	0.92	45
	Lithuania	0.30	0.31	0.32	3
J01GA	Streptomycins				
	Estonia	0.05	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01GA01	streptomycin				
	Estonia	0.05	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	-	
J01GB	Other aminoglycosides				
	Estonia	0.09	0.06	0.07	17
	Latvia	0.15	0.63	0.91	45
	Lithuania	0.29	0.31	0.32	3
J01GB01	tobramycin				
	Estonia	0.01	<0.01	0.02	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J01GB03	gentamicin				
	Estonia	0.07	0.05	0.04	-20
	Latvia	0.13	0.09	0.09	-3
	Lithuania	0.27	0.27	0.24	-11
J01GB04	kanamycin				
	Estonia	<0.01	-	-	
	Latvia	0.01	0.53	0.82	54
	Lithuania	<0.01	0.01	0.05	400
J01GB06	amikacin				
	Estonia	0.01	0.01	0.01	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.02	0.03	0.03	
J01M	QUINOLONE ANTIBACTERIALS				
	Estonia	1.02	1.07	1.16	8
	Latvia	1.28	1.31	1.36	4
	Lithuania	1.14	1.24	1.42	15
J01MA	Fluoroquinolones				
	Estonia	1.02	1.07	1.16	8
	Latvia	1.24	1.26	1.32	4
	Lithuania	1.06	1.17	1.36	16
J01MA01	ofloxacin				
	Estonia	0.09	0.09	0.06	-33
	Latvia	0.23	0.18	0.18	
	Lithuania	0.25	0.31	0.27	-13
J01MA02	ciprofloxacin				
	Estonia	0.63	0.68	0.70	3
	Latvia	0.78	0.85	0.89	6
	Lithuania	0.58	0.61	0.66	8
J01MA06	norfloxacin				
	Estonia	0.28	0.26	0.26	
	Latvia	0.20	0.20	0.19	-3
	Lithuania	0.23	0.23	0.23	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01MA12	levofloxacin				
	Estonia	0.01	0.01	0.11	
	Latvia	-	-	-	
	Lithuania	-	-	0.20	
J01MA14	moxifloxacin				
	Estonia	0.01	0.03	0.03	
	Latvia	0.03	0.04	0.05	24
	Lithuania	0.01	0.02	0.01	-50
J01MB	Other quinolones				
	Estonia	-	-	-	
	Latvia	0.05	0.04	0.04	-6
	Lithuania	0.08	0.07	0.05	-29
J01MB04	pipemidic acid				
	Estonia	-	-	-	
	Latvia	0.05	0.04	0.04	-6
	Lithuania	0.08	0.07	0.05	-29
J01X	OTHER ANTIBACTERIALS				
	Estonia	0.86	0.89	0.91	2
	Latvia	0.37	0.40	0.43	9
	Lithuania	2.28	2.09	1.64	-22
J01XA	Glycopeptide antibacterials				
	Estonia	0.01	0.01	0.01	
	Latvia	0.02	0.02	0.02	-4
	Lithuania	0.01	0.01	0.02	100
J01XA01	vancomycin				
	Estonia	0.01	0.01	0.01	
	Latvia	0.02	0.02	0.02	-4
	Lithuania	0.01	0.01	0.02	100
J01XD	Imidazole derivatives				
	Estonia	0.35	0.36	0.35	-3
	Latvia	0.09	0.12	0.16	25
	Lithuania	1.03	0.82	0.22	-73
J01XD01	metronidazole				
	Estonia	0.35	0.36	0.35	-3
	Latvia	0.07	0.10	0.14	42
	Lithuania	1.03	0.82	0.22	-73
J01XD02	tinidazole				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.02	-39
	Lithuania	-	-	-	
J01XE	Nitrofurantoin derivatives				
	Estonia	0.49	0.51	0.54	6
	Latvia	0.21	0.20	0.21	5
	Lithuania	1.19	1.20	1.36	13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J01XE01	nitrofurantoin				
	Estonia	0.49	0.51	0.54	6
	Latvia	0.21	0.20	0.21	5
	Lithuania	1.19	1.20	1.36	13
J01XX	Other antibacterials				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.06	0.05	0.05	-8
	Lithuania	0.05	0.05	0.04	-20
J01XX07	nitroxoline				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.05	0.05	0.04	-11
	Lithuania	0.04	0.04	0.04	
J01XX08	linezolid				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	<0.01	
J02	ANTIMYCOTICS FOR SYSTEMIC USE				
	Estonia	0.35	0.39	0.38	-3
	Latvia	0.31	0.31	0.33	9
	Lithuania	0.21	0.25	0.26	4
J02A	ANTIMYCOTICS FOR SYSTEMIC USE				
	Estonia	0.34	0.39	0.37	-5
	Latvia	0.31	0.31	0.33	9
	Lithuania	0.21	0.25	0.26	4
J02AA	Antibiotics				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

Consumption of antibiotics for systemic use (J01)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J02AA01	amphotericin B				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J02AB	Imidazole derivatives				
	Estonia	0.12	0.13	0.11	-15
	Latvia	0.10	0.09	0.08	-7
	Lithuania	0.07	0.08	0.08	
J02AB02	ketoconazole				
	Estonia	0.12	0.13	0.11	-15
	Latvia	0.10	0.09	0.08	-7
	Lithuania	0.07	0.08	0.08	
J02AC	Triazole derivatives				
	Estonia	0.23	0.26	0.26	
	Latvia	0.21	0.22	0.25	16
	Lithuania	0.14	0.17	0.18	6
J02AC01	fluconazole				
	Estonia	0.13	0.14	0.13	-7
	Latvia	0.14	0.13	0.14	6
	Lithuania	0.11	0.12	0.13	8
J02AC02	itraconazole				
	Estonia	0.09	0.11	0.12	9
	Latvia	0.06	0.08	0.11	32
	Lithuania	0.03	0.04	0.05	25
J02AC03	voriconazole				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J02AX	Other antimycotics for systemic use				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J02AX04	caspofungin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J04	ANTIMYCOBACTERIALS				
	Estonia	0.32	0.37	0.37	
	Latvia	0.46	0.50	0.11	-79
	Lithuania	0.79	0.80	0.79	-1
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS				
	Estonia	0.30	0.36	0.35	-3
	Latvia	0.46	0.50	0.11	-79
	Lithuania	0.79	0.80	0.79	-1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J04AA	Aminosalicic acid and derivatives				
	Estonia	0.01	0.03	0.01	-67
	Latvia	0.06	0.03	<0.01	
	Lithuania	-	-	-	
J04AA01	4-aminosalicylic acid				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AA02	sodium aminosalicylate				
	Estonia	<0.01	0.01	0.01	
	Latvia	0.06	0.03	<0.01	
	Lithuania	-	-	-	
J04AB	Antibiotics				
	Estonia	0.06	0.04	0.08	100
	Latvia	0.16	0.13	0.11	-18
	Lithuania	0.33	0.32	0.26	-19
J04AB01	cycloserine				
	Estonia	0.04	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AB02	rifampicin				
	Estonia	<0.01	0.02	0.03	50
	Latvia	0.16	0.13	0.11	-18
	Lithuania	0.33	0.32	0.26	-19
J04AB30	capreomycin				
	Estonia	0.02	-	0.03	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AC	Hydrazides				
	Estonia	0.06	<0.01	0.08	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AC01	isoniazid				
	Estonia	0.01	<0.01	0.08	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AC51	isoniazid, combinations				
	Estonia	0.05	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AD	Thiocarbamide derivatives				
	Estonia	0.04	0.02	0.04	100
	Latvia	0.04	0.05	<0.01	
	Lithuania	0.05	0.07	0.07	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J04AD01	protonamide				
	Estonia	0.04	0.02	0.04	100
	Latvia	0.04	0.05	<0.01	
	Lithuania	0.05	0.07	0.07	
J04AK	Other drugs for treatment of tuberculosis				
	Estonia	0.13	0.24	0.06	-75
	Latvia	0.21	0.29	<0.01	
	Lithuania	0.42	0.41	0.45	10
J04AK01	pyrazinamide				
	Estonia	0.04	0.08	0.06	-25
	Latvia	0.09	0.11	<0.01	
	Lithuania	0.19	0.18	0.22	22
J04AK02	ethambutol				
	Estonia	0.09	0.15	-	
	Latvia	0.12	0.18	<0.01	
	Lithuania	0.23	0.23	0.23	
J04AM	Combinations of drugs for treatment of tuberculosis				
	Estonia	0.01	0.04	0.07	75
	Latvia	-	-	-	
	Lithuania	-	0.01	0.03	200
J04AM02	rifampicin and isoniazid				
	Estonia	0.01	0.04	0.07	75
	Latvia	-	-	-	
	Lithuania	-	0.01	0.03	200
J04B	DRUGS FOR TREATMENT OF LEPRO				
	Estonia	0.01	0.01	0.02	100
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04BA	Drugs for treatment of lepra				
	Estonia	0.01	0.01	0.02	100
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04BA02	dapsone				
	Estonia	0.01	0.01	0.02	100
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05	ANTIVIRALS FOR SYSTEMIC USE				
	Estonia	2.61	3.19	3.40	7
	Latvia	0.73	0.83	0.92	11
	Lithuania	0.25	0.47	0.20	-57
J05A	DIRECT ACTING ANTIVIRALS				
	Estonia	2.61	3.19	3.40	7
	Latvia	0.73	0.83	0.92	11
	Lithuania	0.25	0.47	0.20	-57

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors				
	Estonia	0.24	0.25	0.32	28
	Latvia	0.26	0.27	0.26	-7
	Lithuania	0.17	0.13	0.13	
J05AB01	aciclovir				
	Estonia	0.04	0.04	0.05	25
	Latvia	0.04	0.05	0.05	18
	Lithuania	0.04	0.05	0.06	20
J05AB04	ribavirin				
	Estonia	0.13	0.13	0.18	38
	Latvia	0.21	0.22	0.19	-12
	Lithuania	0.12	0.07	0.06	-14
J05AB11	valaciclovir				
	Estonia	0.06	0.07	0.09	29
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.02	100
J05AB14	valganciclovir				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	0.01	0.01	-8
	Lithuania	-	-	-	
J05AE	Protease inhibitors				
	Estonia	0.15	0.37	0.37	
	Latvia	0.05	0.09	0.11	17
	Lithuania	0.03	0.06	<0.01	
J05AE01	saquinavir				
	Estonia	-	-	-	
	Latvia	0.03	0.02	0.01	-23
	Lithuania	<0.01	<0.01	-	
J05AE03	ritonavir				
	Estonia	0.02	0.13	0.04	-69
	Latvia	0.01	0.04	0.05	22
	Lithuania	<0.01	<0.01	-	
J05AE04	nelfinavir				
	Estonia	0.02	0.04	0.01	-75
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05AE06	lopinavir				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.05	-	
J05AE07	fosamprenavir				
	Estonia	0.10	0.14	0.19	36
	Latvia	<0.01	0.01	0.02	30
	Lithuania	<0.01	<0.01	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J05AE08	atazanavir				
	Estonia	0.02	0.02	0.04	100
	Latvia	0.01	0.01	0.02	53
	Lithuania	-	<0.01	-	
J05AE10	darunavir				
	Estonia	0.01	0.04	0.09	125
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J05AE12	boceprevir				
	Estonia	-	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors				
	Estonia	0.52	0.35	0.20	-43
	Latvia	0.09	0.07	0.11	44
	Lithuania	0.01	0.01	0.02	100
J05AF01	zidovudine				
	Estonia	0.04	0.02	0.01	-50
	Latvia	0.01	0.01	0.03	85
	Lithuania	-	-	-	
J05AF02	didanosine				
	Estonia	0.24	0.17	0.09	-47
	Latvia	0.01	0.01	0.01	-13
	Lithuania	-	-	-	
J05AF04	stavudine				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AF05	lamivudine				
	Estonia	0.24	0.15	0.09	-40
	Latvia	0.03	0.02	0.03	17
	Lithuania	-	-	-	
J05AF06	abacavir				
	Estonia	<0.01	0.01	0.01	
	Latvia	0.02	0.01	0.02	37
	Lithuania	-	-	-	
J05AF07	tenofovir disoproxil				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.02	148
	Lithuania	<0.01	0.01	0.01	
J05AF10	entecavir				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J05AG	Non-nucleoside reverse transcriptase inhibitors				
	Estonia	0.51	0.63	0.58	-8
	Latvia	0.15	0.17	0.19	8
	Lithuania	<0.01	-	0.01	
J05AG01	nevirapine				
	Estonia	0.02	0.04	0.04	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AG03	efavirenz				
	Estonia	0.49	0.59	0.54	-8
	Latvia	0.14	0.17	0.19	9
	Lithuania	<0.01	-	0.01	
J05AH	Neuraminidase inhibitors				
	Estonia	0.06	0.02	0.01	-50
	Latvia	<0.01	0.07	0.01	-84
	Lithuania	0.01	0.24	0.01	-96
J05AH01	zanamivir				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.10	<0.01	
J05AH02	oseltamivir				
	Estonia	0.06	0.02	0.01	-50
	Latvia	<0.01	0.07	0.01	-84
	Lithuania	0.01	0.13	<0.01	
J05AR	Antivirals for treatment of HIV infections, combinations				
	Estonia	1.13	1.56	1.89	21
	Latvia	0.18	0.15	0.25	67
	Lithuania	-	-	0.01	
J05AR01	zidovudine and lamivudine				
	Estonia	0.59	0.62	0.48	-23
	Latvia	0.13	0.10	0.14	45
	Lithuania	-	-	-	
J05AR02	lamivudine and abacavir				
	Estonia	0.14	0.44	0.75	70
	Latvia	0.04	0.03	0.07	109
	Lithuania	-	-	-	
J05AR03	tenofovir disoproxil and emtricitabine				
	Estonia	0.02	0.06	0.21	250
	Latvia	<0.01	0.01	0.01	90
	Lithuania	-	-	-	
J05AR04	zidovudine, lamivudine and abacavir				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.03	114
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
J05AR10	lopinavir and ritonavir				
	Estonia	0.38	0.44	0.45	2
	Latvia	-	-	-	
	Lithuania	-	-	0.01	
J05AX	Other antivirals				
	Estonia	<0.01	0.01	0.03	200
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AX08	raltegravir				
	Estonia	<0.01	0.01	0.03	200
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS				
	Estonia	6.88	7.74	8.60	11
	Latvia	4.35	4.39	4.79	9
	Lithuania	4.85	5.35	5.56	4
L02	ENDOCRINE THERAPY				
	Estonia	3.18	3.54	3.80	7
	Latvia	2.85	2.79	3.12	12
	Lithuania	3.32	3.57	3.60	1
L02A	HORMONES AND RELATED AGENTS				
	Estonia	0.14	0.13	0.14	8
	Latvia	1.38	1.17	1.49	27
	Lithuania	1.61	1.67	1.71	2
L02AB	Progestogens				
	Estonia	0.02	0.01	0.01	
	Latvia	0.04	0.04	0.02	-41
	Lithuania	0.41	0.38	0.43	13
L02AB01	megestrol				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.02	-41
	Lithuania	0.41	0.38	0.43	13
L02AB02	medroxyprogesterone				
	Estonia	0.02	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L02AE	Gonadotropin releasing hormone analogues				
	Estonia	0.12	0.11	0.12	9
	Latvia	1.35	1.14	1.47	29
	Lithuania	1.20	1.30	1.28	-2
L02AE01	buserelin				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L02AE02	leuprorelin				
	Estonia	<0.01	<0.01	-	
	Latvia	0.57	0.18	0.69	291
	Lithuania	0.04	0.02	0.04	100
L02AE03	goserelin				
	Estonia	0.08	0.06	0.06	
	Latvia	0.30	0.27	0.13	-53
	Lithuania	0.28	0.35	0.28	-20
L02AE04	triptorelin				
	Estonia	0.04	0.04	0.04	
	Latvia	0.48	0.69	0.65	-6
	Lithuania	0.87	0.93	0.94	1

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L02AE05	histrelin				
	Estonia	-	<0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	0.02	
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS				
	Estonia	3.05	3.41	3.67	8
	Latvia	1.47	1.62	1.63	1
	Lithuania	1.71	1.89	1.90	1
L02BA	Anti-estrogens				
	Estonia	0.41	0.45	0.51	13
	Latvia	0.81	0.90	0.96	6
	Lithuania	0.89	0.93	1.08	16
L02BA01	tamoxifen				
	Estonia	0.40	0.39	0.46	18
	Latvia	0.81	0.90	0.95	6
	Lithuania	0.89	0.92	1.06	15
L02BA03	fulvestrant				
	Estonia	0.01	0.05	0.06	20
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	<0.01	0.01	
L02BB	Anti-androgens				
	Estonia	1.49	1.80	1.93	7
	Latvia	0.29	0.27	0.23	-16
	Lithuania	0.36	0.45	0.30	-33
L02BB01	flutamide				
	Estonia	-	-	-	
	Latvia	0.09	0.07	0.06	-14
	Lithuania	<0.01	<0.01	-	
L02BB03	bicalutamide				
	Estonia	1.49	1.80	1.93	7
	Latvia	0.20	0.20	0.17	-17
	Lithuania	0.36	0.45	0.30	-33
L02BG	Aromatase inhibitors				
	Estonia	1.14	1.17	1.21	3
	Latvia	0.36	0.45	0.44	-1
	Lithuania	0.46	0.52	0.52	
L02BG03	anastrozole				
	Estonia	0.55	0.52	0.48	-8
	Latvia	0.24	0.33	0.35	6
	Lithuania	0.26	0.29	0.26	-10
L02BG04	letrozole				
	Estonia	0.52	0.56	0.64	14
	Latvia	0.08	0.08	0.06	-28
	Lithuania	0.09	0.11	0.13	18

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L02BG06	exemestane				
	Estonia	0.08	0.09	0.09	
	Latvia	0.05	0.04	0.04	-6
	Lithuania	0.11	0.13	0.14	8
L02BX	Other hormone antagonists and related agents				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L02BX03	abiraterone				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L03	IMMUNOSTIMULANTS				
	Estonia	0.67	0.83	0.88	6
	Latvia	0.90	0.93	0.94	2
	Lithuania	0.74	0.79	0.88	11
L03A	IMMUNOSTIMULANTS				
	Estonia	0.67	0.83	0.88	6
	Latvia	0.90	0.93	0.94	2
	Lithuania	0.74	0.79	0.88	11
L03AA	Colony stimulating factors				
	Estonia	0.01	0.02	0.04	100
	Latvia	0.05	0.08	0.09	15
	Lithuania	0.03	0.04	0.06	50
L03AA02	filgrastim				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.02	0.02	28
	Lithuania	0.03	0.04	0.05	25
L03AA13	pegfilgrastim				
	Estonia	-	0.01	0.02	100
	Latvia	0.04	0.06	0.07	12
	Lithuania	-	-	0.01	
L03AB	Interferons				
	Estonia	0.59	0.71	0.75	6
	Latvia	0.77	0.76	0.78	3
	Lithuania	0.64	0.68	0.73	7
L03AB04	interferon alfa-2a				
	Estonia	0.03	0.03	0.04	33
	Latvia	0.05	0.06	0.06	11
	Lithuania	-	-	-	
L03AB05	interferon alfa-2b				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	-4
	Lithuania	0.12	0.12	0.09	-25

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L03AB07	interferon beta-1a				
	Estonia	0.33	0.41	0.42	2
	Latvia	0.37	0.34	0.37	8
	Lithuania	0.31	0.33	0.36	9
L03AB08	interferon beta-1b				
	Estonia	0.06	0.08	0.10	25
	Latvia	0.10	0.09	0.10	3
	Lithuania	0.04	0.04	0.05	25
L03AB10	peginterferon alfa-2b				
	Estonia	0.08	0.12	0.10	-17
	Latvia	0.06	0.12	0.13	11
	Lithuania	0.12	0.15	0.17	13
L03AB11	peginterferon alfa-2a				
	Estonia	0.09	0.07	0.10	43
	Latvia	0.18	0.14	0.11	-21
	Lithuania	0.04	0.05	0.06	20
L03AX	Other immunostimulants				
	Estonia	0.06	0.09	0.09	
	Latvia	0.08	0.09	0.07	-20
	Lithuania	0.07	0.07	0.09	29
L03AX03	BCG vaccine				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.01	-65
	Lithuania	0.02	0.01	0.04	300
L03AX13	glatiramer acetate				
	Estonia	0.06	0.09	0.09	
	Latvia	0.06	0.07	0.06	-10
	Lithuania	0.06	0.06	0.05	-17
L04	IMMUNOSUPPRESSANTS				
	Estonia	3.03	3.38	3.91	16
	Latvia	0.59	0.67	0.73	9
	Lithuania	0.79	0.99	1.07	8
L04A	IMMUNOSUPPRESSANTS				
	Estonia	3.03	3.38	3.91	16
	Latvia	0.59	0.67	0.73	9
	Lithuania	0.79	0.99	1.07	8
L04AA	Selective immunosuppressants				
	Estonia	0.54	0.57	0.63	11
	Latvia	0.29	0.31	0.37	19
	Lithuania	0.23	0.23	0.26	13
L04AA06	mycophenolic acid				
	Estonia	0.18	0.20	0.21	5
	Latvia	0.13	0.18	0.22	23
	Lithuania	0.15	0.16	0.18	13

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L04AA10	sirolimus				
	Estonia	0.02	0.02	0.02	
	Latvia	0.02	0.01	0.01	-14
	Lithuania	0.01	0.01	0.01	
L04AA13	leflunomide				
	Estonia	0.34	0.34	0.39	15
	Latvia	0.15	0.12	0.13	13
	Lithuania	0.07	0.06	0.07	17
L04AA24	abatacept				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
L04AA27	fingolimod				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AB	Tumor necrosis factor alpha (TNF-α) inhibitors				
	Estonia	0.27	0.36	0.46	28
	Latvia	0.07	0.11	0.10	-6
	Lithuania	0.17	0.27	0.20	-26
L04AB01	etanercept				
	Estonia	0.09	0.10	0.12	20
	Latvia	0.04	0.05	0.06	15
	Lithuania	0.02	0.09	0.11	22
L04AB02	infliximab				
	Estonia	0.09	0.12	0.16	33
	Latvia	0.03	0.06	0.04	-24
	Lithuania	0.12	0.12	0.04	-67
L04AB04	adalimumab				
	Estonia	0.08	0.11	0.14	27
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.05	0.04	-20
L04AB05	certolizumab pegol				
	Estonia	<0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	
L04AB06	golimumab				
	Estonia	<0.01	0.02	0.04	100
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AC	Interleukin inhibitors				
	Estonia	-	0.02	0.04	100
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
L04AC05	ustekinumab				
	Estonia	<0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L04AC07	tocilizumab				
	Estonia	<0.01	0.02	0.03	50
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AD	Calcineurin inhibitors				
	Estonia	0.23	0.25	0.28	12
	Latvia	0.16	0.17	0.17	
	Lithuania	0.14	0.14	0.16	14
L04AD01	ciclosporin				
	Estonia	0.23	0.23	0.22	-4
	Latvia	0.15	0.12	0.12	
	Lithuania	0.14	0.13	0.12	-8
L04AD02	tacrolimus				
	Estonia	<0.01	0.02	0.05	150
	Latvia	0.02	0.05	0.05	4
	Lithuania	<0.01	0.01	0.04	300
L04AX	Other immunosuppressants				
	Estonia	1.98	2.17	2.51	16
	Latvia	0.07	0.09	0.09	6
	Lithuania	0.25	0.35	0.45	29
L04AX01	azathioprine				
	Estonia	0.22	0.23	0.28	22
	Latvia	0.06	0.08	0.08	3
	Lithuania	0.12	0.13	0.14	8
L04AX02	thalidomide				
	Estonia	0.01	0.01	0.03	200
	Latvia	-	-	-	
	Lithuania	-	-	-	
L04AX03	methotrexate				
	Estonia	1.75	1.91	2.18	14
	Latvia	0.01	0.01	0.01	30
	Lithuania	0.13	0.22	0.31	41
L04AX04	lenalidomide				
	Estonia	<0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	<0.01	


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M	MUSCULO-SKELETAL SYSTEM				
	Estonia	60.22	63.49	69.42	9
	Latvia	58.56	63.75	68.19	7
	Lithuania	59.36	66.09	69.33	5
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS				
	Estonia	52.62	55.84	61.02	9
	Latvia	50.77	54.55	58.04	6
	Lithuania	53.39	60.00	62.28	4
M01A	ANTIINFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS, NON-STERIODS				
	Estonia	52.60	55.83	61.00	9
	Latvia	50.75	54.54	58.02	6
	Lithuania	53.37	59.98	62.25	4
M01AB	Acetic acid derivatives and related substances				
	Estonia	13.48	13.38	13.43	
	Latvia	25.84	26.76	28.68	7
	Lithuania	23.61	23.94	25.88	8
M01AB01	indometacin				
	Estonia	0.27	0.23	0.23	
	Latvia	0.40	0.34	0.34	-2
	Lithuania	1.70	1.76	1.90	8
M01AB05	diclofenac				
	Estonia	13.12	13.09	13.12	
	Latvia	21.48	22.19	23.85	7
	Lithuania	18.84	19.03	20.49	8
M01AB15	ketorolac				
	Estonia	-	-	-	
	Latvia	1.26	1.22	1.29	6
	Lithuania	2.35	2.43	2.60	7
M01AB16	aceclofenac				
	Estonia	-	-	0.02	
	Latvia	0.92	1.19	1.41	19
	Lithuania	-	-	0.11	
M01AB55	diclofenac, combinations				
	Estonia	0.08	0.07	0.06	-14
	Latvia	1.77	1.83	1.80	-2
	Lithuania	0.73	0.73	0.77	5
M01AC	Oxicams				
	Estonia	5.67	6.02	5.98	-1
	Latvia	3.45	3.99	4.19	5
	Lithuania	5.51	6.29	6.98	11
M01AC01	piroxicam				
	Estonia	0.15	0.20	0.18	-10
	Latvia	0.13	0.14	0.11	-18
	Lithuania	0.80	0.83	0.89	7

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M01AC05	lornoxicam				
	Estonia	0.95	0.98	0.94	-4
	Latvia	0.64	0.79	0.90	14
	Lithuania	0.93	0.99	1.15	16
M01AC06	meloxicam				
	Estonia	4.57	4.83	4.86	1
	Latvia	2.68	3.06	3.17	3
	Lithuania	3.77	4.47	4.94	11
M01AE	Propionic acid derivatives				
	Estonia	21.79	24.36	27.82	14
	Latvia	15.86	18.49	19.89	8
	Lithuania	18.79	23.10	22.36	-3
M01AE01	ibuprofen				
	Estonia	20.55	22.52	23.38	4
	Latvia	15.50	17.98	19.30	7
	Lithuania	17.68	20.34	18.30	-10
M01AE02	naproxen				
	Estonia	<0.01	0.18	0.43	139
	Latvia	-	-	-	
	Lithuania	-	1.23	1.95	59
M01AE03	ketoprofen				
	Estonia	0.84	0.91	1.05	15
	Latvia	0.20	0.25	0.29	16
	Lithuania	0.68	0.69	0.75	9
M01AE09	flurbiprofen				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.02	0.02	
	Lithuania	-	-	-	
M01AE12	oxaprozin				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	-	-	
M01AE17	dexketoprofen				
	Estonia	0.40	0.44	0.58	32
	Latvia	0.16	0.25	0.29	17
	Lithuania	0.42	0.58	0.80	38
M01AE51	ibuprofen, combinations (ibuprofen + pseudoephedrine)				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	<0.01	-	
M01AE52	naproxen and esomeprazole				
	Estonia	-	0.31	2.38	668
	Latvia	-	-	-	
	Lithuania	-	0.25	0.56	124

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M01AG	Fenamates				
	Estonia	0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
M01AG02	tolfenamic acid				
	Estonia	0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
M01AH	Coxibs				
	Estonia	2.29	2.88	3.73	30
	Latvia	0.33	0.53	1.12	110
	Lithuania	0.81	1.33	1.41	6
M01AH01	celecoxib				
	Estonia	0.14	0.19	0.37	95
	Latvia	0.04	0.04	0.07	102
	Lithuania	0.38	0.52	0.49	-6
M01AH05	etoricoxib				
	Estonia	2.15	2.68	3.35	25
	Latvia	0.28	0.50	1.05	111
	Lithuania	0.44	0.81	0.92	14
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids				
	Estonia	9.36	9.18	10.04	9
	Latvia	5.28	4.76	4.14	-13
	Lithuania	4.65	5.32	5.61	5
M01AX01	nabumetone				
	Estonia	0.47	0.46	0.50	9
	Latvia	0.03	0.02	0.01	-32
	Lithuania	0.07	0.07	0.07	
M01AX05	glucosamine				
	Estonia	8.89	8.73	9.54	9
	Latvia	1.81	1.68	1.70	1
	Lithuania	0.72	1.01	1.03	2
M01AX17	nimesulide				
	Estonia	-	-	-	
	Latvia	3.45	3.06	2.43	-21
	Lithuania	3.85	4.24	4.50	6
M01C	SPECIFIC ANTIRHEUMATIC AGENTS				
	Estonia	0.02	0.01	0.02	100
	Latvia	0.02	0.02	0.02	54
	Lithuania	0.02	0.02	0.03	50
M01CC	Penicillamine and similar agents				
	Estonia	0.02	0.01	0.02	100
	Latvia	0.02	0.02	0.02	54
	Lithuania	0.02	0.02	0.03	50

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M01CC01	penicillamine				
	Estonia	0.02	0.01	0.02	100
	Latvia	0.02	0.02	0.02	54
	Lithuania	0.02	0.02	0.03	50
M03	MUSCLE RELAXANTS				
	Estonia	0.58	0.62	0.69	11
	Latvia	2.69	2.85	3.24	13
	Lithuania	1.52	1.61	1.96	22
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS				
	Estonia	0.58	0.62	0.69	11
	Latvia	2.69	2.85	3.24	13
	Lithuania	1.52	1.61	1.96	22
M03BX	Other centrally acting agents				
	Estonia	0.58	0.62	0.69	11
	Latvia	2.69	2.85	3.24	13
	Lithuania	1.45	1.53	1.88	23
M03BX01	baclofen				
	Estonia	0.13	0.13	0.14	8
	Latvia	0.14	0.16	0.13	-16
	Lithuania	0.20	0.21	0.25	19
M03BX02	tizanidine				
	Estonia	0.45	0.49	0.54	10
	Latvia	0.12	0.12	0.13	6
	Lithuania	-	-	-	
M03BX04	tolperisone				
	Estonia	0.01	0.01	<0.01	
	Latvia	2.43	2.57	2.98	16
	Lithuania	1.25	1.32	1.63	23

Consumption of non-steroidal antiinflammatory and antirheumatic products (M01A)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M04	ANTIGOUT PREPARATIONS				
	Estonia	2.44	2.54	2.91	15
	Latvia	0.88	1.04	1.34	29
	Lithuania	1.06	1.22	1.59	30
M04A	ANTIGOUT PREPARATIONS				
	Estonia	2.44	2.54	2.91	15
	Latvia	0.88	1.04	1.34	29
	Lithuania	1.06	1.22	1.59	30
M04AA	Preparations inhibiting uric acid production				
	Estonia	2.43	2.53	2.90	15
	Latvia	0.88	1.04	1.34	29
	Lithuania	1.06	1.22	1.59	30
M04AA01	allopurinol				
	Estonia	2.43	2.53	2.90	15
	Latvia	0.88	1.03	1.26	22
	Lithuania	1.06	1.21	1.51	25
M04AA03	febuxostat				
	Estonia	-	-	-	
	Latvia	<0.01	0.01	0.08	992
	Lithuania	-	0.01	0.09	800
M04AB	Preparations increasing uric acid excretion				
	Estonia	0.02	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
M04AB03	benzbromarone				
	Estonia	0.02	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
M05	DRUGS FOR TREATMENT OF BONE DISEASES				
	Estonia	4.58	4.49	4.80	7
	Latvia	4.22	5.30	5.56	5
	Lithuania	3.38	3.26	3.57	10
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION				
	Estonia	4.58	4.49	4.80	7
	Latvia	4.22	5.30	5.56	5
	Lithuania	3.38	3.26	3.57	10
M05BA	Bisphosphonates				
	Estonia	2.09	1.86	2.41	30
	Latvia	2.61	2.99	3.30	10
	Lithuania	1.80	1.71	1.76	3
M05BA02	clodronic acid				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.06	-4
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M05BA04	alendronic acid				
	Estonia	0.65	0.56	0.92	64
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	0.40	0.37	0.36	-3
M05BA06	ibandronic acid				
	Estonia	0.93	0.80	0.97	21
	Latvia	0.96	0.92	1.05	15
	Lithuania	0.73	0.73	0.81	11
M05BA07	risedronic acid				
	Estonia	0.52	0.49	0.52	6
	Latvia	1.59	2.00	2.18	9
	Lithuania	0.68	0.61	0.58	-5
M05BB	Bisphosphonates, combinations				
	Estonia	2.42	2.52	2.19	-13
	Latvia	1.19	1.82	1.66	-9
	Lithuania	0.94	0.95	0.80	-16
M05BB03	alendronic acid and colecalciferol				
	Estonia	2.42	2.52	2.19	-13
	Latvia	1.19	1.82	1.66	-9
	Lithuania	0.48	0.45	0.28	-38
M05BB04	risedronic acid, calcium and colecalciferol, sequential				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.46	0.50	0.51	2
M05BX	Other drugs affecting bone structure and mineralization				
	Estonia	0.06	0.10	0.19	90
	Latvia	0.42	0.49	0.61	23
	Lithuania	0.64	0.59	1.02	73
M05BX03	strontium ranelate				
	Estonia	0.06	0.09	0.09	
	Latvia	0.42	0.47	0.53	12
	Lithuania	0.64	0.53	0.58	9
M05BX04	denosumab				
	Estonia	<0.01	0.01	0.10	900
	Latvia	<0.01	0.02	0.08	277
	Lithuania	<0.01	0.07	0.43	514
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
M09AX	Other drugs for disorders of the musculo-skeletal system				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	
M09AX01	hyaluronic acid				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	


Consumption of drugs for treatment of bone disease (M05B)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N	NERVOUS SYSTEM				
	Estonia	85.46	90.70	97.78	8
	Latvia	79.26	80.45	82.26	2
	Lithuania	118.85	123.86	136.40	10
N02	ANALGESICS				
	Estonia	12.56	13.29	14.13	6
	Latvia	13.63	12.22	11.08	-9
	Lithuania	14.58	13.71	14.11	3
N02A	OPIOIDS				
	Estonia	2.74	2.92	3.19	9
	Latvia	2.12	2.31	2.63	14
	Lithuania	2.93	1.71	1.84	8
N02AA	Natural opium alkaloids				
	Estonia	1.01	1.13	1.24	10
	Latvia	0.42	0.46	0.60	30
	Lithuania	0.27	0.29	0.32	10
N02AA01	morphine				
	Estonia	0.18	0.16	0.16	
	Latvia	0.09	0.09	0.10	3
	Lithuania	0.18	0.18	0.20	11
N02AA05	oxycodone				
	Estonia	0.15	0.13	0.12	-8
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N02AA08	dihydrocodeine				
	Estonia	0.03	0.04	0.04	
	Latvia	0.09	0.09	0.09	6
	Lithuania	-	-	-	
N02AA59	codeine, combinations excl. psycholeptics				
	Estonia	0.65	0.80	0.92	15
	Latvia	0.24	0.28	0.41	46
	Lithuania	0.10	0.11	0.13	18
N02AB	Phenylpiperidine derivatives				
	Estonia	0.07	0.07	0.08	14
	Latvia	0.37	0.43	0.49	15
	Lithuania	0.62	0.64	0.67	5
N02AB02	pethidine				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.03	0.03	
N02AB03	fentanyl				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.37	0.42	0.49	15
	Lithuania	0.60	0.62	0.64	3


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N02AX	Other opioids				
	Estonia	1.66	1.72	1.86	8
	Latvia	1.32	1.42	1.54	9
	Lithuania	2.04	0.78	0.85	9
N02AX02	tramadol				
	Estonia	1.63	1.68	1.82	8
	Latvia	1.32	1.41	1.53	8
	Lithuania	2.04	0.78	0.85	9
N02AX52	tramadol, combinations				
	Estonia	0.03	0.03	0.04	33
	Latvia	<0.01	0.01	0.01	37
	Lithuania	-	<0.01	<0.01	
N02B	OTHER ANALGESICS AND ANTIPYRETICS				
	Estonia	9.52	10.02	10.52	5
	Latvia	11.41	9.79	8.30	-15
	Lithuania	11.38	11.67	11.88	2
N02BA	Salicylic acid and derivatives				
	Estonia	2.26	2.13	2.13	
	Latvia	6.46	4.69	3.51	-25
	Lithuania	1.63	1.61	1.99	24
N02BA01	acetylsalicylic acid				
	Estonia	1.30	1.31	1.27	-3
	Latvia	0.72	0.71	0.62	-12
	Lithuania	1.39	1.40	1.39	-1
N02BA03	choline salicylate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.14	0.10	0.08	-20

Consumption of opioids (N02A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N02BA51	acetylsalicylic acid, combinations excl. psycholeptics				
	Estonia	0.95	0.82	0.86	5
	Latvia	5.74	3.98	2.89	-28
	Lithuania	0.11	0.11	0.52	373
N02BB	Pyrazolones				
	Estonia	0.04	0.02	0.01	-50
	Latvia	0.84	0.82	0.76	-7
	Lithuania	1.13	1.10	1.09	-1
N02BB02	metamizole sodium				
	Estonia	0.04	0.02	0.01	-50
	Latvia	0.84	0.82	0.76	-7
	Lithuania	1.13	1.10	1.09	-1
N02BE	Anilides				
	Estonia	7.21	7.84	8.37	7
	Latvia	4.09	4.26	4.02	-6
	Lithuania	8.62	8.96	8.79	-2
N02BE01	paracetamol				
	Estonia	4.77	5.16	5.67	10
	Latvia	1.64	1.81	1.72	-5
	Lithuania	2.74	3.14	3.03	-4
N02BE51	paracetamol, combinations excl. psycholeptics				
	Estonia	2.44	2.68	2.70	1
	Latvia	2.45	2.45	2.29	-6
	Lithuania	5.89	5.82	5.76	-1
N02BG	Other analgesics and antipyretics				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.01	0.01	44
	Lithuania	<0.01	0.01	0.01	
N02BG07	flupirtine				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.01	0.01	44
	Lithuania	<0.01	0.01	0.01	
N02C	ANTIMIGRAINE PREPARATIONS				
	Estonia	0.30	0.35	0.42	20
	Latvia	0.10	0.13	0.15	20
	Lithuania	0.27	0.33	0.40	21
N02CC	Selective serotonin (5HT1) agonists				
	Estonia	0.30	0.35	0.42	20
	Latvia	0.10	0.13	0.15	20
	Lithuania	0.27	0.33	0.40	21
N02CC01	sumatriptan				
	Estonia	0.26	0.30	0.35	17
	Latvia	0.09	0.11	0.13	20
	Lithuania	0.23	0.28	0.35	25

Consumption of other analgesics and antipyretics (N02B)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N02CC02	naratriptan				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.01	
N02CC03	zolmitriptan				
	Estonia	0.03	0.03	0.03	
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.02	
N02CC04	rizatriptan				
	Estonia	<0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
N02CC06	eletriptan				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	6
	Lithuania	<0.01	0.01	<0.01	
N02CC07	frovatriptan				
	Estonia	<0.01	0.01	0.02	100
	Latvia	<0.01	0.01	0.01	24
	Lithuania	<0.01	0.01	0.01	
N03	ANTIEPILEPTICS				
	Estonia	6.20	6.29	6.93	10
	Latvia	6.53	6.97	7.22	4
	Lithuania	7.81	8.20	9.09	11
N03A	ANTIEPILEPTICS				
	Estonia	6.20	6.29	6.93	10
	Latvia	6.53	6.97	7.22	4
	Lithuania	7.81	8.20	9.09	11

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N03AA	Barbiturates and derivatives				
	Estonia	0.55	0.50	0.53	6
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AA02	phenobarbital				
	Estonia	0.48	0.44	0.46	5
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AA03	primidone				
	Estonia	0.07	0.06	0.07	17
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AB	Hydantoin derivatives				
	Estonia	0.06	0.06	0.05	-17
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AB02	phenytoin				
	Estonia	0.06	0.06	0.05	-17
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AD	Succinimide derivatives				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AD01	ethosuximide				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AE	Benzodiazepine derivatives				
	Estonia	0.67	0.67	0.74	10
	Latvia	1.86	1.86	1.83	-1
	Lithuania	2.30	2.32	2.42	4
N03AE01	clonazepam				
	Estonia	0.67	0.67	0.74	10
	Latvia	1.86	1.86	1.83	-1
	Lithuania	2.30	2.32	2.42	4
N03AF	Carboxamide derivatives				
	Estonia	2.88	2.80	2.98	6
	Latvia	1.85	2.00	2.04	2
	Lithuania	2.54	2.64	2.92	11
N03AF01	carbamazepine				
	Estonia	2.11	2.02	2.14	6
	Latvia	1.49	1.63	1.68	3
	Lithuania	1.19	1.25	1.44	15

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N03AF02	oxcarbazepine				
	Estonia	0.77	0.78	0.84	8
	Latvia	0.36	0.36	0.36	
	Lithuania	1.36	1.39	1.48	6
N03AG	Fatty acid derivatives				
	Estonia	1.16	1.18	1.27	8
	Latvia	1.49	1.59	1.65	3
	Lithuania	1.66	1.73	1.89	9
N03AG01	valproic acid				
	Estonia	1.15	1.17	1.26	8
	Latvia	1.49	1.59	1.65	3
	Lithuania	1.62	1.70	1.87	10
N03AG04	vigabatrin				
	Estonia	<0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
N03AG06	tiagabine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.03	0.03	
N03AX	Other antiepileptics				
	Estonia	0.86	1.08	1.35	25
	Latvia	1.33	1.52	1.70	12
	Lithuania	1.31	1.5	1.86	24
N03AX09	lamotrigine				
	Estonia	0.27	0.30	0.36	20
	Latvia	0.49	0.54	0.54	
	Lithuania	0.49	0.54	0.67	24
N03AX11	topiramate				
	Estonia	0.18	0.17	0.18	6
	Latvia	0.22	0.22	0.22	
	Lithuania	0.31	0.33	0.36	9
N03AX12	gabapentin				
	Estonia	0.18	0.26	0.37	42
	Latvia	0.50	0.63	0.78	23
	Lithuania	0.25	0.26	0.28	8
N03AX14	levetiracetam				
	Estonia	0.02	0.10	0.16	60
	Latvia	<0.01	0.01	0.02	153
	Lithuania	0.01	0.02	0.04	100
N03AX16	pregabalin				
	Estonia	0.21	0.24	0.27	13
	Latvia	0.11	0.12	0.14	13
	Lithuania	0.25	0.37	0.52	41

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N03AX21	retigabine				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
N04	ANTI-PARKINSON DRUGS				
	Estonia	3.50	3.57	3.81	7
	Latvia	4.18	4.23	4.35	3
	Lithuania	4.41	4.67	5.27	13
N04A	ANTICHOLINERGIC AGENTS				
	Estonia	0.61	0.61	0.59	-3
	Latvia	1.93	1.94	1.95	
	Lithuania	1.58	1.59	1.73	9
N04AA	Tertiary amines				
	Estonia	0.61	0.61	0.59	-3
	Latvia	1.93	1.94	1.95	
	Lithuania	1.58	1.59	1.73	9
N04AA01	trihexyphenidyl				
	Estonia	0.61	0.61	0.59	-3
	Latvia	1.93	1.94	1.95	
	Lithuania	1.58	1.59	1.73	9
N04B	DOPAMINERGIC AGENTS				
	Estonia	2.88	2.96	3.21	8
	Latvia	2.25	2.29	2.39	5
	Lithuania	2.83	3.07	3.54	15
N04BA	Dopa and dopa derivatives				
	Estonia	1.28	1.26	1.34	6
	Latvia	0.68	0.71	0.79	10
	Lithuania	1.36	1.40	1.54	10

Consumption of antiepileptics (N03)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N04BA02	levodopa and decarboxylase inhibitor				
	Estonia	1.06	1.03	1.08	5
	Latvia	0.59	0.61	0.67	10
	Lithuania	1.00	1.06	1.20	13
N04BA03	levodopa, decarboxylase inhibitor and COMT inhibitor				
	Estonia	0.22	0.23	0.26	13
	Latvia	0.10	0.10	0.12	14
	Lithuania	0.36	0.34	0.35	3
N04BB	Adamantane derivatives				
	Estonia	0.33	0.32	0.36	13
	Latvia	0.61	0.63	0.65	2
	Lithuania	0.75	0.78	0.84	8
N04BB01	amantadine				
	Estonia	0.33	0.32	0.36	13
	Latvia	0.61	0.63	0.65	2
	Lithuania	0.75	0.78	0.84	8
N04BC	Dopamine agonists				
	Estonia	0.77	0.82	0.84	2
	Latvia	0.36	0.42	0.47	11
	Lithuania	0.71	0.79	0.99	25
N04BC01	bromocriptine				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.02	2
	Lithuania	-	-	-	
N04BC04	ropinirole				
	Estonia	0.45	0.43	0.44	2
	Latvia	0.28	0.33	0.35	7
	Lithuania	0.44	0.46	0.63	37
N04BC05	pramipexole				
	Estonia	0.32	0.39	0.40	3
	Latvia	0.06	0.08	0.11	31
	Lithuania	0.27	0.34	0.35	3
N04BD	Monoamine oxidase B inhibitors				
	Estonia	0.50	0.55	0.67	22
	Latvia	0.59	0.52	0.49	-5
	Lithuania	<0.01	0.09	0.16	78
N04BD01	selegiline				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.59	0.52	0.49	-6
	Lithuania	-	-	-	
N04BD02	rasagiline				
	Estonia	0.50	0.55	0.67	22
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.09	0.16	78


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N04BX	Other dopaminergic agents				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
N04BX02	entacapone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	0.01	
N05	PSYCHOLEPTICS				
	Estonia	33.97	35.67	38.05	7
	Latvia	24.87	26.63	27.84	5
	Lithuania	51.00	53.47	59.38	11
N05A	ANTIPSYCHOTICS				
	Estonia	6.10	6.38	6.93	9
	Latvia	8.52	8.79	9.03	3
	Lithuania	9.41	10.12	11.49	14
N05AA	Phenothiazines with aliphatic side-chain				
	Estonia	0.23	0.18	0.20	11
	Latvia	0.15	0.16	0.18	14
	Lithuania	0.15	0.15	0.15	
N05AA01	chlorpromazine				
	Estonia	0.15	0.11	0.12	9
	Latvia	-	-	-	
	Lithuania	-	-	-	
N05AA02	levomepromazine				
	Estonia	0.09	0.07	0.08	14
	Latvia	0.15	0.16	0.18	14
	Lithuania	0.15	0.15	0.15	
N05AB	Phenothiazines with piperazine structure				
	Estonia	0.07	0.07	0.07	
	Latvia	-	-	-	
	Lithuania	0.13	0.09	0.08	-11
N05AB02	fluphenazine				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	0.13	0.09	0.08	-11
N05AB03	perphenazine				
	Estonia	0.06	0.07	0.06	-14
	Latvia	-	-	-	
	Lithuania	-	-	-	
N05AD	Butyrophenone derivatives				
	Estonia	1.19	1.15	1.16	1
	Latvia	2.86	2.85	3.00	5
	Lithuania	2.17	2.22	2.35	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N05AD01	haloperidol				
	Estonia	0.82	0.79	0.80	1
	Latvia	2.62	2.59	2.72	5
	Lithuania	1.81	1.86	1.95	5
N05AD03	melperone				
	Estonia	0.37	0.36	0.36	
	Latvia	0.24	0.27	0.28	3
	Lithuania	0.36	0.35	0.40	14
N05AE	Indole derivatives				
	Estonia	0.14	0.17	0.17	
	Latvia	0.30	0.32	0.28	-13
	Lithuania	0.24	0.18	0.27	50
N05AE03	sertindole				
	Estonia	0.13	0.13	0.13	
	Latvia	0.09	0.12	0.10	-18
	Lithuania	-	-	-	
N05AE04	ziprasidone				
	Estonia	0.02	0.04	0.04	
	Latvia	0.22	0.20	0.18	-10
	Lithuania	0.24	0.18	0.27	50
N05AF	Thioxanthene derivatives				
	Estonia	0.79	0.75	0.74	-1
	Latvia	1.62	1.68	1.72	3
	Lithuania	0.86	0.96	0.97	1
N05AF01	flupentixol				
	Estonia	0.17	0.17	0.17	
	Latvia	0.28	0.29	0.31	6
	Lithuania	0.18	0.20	0.22	10
N05AF03	chlorprothixene				
	Estonia	0.29	0.27	0.27	
	Latvia	0.71	0.74	0.78	5
	Lithuania	0.32	0.38	0.34	-11
N05AF05	zuclopenthixol				
	Estonia	0.33	0.32	0.30	-6
	Latvia	0.64	0.65	0.64	-1
	Lithuania	0.35	0.39	0.41	5
N05AH	Diazepines, oxazepines, thiazepines and oxepines				
	Estonia	2.63	2.95	3.41	16
	Latvia	2.14	2.35	2.42	3
	Lithuania	3.54	4.07	4.82	18
N05AH02	clozapine				
	Estonia	0.48	0.51	0.54	6
	Latvia	0.63	0.57	0.50	-12
	Lithuania	0.37	0.39	0.42	8

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N05AH03	olanzapine				
	Estonia	0.99	1.08	1.25	16
	Latvia	0.57	0.72	0.82	14
	Lithuania	1.71	1.90	2.30	21
N05AH04	quetiapine				
	Estonia	1.16	1.37	1.62	18
	Latvia	0.94	1.06	1.10	3
	Lithuania	1.46	1.79	2.10	17
N05AL	Benzamides				
	Estonia	0.10	0.10	0.10	
	Latvia	0.44	0.44	0.43	-3
	Lithuania	1.34	1.41	1.68	19
N05AL01	sulpiride				
	Estonia	0.05	0.05	0.05	
	Latvia	0.14	0.14	0.14	
	Lithuania	0.06	0.07	0.08	14
N05AL03	tiapride				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.90	0.96	1.19	24
N05AL05	amisulpride				
	Estonia	0.05	0.06	0.05	-17
	Latvia	0.30	0.30	0.29	-4
	Lithuania	0.38	0.38	0.41	8
N05AN	Lithium				
	Estonia	0.16	0.16	0.17	6
	Latvia	-	-	-	
	Lithuania	-	-	-	
N05AN01	lithium				
	Estonia	0.16	0.16	0.17	6
	Latvia	-	-	-	
	Lithuania	-	-	-	
N05AX	Other antipsychotics				
	Estonia	0.79	0.83	0.91	10
	Latvia	1.00	0.99	1.00	1
	Lithuania	0.98	1.05	1.18	12
N05AX08	risperidone				
	Estonia	0.49	0.50	0.55	10
	Latvia	0.73	0.73	0.75	2
	Lithuania	0.74	0.81	0.90	11
N05AX12	aripiprazole				
	Estonia	0.30	0.33	0.36	9
	Latvia	0.27	0.26	0.26	
	Lithuania	0.24	0.24	0.26	8


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N05AX13	paliperidone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	0.02	
N05B	ANXIOLYTICS				
	Estonia	13.10	13.33	13.83	4
	Latvia	11.66	12.62	13.67	8
	Lithuania	36.40	37.16	40.53	9
N05BA	Benzodiazepine derivatives				
	Estonia	13.10	13.33	13.83	4
	Latvia	11.44	12.37	13.40	8
	Lithuania	36.34	37.10	40.46	9
N05BA01	diazepam				
	Estonia	6.10	6.14	6.46	5
	Latvia	3.26	3.37	3.51	4
	Lithuania	5.95	5.84	6.08	4
N05BA02	chlordiazepoxide				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.21	0.21	0.19	-10
	Lithuania	0.14	0.12	0.12	
N05BA03	medazepam				
	Estonia	-	-	-	
	Latvia	0.10	0.11	0.11	-2
	Lithuania	0.92	0.90	0.80	-11
N05BA04	oxazepam				
	Estonia	0.05	0.04	0.05	25
	Latvia	0.85	0.81	0.80	-1
	Lithuania	0.35	0.33	0.33	

Consumption of antipsychotics (N05A)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N05BA05	potassium clorazepate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.70	0.71	0.77	8
N05BA06	lorazepam				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.48	0.59	0.75	28
	Lithuania	18.77	18.57	19.97	8
N05BA08	bromazepam				
	Estonia	1.41	1.40	1.43	2
	Latvia	2.32	2.54	2.85	12
	Lithuania	4.83	5.21	5.91	13
N05BA12	alprazolam				
	Estonia	5.55	5.74	5.89	3
	Latvia	4.23	4.73	5.18	10
	Lithuania	4.69	5.43	6.49	20
N05BE	Azaspirodecanedione derivatives				
	Estonia	<0.01	-	-	
	Latvia	0.22	0.26	0.27	7
	Lithuania	0.06	0.06	0.06	
N05BE01	buspiron				
	Estonia	<0.01	-	-	
	Latvia	0.22	0.26	0.27	7
	Lithuania	0.06	0.06	0.06	
N05C	HYPNOTICS AND SEDATIVES				
	Estonia	14.77	15.96	17.29	8
	Latvia	4.69	5.21	5.13	-2
	Lithuania	5.19	6.19	7.36	19

Consumption of anxiolytics (N05B)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N05CD	Benzodiazepine derivatives				
	Estonia	2.08	1.94	1.45	-25
	Latvia	1.15	1.11	0.38	-66
	Lithuania	1.74	1.85	1.75	-5
N05CD02	nitrazepam				
	Estonia	1.77	1.60	1.03	-36
	Latvia	0.89	0.84	0.05	-94
	Lithuania	1.12	1.01	0.65	-36
N05CD04	estazolam				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.05	0.05	0.06	20
N05CD05	triazolam				
	Estonia	0.04	0.04	0.05	25
	Latvia	0.11	0.10	0.14	33
	Lithuania	0.41	0.60	0.83	38
N05CD08	midazolam				
	Estonia	0.27	0.30	0.37	23
	Latvia	0.15	0.17	0.19	15
	Lithuania	0.16	0.19	0.21	11
N05CF	Benzodiazepine related drugs				
	Estonia	12.62	13.94	15.76	13
	Latvia	3.54	4.10	4.75	16
	Lithuania	3.44	4.32	5.59	29
N05CF01	zopiclone				
	Estonia	10.63	11.67	13.09	12
	Latvia	2.46	2.84	3.30	16
	Lithuania	1.62	2.09	2.91	39
N05CF02	zolpidem				
	Estonia	1.99	2.27	2.67	18
	Latvia	1.08	1.27	1.45	14
	Lithuania	1.82	2.23	2.68	20
N05CH	Melatonin receptor agonists				
	Estonia	0.07	0.08	0.09	13
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.02	100
N05CH01	melatonin				
	Estonia	0.07	0.08	0.09	13
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.02	100
N06	PSYCHOANALEPTICS				
	Estonia	21.39	23.49	25.55	9
	Latvia	17.53	17.16	17.66	3
	Lithuania	30.18	33.10	37.01	12

Consumption of hypnotics and sedatives (N05C)




ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N06A	ANTIDEPRESSANTS				
	Estonia	15.83	17.81	19.91	12
	Latvia	7.72	8.65	9.47	9
	Lithuania	19.16	20.76	23.40	13
N06AA	Non-selective monoamine reuptake inhibitors				
	Estonia	2.05	1.99	2.06	4
	Latvia	1.60	1.59	1.64	3
	Lithuania	1.42	1.42	1.46	3
N06AA04	clomipramine				
	Estonia	0.07	0.06	0.07	17
	Latvia	0.20	0.20	0.20	-2
	Lithuania	0.07	0.07	0.07	
N06AA09	amitriptyline				
	Estonia	1.47	1.44	1.50	4
	Latvia	1.20	1.20	1.25	4
	Lithuania	1.29	1.30	1.34	3
N06AA10	nortriptyline				
	Estonia	0.51	0.48	0.49	2
	Latvia	0.20	0.19	0.19	
	Lithuania	0.06	0.06	0.06	
N06AB	Selective serotonin reuptake inhibitors				
	Estonia	10.18	11.46	12.79	12
	Latvia	4.65	5.44	6.00	10
	Lithuania	12.03	13.25	14.94	13
N06AB03	fluoxetine				
	Estonia	2.31	2.42	2.55	5
	Latvia	0.28	0.31	0.32	2
	Lithuania	0.45	0.50	0.53	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N06AB04	citalopram				
	Estonia	1.86	1.65	1.66	1
	Latvia	0.43	0.48	0.54	14
	Lithuania	1.17	1.09	1.12	3
N06AB05	paroxetine				
	Estonia	1.59	1.70	1.87	10
	Latvia	1.50	1.72	1.88	9
	Lithuania	2.13	2.40	2.65	10
N06AB06	sertraline				
	Estonia	1.45	1.64	2.03	24
	Latvia	0.68	0.63	0.70	11
	Lithuania	3.99	4.09	4.40	8
N06AB08	fluvoxamine				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.12	0.12	0.14	16
	Lithuania	0.22	0.19	0.17	-11
N06AB10	escitalopram				
	Estonia	2.96	4.03	4.67	16
	Latvia	1.64	2.17	2.42	11
	Lithuania	4.08	5.00	6.08	22
N06AX	Other antidepressants				
	Estonia	3.60	4.35	5.05	16
	Latvia	1.46	1.62	1.82	13
	Lithuania	5.71	6.08	7.00	15
N06AX05	trazodone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.09	0.10	0.11	10
N06AX11	mirtazapine				
	Estonia	1.21	1.41	1.52	8
	Latvia	0.48	0.55	0.59	7
	Lithuania	2.94	3.14	3.32	6
N06AX12	bupropion				
	Estonia	0.17	0.18	0.21	17
	Latvia	0.13	0.14	0.15	8
	Lithuania	0.17	0.17	0.19	12
N06AX14	tianeptine				
	Estonia	0.65	0.79	0.90	14
	Latvia	0.23	0.26	0.34	30
	Lithuania	0.44	0.47	0.45	-4
N06AX16	venlafaxine				
	Estonia	1.02	1.26	1.62	29
	Latvia	0.39	0.43	0.47	8
	Lithuania	0.77	0.77	0.82	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N06AX17	milnacipran				
	Estonia	0.03	0.04	0.04	
	Latvia	0.01	0.01	<0.01	
	Lithuania	-	-	-	
N06AX21	duloxetine				
	Estonia	0.48	0.61	0.70	15
	Latvia	0.17	0.17	0.17	3
	Lithuania	1.05	1.06	1.20	13
N06AX22	agomelatine				
	Estonia	0.03	0.06	0.07	17
	Latvia	0.05	0.05	0.09	68
	Lithuania	0.25	0.37	0.92	149
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS				
	Estonia	0.43	0.48	0.56	17
	Latvia	6.03	6.25	6.35	2
	Lithuania	8.23	8.45	9.44	12
N06BA	Centrally acting sympathomimetics				
	Estonia	0.07	0.17	0.27	59
	Latvia	0.01	0.01	0.01	15
	Lithuania	0.01	0.01	0.01	
N06BA04	methylphenidate				
	Estonia	0.07	0.17	0.26	53
	Latvia	<0.01	0.01	0.01	15
	Lithuania	0.01	0.01	0.01	
N06BA09	atomoxetine				
	Estonia	<0.01	<0.01	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

Consumption of antidepressants (N06A)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N06BC	Xanthine derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	0.01	<0.01	
	Lithuania	-	-	-	
N06BC01	caffeine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	0.01	<0.01	
	Lithuania	-	-	-	
N06BX	Other psychostimulants and nootropics				
	Estonia	0.35	0.31	0.29	-6
	Latvia	6.02	6.23	6.34	2
	Lithuania	8.22	8.45	9.43	12
N06BX02	pyritinol				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.03	-10
	Lithuania	-	-	-	
N06BX03	piracetam				
	Estonia	0.31	0.27	0.26	-4
	Latvia	1.78	1.87	1.90	2
	Lithuania	0.57	0.61	0.74	21
N06BX18	vinpocetine				
	Estonia	0.04	0.04	0.03	-25
	Latvia	4.20	4.32	4.40	2
	Lithuania	7.66	7.84	8.69	11
N06D	ANTI-DEMENTIA DRUGS				
	Estonia	5.14	5.20	5.07	-3
	Latvia	3.79	2.27	1.85	-19
	Lithuania	2.80	3.89	4.18	7
N06DA	Anticholinesterases				
	Estonia	0.07	0.13	0.22	69
	Latvia	<0.01	0.04	0.06	55
	Lithuania	0.54	0.68	0.85	25
N06DA02	donepezil				
	Estonia	0.07	0.13	0.22	69
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.54	0.68	0.85	25
N06DA04	galantamine				
	Estonia	<0.01	-	<0.01	
	Latvia	<0.01	0.04	0.06	58
	Lithuania	-	-	-	
N06DX	Other anti-dementia drugs				
	Estonia	5.06	5.07	4.85	-4
	Latvia	3.79	2.23	1.79	-20
	Lithuania	2.25	3.21	3.33	4

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N06DX01	memantine				
	Estonia	0.07	0.06	0.06	
	Latvia	0.06	0.06	0.07	14
	Lithuania	0.33	0.40	0.47	18
N06DX02	Ginkgo folium				
	Estonia	5.00	5.01	4.78	-5
	Latvia	3.73	2.17	1.72	-21
	Lithuania	1.92	2.81	2.87	2
N07	OTHER NERVOUS SYSTEM DRUGS				
	Estonia	7.84	8.39	9.33	11
	Latvia	12.51	13.24	14.12	7
	Lithuania	10.87	10.72	11.54	8
N07A	PARASYMPATHOMIMETICS				
	Estonia	0.29	0.30	0.30	
	Latvia	0.08	0.09	0.09	
	Lithuania	0.02	0.02	0.02	
N07AA	Anticholinesterases				
	Estonia	0.29	0.29	0.30	3
	Latvia	0.08	0.09	0.09	
	Lithuania	0.02	0.02	0.02	
N07AA01	neostigmine				
	Estonia	0.04	0.04	0.04	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.02	0.02	
N07AA02	pyridostigmine				
	Estonia	0.24	0.24	0.25	4
	Latvia	0.08	0.09	0.09	-2
	Lithuania	-	-	-	
N07AA51	neostigmine, combinations				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
N07B	DRUGS USED IN ADDICTIVE DISORDERS				
	Estonia	2.38	2.61	2.82	8
	Latvia	0.20	0.22	0.24	11
	Lithuania	0.83	0.80	0.82	3
N07BA	Drugs used in nicotine dependence				
	Estonia	0.83	0.94	1.07	14
	Latvia	0.17	0.18	0.20	7
	Lithuania	0.36	0.37	0.39	5
N07BA01	nicotine				
	Estonia	0.82	0.92	1.04	13
	Latvia	0.15	0.17	0.18	7
	Lithuania	0.35	0.36	0.38	6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N07BA03	varenicline				
	Estonia	0.01	0.02	0.02	
	Latvia	0.01	0.01	0.01	15
	Lithuania	0.01	0.01	0.02	100
N07BB	Drugs used in alcohol dependence				
	Estonia	0.16	0.16	0.18	13
	Latvia	0.01	0.01	0.01	16
	Lithuania	0.01	0.02	0.01	-50
N07BB01	disulfiram				
	Estonia	0.15	0.15	0.18	20
	Latvia	-	-	-	
	Lithuania	-	<0.01	-	
N07BB04	naltrexone				
	Estonia	0.01	0.01	0.01	
	Latvia	0.01	0.01	0.01	16
	Lithuania	0.01	0.02	0.01	-50
N07BC	Drugs used in opioid dependence				
	Estonia	1.39	1.52	1.57	3
	Latvia	0.02	0.03	0.03	29
	Lithuania	0.46	0.41	0.42	2
N07BC01	buprenorphine				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.02	97
	Lithuania	<0.01	<0.01	0.01	
N07BC02	methadone				
	Estonia	1.37	1.51	1.55	3
	Latvia	-	-	-	
	Lithuania	0.46	0.41	0.41	
N07BC51	buprenorphine, combinations				
	Estonia	0.01	0.01	0.01	
	Latvia	0.02	0.02	0.02	
	Lithuania	-	-	-	
N07C	ANTIVERTIGO PREPARATIONS				
	Estonia	5.18	5.48	6.20	13
	Latvia	12.22	12.92	13.78	7
	Lithuania	10.01	9.90	10.69	8
N07CA	Antivertigo preparations				
	Estonia	5.18	5.48	6.20	13
	Latvia	12.22	12.92	13.78	7
	Lithuania	10.01	9.90	10.69	8
N07CA01	betahistine				
	Estonia	3.15	3.70	4.35	18
	Latvia	6.43	7.54	8.93	18
	Lithuania	2.71	3.62	4.53	25

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
N07CA02	cinnarizine				
	Estonia	2.03	1.79	1.85	3
	Latvia	3.95	3.58	3.25	-9
	Lithuania	5.22	3.98	3.72	-7
N07CA52	cinnarizine, combinations				
	Estonia	-	-	-	
	Latvia	1.84	1.80	1.60	-11
	Lithuania	2.08	2.30	2.44	6
N07X	OTHER NERVOUS SYSTEM DRUGS				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	<0.01	<0.01	0.01	
N07XX	Other nervous system drugs				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	<0.01	<0.01	0.01	
N07XX02	riluzole				
	Estonia	-	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	-18
	Lithuania	<0.01	<0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
P	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS				
	Estonia	0.80	0.78	0.84	8
	Latvia	0.67	0.71	0.74	4
	Lithuania	0.60	0.73	0.77	5
P01	ANTIPROTOZOALS				
	Estonia	0.68	0.64	0.69	8
	Latvia	0.35	0.37	0.37	2
	Lithuania	0.27	0.39	0.38	-3
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES				
	Estonia	<0.01	-	-	
	Latvia	0.23	0.25	0.24	-1
	Lithuania	-	-	-	
P01AB	Nitroimidazole derivatives				
	Estonia	-	-	-	
	Latvia	0.23	0.25	0.24	-1
	Lithuania	0.10	0.20	0.17	-15
P01AB01	metronidazole				
	Estonia	-	-	-	
	Latvia	0.22	0.25	0.24	-1
	Lithuania	0.09	0.19	0.16	-16
P01AB02	tinidazole				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.01	
P01AB03	ornidazole				
	Estonia	-	-	-	
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P01B	ANTIMALARIALS				
	Estonia	0.68	0.64	0.68	6
	Latvia	0.13	0.12	0.13	9
	Lithuania	0.17	0.18	0.21	17
P01BA	Aminoquinolines				
	Estonia	0.66	0.63	0.66	5
	Latvia	0.12	0.12	0.13	10
	Lithuania	0.17	0.18	0.21	17
P01BA02	hydroxychloroquine				
	Estonia	0.66	0.63	0.66	5
	Latvia	0.12	0.12	0.13	10
	Lithuania	0.17	0.18	0.21	17
P01BB	Biguanides				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
P01BB51	proguanil, combinations				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
P01BC	Methanolquinolines				
	Estonia	0.01	<0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
P01BC02	mefloquine				
	Estonia	0.01	<0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
P02	ANTHELMINTICS				
	Estonia	0.13	0.14	0.15	7
	Latvia	0.31	0.34	0.36	6
	Lithuania	0.33	0.35	0.38	9
P02C	ANTINEMATODAL AGENTS				
	Estonia	0.13	0.14	0.15	7
	Latvia	0.31	0.34	0.36	6
	Lithuania	0.33	0.35	0.38	9
P02CA	Benzimidazole derivatives				
	Estonia	0.12	0.14	0.15	7
	Latvia	0.17	0.18	0.19	3
	Lithuania	0.27	0.28	0.32	14
P02CA01	mebendazole				
	Estonia	0.12	0.14	0.15	7
	Latvia	0.17	0.18	0.19	3
	Lithuania	0.27	0.28	0.32	14
P02CC	Tetrahydropyrimidine derivatives				
	Estonia	-	-	-	
	Latvia	0.13	0.15	0.16	8
	Lithuania	0.05	0.06	0.06	
P02CC01	pyrantel				
	Estonia	-	-	-	
	Latvia	0.13	0.15	0.16	8
	Lithuania	0.05	0.06	0.06	
P02CE	Imidazothiazole derivatives				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.01	11
	Lithuania	0.01	0.01	0.01	
P02CE01	levamisole				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.01	11
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R	RESPIRATORY SYSTEM				
	Estonia	60.26	62.67	69.05	10
	Latvia	53.92	53.11	56.54	6
	Lithuania	55.88	57.48	63.31	10
R01	NASAL PREPARATIONS				
	Estonia	26.28	26.65	29.88	12
	Latvia	22.74	20.94	23.94	14
	Lithuania	20.32	20.51	23.27	13
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE				
	Estonia	24.20	24.56	27.92	14
	Latvia	22.42	20.64	23.62	14
	Lithuania	19.69	19.85	22.49	13
R01AA	Sympathomimetics, plain				
	Estonia	19.10	18.87	20.94	11
	Latvia	18.90	16.80	19.33	15
	Lithuania	14.71	14.34	16.41	14
R01AA05	oxymetazoline				
	Estonia	0.21	0.07	-	
	Latvia	0.39	0.12	0.29	129
	Lithuania	0.15	0.04	0.35	775
R01AA07	xylometazoline				
	Estonia	18.69	18.64	20.87	12
	Latvia	15.27	15.99	16.84	5
	Lithuania	14.25	14.03	15.64	11
R01AA08	naphazoline				
	Estonia	0.20	0.17	0.07	-59
	Latvia	3.24	0.68	2.20	221
	Lithuania	0.31	0.27	0.42	56
R01AB	Sympathomimetics, combinations excl. corticosteroids				
	Estonia	-	-	0.74	
	Latvia	-	-	-	
	Lithuania	2.59	2.80	2.94	5
R01AB01	phenylephrine and dimetinden				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	2.45	2.45	2.60	6
R01AB06	xylometazoline				
	Estonia	-	-	0.74	
	Latvia	-	-	-	
	Lithuania	0.15	0.35	0.34	-3
R01AC	Antiallergic agents, excl. corticosteroids				
	Estonia	0.22	0.17	0.24	41
	Latvia	0.05	0.05	0.08	55
	Lithuania	0.07	0.08	0.12	50

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R01AC03	azelastine				
	Estonia	0.22	0.17	0.24	41
	Latvia	0.05	0.05	0.08	55
	Lithuania	0.07	0.08	0.12	50
R01AD	Corticosteroids				
	Estonia	4.88	5.52	6.00	9
	Latvia	3.47	3.79	4.20	11
	Lithuania	2.32	2.63	3.02	15
R01AD01	beclometasone				
	Estonia	0.35	0.23	0.21	-9
	Latvia	0.24	0.21	0.21	-2
	Lithuania	0.32	0.18	0.01	-94
R01AD05	budesonide				
	Estonia	1.48	1.10	1.09	-1
	Latvia	1.45	1.43	1.44	
	Lithuania	0.30	0.26	0.26	
R01AD08	fluticasone				
	Estonia	0.93	0.75	0.76	1
	Latvia	0.70	0.70	0.74	6
	Lithuania	0.40	0.39	0.41	5
R01AD09	mometasone				
	Estonia	1.83	2.29	2.33	2
	Latvia	0.57	0.89	1.12	25
	Lithuania	1.10	1.31	1.71	31
R01AD12	fluticasone furoate				
	Estonia	0.30	1.16	1.61	39
	Latvia	0.51	0.55	0.70	27
	Lithuania	0.20	0.49	0.64	31
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE				
	Estonia	2.08	2.08	1.96	-6
	Latvia	0.32	0.30	0.32	8
	Lithuania	0.63	0.66	0.78	18
R01BA	Sympathomimetics				
	Estonia	2.08	2.08	1.96	-6
	Latvia	0.32	0.30	0.32	8
	Lithuania	0.63	0.66	0.78	18
R01BA02	pseudoephedrine				
	Estonia	1.04	1.08	1.20	11
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.01	-50
R01BA52	pseudoephedrine, combinations				
	Estonia	1.04	1.01	0.76	-25
	Latvia	0.32	0.30	0.32	8
	Lithuania	0.53	0.56	0.67	20


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R01BA53	phenylephrine, combinations				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.08	0.08	0.10	25
R02	THROAT PREPARATIONS				
	Estonia	0.25	0.23	0.38	65
	Latvia	0.88	0.92	0.81	-12
	Lithuania	2.36	2.47	2.71	10
R02A	THROAT PREPARATIONS				
	Estonia	0.25	0.23	0.38	65
	Latvia	0.88	0.92	0.81	-12
	Lithuania	2.36	2.47	2.71	10
R02AA	Antiseptics				
	Estonia	0.25	0.21	0.32	52
	Latvia	0.88	0.92	0.81	-12
	Lithuania	2.12	2.22	2.43	9
R02AA01	ambazone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.18	0.11	0.11	
R02AA02	dequalinium				
	Estonia	0.24	0.21	0.31	48
	Latvia	0.56	0.59	0.52	-12
	Lithuania	0.37	0.40	0.47	18
R02AA05	chlorhexidine				
	Estonia	0.02	<0.01	<0.01	
	Latvia	0.32	0.33	0.29	-11
	Lithuania	0.26	0.20	0.15	-25
R02AA06	cetylpyridinium				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.12	0.21	0.29	38
R02AA16	benzalkonium				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.05	0.09	0.10	11
R02AA20	various antiseptics				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	1.15	1.21	1.31	8
R02AX	Other throat preparations				
	Estonia	-	0.02	0.06	200
	Latvia	-	-	-	
	Lithuania	-	0.01	0.04	300

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R02AX01	flurbiprofen				
	Estonia	-	0.02	0.06	200
	Latvia	-	-	-	
	Lithuania	-	0.01	0.04	300
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES				
	Estonia	18.21	18.64	20.16	8
	Latvia	17.73	17.77	17.71	
	Lithuania	18.99	18.79	20.91	11
R03A	ADRENERGICS, INHALANTS				
	Estonia	11.87	12.28	13.66	11
	Latvia	11.81	11.65	12.38	6
	Lithuania	12.82	12.72	14.62	15
R03AC	Selective beta-2-adrenoreceptor agonists				
	Estonia	5.23	5.10	5.46	7
	Latvia	5.99	6.16	6.40	4
	Lithuania	6.12	6.46	7.19	11
R03AC02	salbutamol				
	Estonia	2.68	2.64	2.75	4
	Latvia	5.13	5.25	5.54	5
	Lithuania	4.93	5.32	6.03	13
R03AC04	fenoterol				
	Estonia	0.44	0.39	0.38	-3
	Latvia	0.62	0.59	0.58	-2
	Lithuania	0.05	0.05	0.04	-20
R03AC12	salmeterol				
	Estonia	0.46	0.38	0.34	-11
	Latvia	0.08	0.18	0.14	-26
	Lithuania	0.49	0.43	0.39	-9
R03AC13	formoterol				
	Estonia	1.64	1.60	1.46	-9
	Latvia	0.15	0.12	0.09	-21
	Lithuania	0.66	0.67	0.72	7
R03AC18	indacaterol				
	Estonia	-	0.09	0.53	489
	Latvia	<0.01	0.02	0.06	246
	Lithuania	-	-	-	
R03AK	Adrenergics and other drugs for obstructive airway diseases				
	Estonia	6.64	7.18	8.20	14
	Latvia	5.83	5.49	5.97	9
	Lithuania	6.70	6.26	7.44	19
R03AK03	fenoterol and other drugs for obstructive airway diseases				
	Estonia	0.62	0.75	0.78	4
	Latvia	2.02	1.29	1.28	-1
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R03AK06	salmeterol and other drugs for obstructive airway diseases				
	Estonia	3.21	3.36	3.75	12
	Latvia	2.58	2.78	2.96	7
	Lithuania	3.64	3.08	3.89	26
R03AK07	formoterol and other drugs for obstructive airway diseases				
	Estonia	2.80	3.08	3.67	19
	Latvia	1.22	1.42	1.72	21
	Lithuania	3.06	3.18	3.55	12
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS				
	Estonia	3.56	3.53	3.58	1
	Latvia	2.36	2.44	1.43	-41
	Lithuania	3.49	3.49	3.64	4
R03BA	Glucocorticoids				
	Estonia	2.40	2.31	1.84	-20
	Latvia	1.71	1.77	1.33	-25
	Lithuania	1.57	1.58	1.56	-1
R03BA01	beclometasone				
	Estonia	0.91	0.72	0.12	-83
	Latvia	0.88	0.89	0.25	-72
	Lithuania	0.13	0.13	0.01	-92
R03BA02	budesonide				
	Estonia	1.23	1.29	1.34	4
	Latvia	0.43	0.45	0.37	-19
	Lithuania	0.65	0.66	0.68	3
R03BA05	fluticasone				
	Estonia	0.26	0.30	0.37	23
	Latvia	0.40	0.43	0.72	67
	Lithuania	0.79	0.80	0.87	9
R03BB	Anticholinergics				
	Estonia	1.16	1.22	1.74	43
	Latvia	0.65	0.67	0.11	-84
	Lithuania	1.93	1.91	2.08	9
R03BB01	ipratropium bromide				
	Estonia	1.16	1.22	1.19	-2
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
R03BB04	tiotropium bromide				
	Estonia	<0.01	<0.01	0.55	
	Latvia	0.65	0.67	0.11	-84
	Lithuania	1.92	1.91	2.08	9
R03C	ADRENERGICS FOR SYSTEMIC USE				
	Estonia	0.29	0.29	0.26	-10
	Latvia	0.22	0.23	0.22	-3
	Lithuania	0.34	0.34	0.32	-6

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R03CC	Selective beta-2-adrenoreceptor agonists				
	Estonia	0.29	0.29	0.26	-10
	Latvia	0.22	0.23	0.22	-3
	Lithuania	0.34	0.33	0.31	-6
R03CC02	salbutamol				
	Estonia	0.29	0.29	0.26	-10
	Latvia	0.22	0.23	0.22	-3
	Lithuania	0.34	0.33	0.31	-6
R03D	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES				
	Estonia	2.50	2.53	2.66	5
	Latvia	3.34	3.45	3.68	7
	Lithuania	2.34	2.24	2.33	4
R03DA	Xanthines				
	Estonia	1.63	1.56	1.65	6
	Latvia	2.58	2.57	2.63	2
	Lithuania	1.48	1.45	1.49	3
R03DA04	theophylline				
	Estonia	1.58	1.51	1.60	6
	Latvia	2.20	2.20	2.25	2
	Lithuania	0.78	0.77	0.80	4
R03DA05	aminophylline				
	Estonia	0.06	0.05	0.05	
	Latvia	0.38	0.37	0.38	1
	Lithuania	0.70	0.68	0.69	1
R03DC	Leukotriene receptor antagonists				
	Estonia	0.86	0.98	1.00	2
	Latvia	0.76	0.88	1.01	15
	Lithuania	0.86	0.79	0.84	6
R03DC03	montelukast				
	Estonia	0.86	0.98	1.00	2
	Latvia	0.76	0.88	1.01	15
	Lithuania	0.86	0.79	0.84	6
R03DX	Other systemic drugs for obstructive airway diseases				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.04	
	Lithuania	-	-	-	
R03DX07	roflumilast				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.04	
	Lithuania	-	-	-	
R05	COUGH AND COLD PREPARATIONS				
	Estonia	6.18	6.95	7.13	3
	Latvia	6.03	6.60	6.90	4
	Lithuania	6.93	7.79	7.79	

Consumption of antiasthmatics (R03)



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS				
	Estonia	6.06	6.83	7.01	3
	Latvia	5.86	6.48	6.78	5
	Lithuania	6.85	7.69	7.73	1
R05CA	Expectorants				
	Estonia	0.18	0.19	0.24	26
	Latvia	0.04	0.04	0.03	-24
	Lithuania	0.06	0.06	0.03	-50
R05CA03	guaifenesin				
	Estonia	0.18	0.19	0.24	26
	Latvia	0.04	0.04	0.03	-24
	Lithuania	0.06	0.06	0.03	-50
R05CB	Mucolytics				
	Estonia	5.87	6.64	6.77	2
	Latvia	5.82	6.44	6.75	5
	Lithuania	6.64	7.52	7.59	1
R05CB01	acetylcysteine				
	Estonia	2.79	3.20	3.39	6
	Latvia	1.75	1.78	2.10	18
	Lithuania	2.64	2.69	2.76	3
R05CB02	bromhexine				
	Estonia	1.14	0.97	0.84	-13
	Latvia	2.17	2.24	2.20	-2
	Lithuania	0.87	0.79	0.79	
R05CB03	carbocisteine				
	Estonia	0.08	0.09	0.22	144
	Latvia	0.12	0.11	0.10	-10
	Lithuania	0.10	0.12	0.14	17


ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R05CB06	ambroxol				
	Estonia	1.85	2.36	2.32	-2
	Latvia	1.78	2.30	2.35	2
	Lithuania	3.02	3.91	3.89	-1
R05CB13	dornase alfa (desoxyribonuclease)				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.17	0.13	0.12	-8
	Lithuania	0.08	0.10	0.07	-30
R05DA	Opium alkaloids and derivatives				
	Estonia	<0.01	-	-	
	Latvia	0.13	0.13	0.12	-8
	Lithuania	0.02	0.03	-	
R05DA08	pholcodine				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.03	-	
R05DA09	dextromethorphan				
	Estonia	-	-	-	
	Latvia	0.13	0.13	0.12	-8
	Lithuania	<0.01	-	-	
R05DB	Other cough suppressants				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.04	<0.01	<0.01	
	Lithuania	0.06	0.07	0.07	
R05DB09	oxeladin				
	Estonia	0.10	0.10	0.09	-10
	Latvia	0.04	<0.01	<0.01	
	Lithuania	0.06	0.07	0.07	
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS				
	Estonia	0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
R05FA	Opium derivatives and expectorants				
	Estonia	0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	
R05FA02	opium derivatives and expectorants				
	Estonia	0.01	0.02	0.03	50
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R06	ANTI-HISTAMINES FOR SYSTEMIC USE				
	Estonia	9.34	10.20	11.50	13
	Latvia	6.36	6.74	7.05	5
	Lithuania	7.28	7.92	8.63	9
R06A	ANTI-HISTAMINES FOR SYSTEMIC USE				
	Estonia	9.34	10.20	11.50	13
	Latvia	6.36	6.74	7.05	5
	Lithuania	7.28	7.92	8.63	9
R06AA	Aminoalkyl ethers				
	Estonia	0.53	0.62	0.61	-2
	Latvia	2.00	2.09	1.95	-7
	Lithuania	1.58	1.74	1.83	5
R06AA04	clemastine				
	Estonia	0.53	0.62	0.61	-2
	Latvia	2.00	2.09	1.95	-7
	Lithuania	1.58	1.74	1.83	5
R06AC	Substituted ethylene diamines				
	Estonia	-	-	-	
	Latvia	0.49	0.50	0.52	5
	Lithuania	-	-	-	
R06AC03	chloropyramine				
	Estonia	-	-	-	
	Latvia	0.49	0.50	0.52	5
	Lithuania	-	-	-	
R06AE	Piperazine derivatives				
	Estonia	4.34	4.71	5.54	18
	Latvia	1.91	2.02	2.34	16
	Lithuania	2.06	2.04	2.36	16
R06AE07	cetirizine				
	Estonia	3.95	4.36	5.12	17
	Latvia	1.57	1.67	2.03	22
	Lithuania	1.92	1.91	2.24	17
R06AE09	levocetirizine				
	Estonia	0.39	0.35	0.42	20
	Latvia	0.34	0.35	0.31	-12
	Lithuania	0.14	0.13	0.12	-8
R06AX	Other antihistamines for systemic use				
	Estonia	4.47	4.87	5.35	10
	Latvia	1.96	2.13	2.23	5
	Lithuania	3.62	4.14	4.44	7
R06AX13	loratadine				
	Estonia	2.58	2.73	3.18	16
	Latvia	1.15	1.24	1.22	-2
	Lithuania	2.34	2.75	2.75	
R06AX17	ketotifen				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.27	0.25	0.24	-2
	Lithuania	0.01	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
R06AX22	ebastine				
	Estonia	0.98	1.10	1.12	2
	Latvia	0.11	0.10	0.10	-4
	Lithuania	0.77	0.88	0.83	-6
R06AX26	fexofenadine				
	Estonia	-	-	-	
	Latvia	0.03	0.02	<0.01	
	Lithuania	0.22	0.15	-	
R06AX27	desloratadine				
	Estonia	0.91	1.01	0.99	-2
	Latvia	0.40	0.51	0.66	29
	Lithuania	0.28	0.34	0.71	109
R06AX28	rupatadine				
	Estonia	-	0.02	0.05	150
	Latvia	<0.01	0.01	0.02	198
	Lithuania	-	0.03	0.15	400
R07	OTHER RESPIRATORY SYSTEM PRODUCTS				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	
R07A	OTHER RESPIRATORY SYSTEM PRODUCTS				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	
R07AB	Respiratory stimulants				
	Estonia	-	-	-	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	
R07AB02	nikethamide				
	Estonia	-	-	-	
	Latvia	0.18	0.14	0.14	-5
	Lithuania	-	-	-	

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
S	SENSORY ORGANS				
	Estonia	21.43	20.38	24.00	18
	Latvia	17.09	19.17	21.34	11
	Lithuania	15.10	16.51	19.52	18
S01	OPHTHALMOLOGICALS				
	Estonia	21.43	20.38	24.00	18
	Latvia	17.09	19.17	21.34	11
	Lithuania	15.10	16.51	19.52	18
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS				
	Estonia	21.43	20.38	24.00	18
	Latvia	17.09	19.17	21.34	11
	Lithuania	15.10	16.51	19.52	18
S01EA	Sympathomimetics in glaucoma therapy				
	Estonia	-	<0.01	<0.01	
	Latvia	0.67	0.65	0.79	21
	Lithuania	0.28	0.69	1.19	72
S01EA05	brimonidine				
	Estonia	-	<0.01	<0.01	
	Latvia	0.67	0.65	0.79	21
	Lithuania	0.28	0.69	1.19	72
S01EB	Parasympathomimetics				
	Estonia	0.08	0.07	0.07	
	Latvia	0.04	0.04	0.01	-70
	Lithuania	0.01	<0.01	-	
S01EB01	pilocarpine				
	Estonia	0.01	<0.01	0.01	
	Latvia	0.04	0.04	0.01	-70
	Lithuania	0.01	<0.01	-	
S01EB51	pilocarpine, combinations				
	Estonia	0.08	0.07	0.06	-14
	Latvia	-	-	-	
	Lithuania	-	-	-	
S01EC	Carbonic anhydrase inhibitors				
	Estonia	1.69	1.66	1.93	16
	Latvia	1.38	1.55	1.70	10
	Lithuania	1.77	1.84	2.66	45
S01EC01	acetazolamide				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.11	0.11	0.10	-6
	Lithuania	0.07	0.07	0.07	
S01EC03	dorzolamide				
	Estonia	0.59	0.60	0.72	20
	Latvia	0.55	0.61	0.63	2
	Lithuania	0.65	0.71	0.86	21

ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
S01EC04	brinzolamide				
	Estonia	1.05	1.01	1.15	14
	Latvia	0.72	0.83	0.97	17
	Lithuania	1.05	1.07	1.72	61
S01ED	Beta blocking agents				
	Estonia	12.68	12.12	14.79	22
	Latvia	9.83	10.82	12.10	12
	Lithuania	7.06	7.26	7.91	9
S01ED01	timolol				
	Estonia	6.10	5.75	7.54	31
	Latvia	4.70	4.99	5.86	17
	Lithuania	2.10	1.94	1.98	2
S01ED02	betaxolol				
	Estonia	1.25	1.13	1.17	4
	Latvia	0.90	0.89	0.79	-12
	Lithuania	0.80	0.73	0.72	-1
S01ED51	timolol, combinations				
	Estonia	5.34	5.23	6.08	16
	Latvia	4.22	4.94	5.45	10
	Lithuania	4.16	4.59	5.21	14
S01EE	Prostaglandin analogues				
	Estonia	6.97	6.52	7.22	11
	Latvia	5.17	6.11	6.74	10
	Lithuania	5.99	6.73	7.77	15
S01EE01	latanoprost				
	Estonia	5.18	4.57	4.94	8
	Latvia	4.59	5.45	6.02	10
	Lithuania	4.71	4.84	5.45	13
S01EE03	bimatoprost				
	Estonia	-	-	<0.01	
	Latvia	0.09	0.15	0.22	48
	Lithuania	<0.01	0.29	0.66	128
S01EE04	travoprost				
	Estonia	1.79	1.95	2.19	12
	Latvia	0.44	0.41	0.34	-16
	Lithuania	1.28	1.59	1.57	-1
S01EE05	tafluprost				
	Estonia	-	0.01	0.09	800
	Latvia	0.05	0.10	0.16	58
	Lithuania	-	<0.01	0.09	



ATC code	ATC group / INN	DDD/1000/day			Relative change %
		2010	2011	2012	
V	VARIOUS				
	Estonia	0.08	0.09	0.12	33
	Latvia	0.06	0.05	0.05	2
	Lithuania	0.05	0.05	0.06	20
V03	ALL OTHER THERAPEUTIC PRODUCTS				
	Estonia	0.08	0.09	0.12	33
	Latvia	0.06	0.05	0.05	2
	Lithuania	0.05	0.05	0.06	20
V03A	ALL OTHER THERAPEUTIC PRODUCTS				
	Estonia	0.08	0.09	0.12	33
	Latvia	0.06	0.05	0.05	2
	Lithuania	0.05	0.05	0.06	20
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia				
	Estonia	0.03	0.04	0.06	50
	Latvia	0.01	0.01	0.02	39
	Lithuania	0.01	0.02	0.02	
V03AE01	polystyrene sulfonate				
	Estonia	0.02	0.03	0.03	
	Latvia	0.01	0.01	0.01	58
	Lithuania	0.01	0.01	0.02	100
V03AE02	sevelamer				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
V03AE03	lanthanum carbonate				
	Estonia	<0.01	0.01	0.02	100
	Latvia	<0.01	0.01	0.01	22
	Lithuania	-	-	-	
V03AE04	calcium acetate and magnesium carbonate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	0.01	
V03AF	Detoxifying agents for antineoplastic treatment				
	Estonia	0.05	0.05	0.06	20
	Latvia	0.04	0.04	0.03	-12
	Lithuania	0.04	0.04	0.04	
V03AF03	calcium folinate				
	Estonia	0.05	0.05	0.04	-20
	Latvia	0.04	0.04	0.03	-12
	Lithuania	0.04	0.03	0.03	
V03AF10	sodium levofolinate				
	Estonia	-	-	0.02	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	0.01	

8. Top 15 most used prescription-only medicines

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	C09AA05	ramipril	62.86
2	C08CA01	amlodipine	37.05
3	C07AB02	metoprolol	22.31
4	C10AA07	rosuvastatin	19.42
5	C09AA02	enalapril	18.91
6	A02BC01	omeprazole	18.73
7	A10BA02	metformin	17.57
8	C09CA07	telmisartan	16.72
9	C09BA02	enalapril and diuretics	14.82
10	H03AA01	levothyroxine sodium	13.32
11	C07AB12	nebivolol	13.28
12	M01AB05	diclofenac	13.12
13	N05CF01	zopiclone	13.09
14	C09AA09	fosinopril	12.81
15	C01EB15	trimetazidine	11.33

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	C09BA04	perindopril and diuretics	33.16
2	C10AA05	atorvastatin	30.31
3	M01AB05	diclofenac	23.85
4	C09AA02	enalapril	22.92
5	C09AA04	perindopril	21.00
6	C08CA01	amlodipine	20.28
7	C09BB04	perindopril and amlodipine	19.59
8	C09AA05	ramipril	19.47
9	A02BC01	omeprazole	17.95
10	C07AB07	bisoprolol	17.12
11	C07AB02	metoprolol	13.52
12	C09BA02	enalapril and diuretics	13.27
13	A10BA02	metformin	13.22
14	C09BA06	quinapril and diuretics	11.30
15	H03AA01	levothyroxine sodium	10.59

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	C09AA05	ramipril	38.90
2	C07AB12	nebivolol	30.26
3	C01EB15	trimetazidine	22.92
4	C09AA04	perindopril	21.32
5	M01AB05	diclofenac	20.49
6	N05BA06	lorazepam	19.97
7	C09BA04	perindopril and diuretics	19.64
8	C09CA03	valsartan	19.45
9	C07AB02	metoprolol	18.34
10	C02AC05	moxonidine	17.18
11	C08CA13	lercanidipine	15.42
12	C09CA07	telmisartan	12.50
13	C09AA02	enalapril	11.75
14	H03AA01	levothyroxine sodium	11.58
15	C09BB04	perindopril and amlodipine	11.41

9. Top 15 most used ATC 3rd level groups

ESTONIA			
No	ATC	ATC group	DDD/1000/day
1	C09A	ACE INHIBITORS, PLAIN	95.73
2	B01A	ANTITHROMBOTIC AGENTS	78.83
3	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	65.60
4	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	61.00
5	C07A	BETA BLOCKING AGENTS	40.38
6	C10A	LIPID MODIFYING AGENTS, PLAIN	39.18
7	C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN	38.46
8	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	37.44
9	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	30.48
10	C09B	ACE INHIBITORS, COMBINATIONS	29.35
11	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	27.92
12	G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	27.40
13	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	24.00
14	N06A	ANTIDEPRESSANTS	19.91
15	C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	19.83

LATVIA			
No	ATC	ATC group	DDD/1000/day
1	C09B	ACE INHIBITORS, COMBINATIONS	84.88
2	B01A	ANTITHROMBOTIC AGENTS	74.04
3	C09A	ACE INHIBITORS, PLAIN	69.13
4	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	58.02
5	C10A	LIPID MODIFYING AGENTS, PLAIN	41.68
6	C07A	BETA BLOCKING AGENTS	40.12
7	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	36.73
8	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	31.86
9	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	28.26
10	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	23.62
11	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	21.34
12	N07C	ANTIVERTIGO PREPARATIONS	13.78
13	N05B	ANXIOLYTICS	13.67
14	R03A	ADRENERGICS, INHALANTS	12.38
15	A10A	INSULINS AND ANALOGUES	11.05

LITHUANIA			
No	ATC	ATC group	DDD/1000/day
1	C09A	ACE INHIBITORS, PLAIN	111.79
2	B01A	ANTITHROMBOTIC AGENTS	63.49
3	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	62.25
4	C07A	BETA BLOCKING AGENTS	57.95
5	C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN	44.24
6	C09B	ACE INHIBITORS, COMBINATIONS	44.18
7	N05B	ANXIOLYTICS	40.53
8	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	33.70
9	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	31.87
10	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	25.58
11	C01E	OTHER CARDIAC PREPARATIONS	25.23
12	N06A	ANTIDEPRESSANTS	23.40
13	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	22.49
14	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	19.52
15	C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	17.25

10. TOP 15 of over-the-counter medicines

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC30	acetylsalicylic acid combinations	51.55
2	R01AA07	xylometazoline	20.87
3	M01AE01	ibuprofen	19.71
4	B01AC06	acetylsalicylic acid	13.40
5	N02BE01	paracetamol	5.49
6	A06AD11	lactulose	5.44
7	N06DX02	ginkgo folium	4.78
8	R05CB01	acetylcysteine	3.38
9	A06AB02	bisacodyl	3.24
10	A06AB08	sodium picosulfate	2.75
11	R06AE07	cetirizine	2.37
12	R05CB06	ambroxol	2.32
13	G04CX02	sabalis serrulatae fructus	2.29
14	R06AX13	loratadine	2.18
15	A03AD02	drotaverine	1.42

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC06	acetylsalicylic acid	64.61
2	M01AE01	ibuprofen	18.45
3	R01AA07	xylometazoline	16.84
4	A01AA01	sodium fluoride	6.33
5	A03AD02	drotaverine	4.22
6	A09AA02	multienzymes (lipase, protease etc.)	4.04
7	A03BA04	belladonna total alkaloids	3.16
8	B03AD02	ferrous fumarate	3.11
9	N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	2.89
10	A02BA02	ranitidine	2.83
11	A06AB02	bisacodyl	2.72
12	R05CB06	ambroxol	2.35
13	N02BE51	paracetamol, combinations excl. psycholeptics	2.29
14	R01AA08	naphazoline	2.20
15	R05CB02	bromhexine	2.20

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC06	acetylsalicylic acid	47.53
2	R01AA07	xylometazoline	15.64
3	M01AE01	ibuprofen	7.42
4	N02BE51	paracetamol, combinations excl. psycholeptics	5.76
5	R05CB06	ambroxol	3.89
6	A03AD02	drotaverine	3.23
7	A02BA02	ranitidine	3.23
8	N02BE01	paracetamol	3.02
9	R05CB01	acetylcysteine	2.76
10	A06AD11	lactulose	2.42
11	A06AB02	bisacodyl	2.27
12	A06AB08	sodium picosulfate	2.24
13	N06DX02	ginkgo folium	1.97
14	A02BC02	pantoprazole	1.57
15	N02BA01	acetylsalicylic acid	1.39

11. Contacts



■ **Estonian State Agency of Medicines
(Ravimiamet)**

1 Nooruse Street
50411 Tartu
Estonia
info@ravimiamet.ee
www.ravimiamet.ee



Zāļu valsts aģentūra

■ **Latvian State Agency of Medicines
(Zāļu valsts aģentūra)**

15 Jersikas Street
LV-1003 Riga
Latvia
info@zva.gov.lv
www.zva.gov.lv



■ **Lithuanian State Medicines Control Agency
(Valstybinė vaistų kontrolės tarnyba)**

139A Žirmūnų Street
09120 Vilnius
Lithuania
vvkt@vvkt.lt
www.vvkt.lt

12. References

1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD methodology. (http://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system)
2. Estonian Statistics on Medicines. (<http://www.ravimiamet.ee/en/statistics-medicines>)
3. Statistics on medicines consumption of Latvia (http://www.zva.gov.lv/doc_upl/Zalu_paterina_statistika_2012-20130604.pdf)
4. Medicines consumption 2012 in Lithuania. (<http://www.vvkt.lt/Annual-Reports>)
5. Estonian Health Insurance. Health Insurance in Estonia. (<http://www.haigekassa.ee/eng/health-insurance-in-estonia>)
6. Statistics Estonia. (<http://www.stat.ee>)
7. Pudersell, K., Vetka, A., Rootslane, L., Mathiesen, M., Vendla, K., Laasalu, K.: PPRI Pharma Profile Estonia 2007. June; Pharmaceutical Pricing and Reimbursement Information; Commissioned by the European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth. (<http://whocc.goeg.at/Publications/CountryReports>)
8. Central Statistical Bureau of Latvia. (<http://data.csb.gov.lv/DATABASEEN/ledz/databasetree.asp>)
9. World Health Organization. Global Health Expenditure Database. (<http://apps.who.int/nha/database/PreDataExplorer.aspx?d=1>)
10. The World Bank. Health expenditure per capita. (<http://data.worldbank.org/indicator/SH.XPD.PCAP/countries>)
11. The Centre for Disease Prevention and Control of Latvia. (<http://www.spkc.gov.lv>)
12. The National Health Service of Latvia. (<http://www.vmnvd.gov.lv>)
13. Garuoliene K., Alonderis T., Marcinkevičius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth. 2011; 17(1): 1-4.

